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Genetic manipulations of Mycobacterium tuberculosis are complicated by its slow growth, 
inefficient DNA uptake, and relatively high levels of illegitimate recombination. Most methods 
for construction of gene replacement mutants are lengthy and complicated, and the lack of 
generalized transducing phages that infect M. tuberculosis prevents simple construction of 
isogenic mutant strains. Characterization and genomic analysis of mycobacteriophages has 
provided numerous molecular and genetic tools for the mycobacteria. Recently, genes encoding 
homologues of the Escherichia coli Rac prophage RecET proteins were revealed in the genome 
of mycobacteriophage Chec9c. RecE and RecT are functional analogues of the phage λ Red 
recombination proteins, Exo (exonuclease) and Beta (recombinase), respectively. These 
recombination enzymes act coordinately to promote high levels of recombination in vivo in E. 
coli and related bacteria using short regions of homology, facilitating the development of a 
powerful genetic technique called ‘recombineering.’  
Biochemical characterization of Che9c gp60 and gp61 demonstrated that they possess 
exonuclease and DNA binding activities, respectively, similar to RecET and λ Exo/Beta. 
Expression of gp60/gp61 in M. smegmatis and M. tuberculosis substantially increases 
homologous recombination such that 90% of recovered colonies are the desired gene 
replacement mutants. Further development of this system demonstrated that Che9c gp61 
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facilitates introduction of selectable and non-selectable point mutations on mycobacterial 
genomes at high frequencies using short (<50 nt) ssDNA substrates.  
The mycobacterial recombineering system provides a simple and efficient method for 
mutagenesis with minimal DNA manipulation. While it is clear that similar phage-encoded 
recombinase homologues are rare, they can be readily identified by genomic studies and by in 
vivo characterization. Several putative recombination systems have been identified in 
mycobacteriophages Halo, BPs, and Giles, and recombineering of drug-resistance point 
mutations provides an easy assay for recombinase activity. Analysis of recombinases from 
various phages – including λ Beta and E. coli RecT – indicates that these proteins function best 
in their native bacteria. The mycobacteriophage-encoded proteins exhibited varying levels of 
activity, suggesting that analysis of multiple proteins is required to achieve optimal 
recombination frequencies. The apparent species-specific nature of these recombinases suggests 
the recombineering technology could likely be extended to any bacterial system through 
characterization of host-specific bacteriophages. 
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1.0  INTRODUCTION 
Tuberculosis kills more than one million people each year, and it is estimated that one-third of 
the global population is currently infected with the causative agent of this disease, 
Mycobacterium tuberculosis [1]. The world struggles to control this epidemic, yet close to ten 
million new cases are reported each year. Antibiotic resistance in pathogenic bacteria is a 
continual concern, but it is even more devastating in M. tuberculosis when coupled with its 
persistence. The recent emergence of multiple drug-resistant (MDR) and extensively drug-
resistant (XDR) strains of M. tuberculosis emphasizes the need for new treatments. Advances in 
understanding the mechanisms of drug resistance and persistence are therefore critical to 
improving drug treatments [194].  
 Scientific study of M. tuberculosis requires intricate genetic, molecular, and biochemical 
approaches to determine what makes it such a successful pathogen. In particular, inactivation of 
genes by allelic replacement is a crucial first step to understanding gene product function. 
However, there are several road-blocks to basic genetics in this organism: slow growth, 
inefficient DNA uptake, and relatively high rates of illegitimate recombination.  Although 
numerous genetic tools have been developed to overcome these limitations, none offer a stream-
lined method to manipulate the bacterial chromosome for multiple types of mutagenesis. Clearly 
there is a need for efficient genetic techniques in M. tuberculosis, as well as the other 
mycobacteria that are studied as model systems. 
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1.1 GENETICS AND RECOMBINATION IN MYCOBACTERIA 
Traditional genetic techniques have been developed and extensively utilized in several 
genetically tractable bacterial species, such as Escherichia coli and Bacillus subtilis. For 
example, to study gene function, gene replacement mutants are often constructed in bacteria 
using allelic exchange substrates (AESs) that contain homology to a target gene flanking a 
selectable marker. Homologous recombination facilitates replacement of the endogenous gene 
with the selectable marker, resulting in a mutant strain. A variety of strategies have been 
developed for these types of genetic manipulations in several model bacterial systems such as E. 
coli; however, this is not a simple task in most mycobacteria. While some species, such as the 
non-pathogenic fast-growing species Mycobacterium smegmatis, are easier to use for traditional 
genetics, others like M. tuberculosis present huge difficulties for even simple mutagenesis such 
as allelic gene replacement. This section will examine the obstacles inherent to mycobacterial 
genetics and the strategies developed to overcome these.  
1.1.1 Barriers to genetics in M. tuberculosis 
M. tuberculosis genetic studies are hindered by two factors related to its growth and cell biology. 
First, the extremely slow growth rate (>24 hour doubling time) of this bacterium reduces the 
speed with which any experiments can be performed. Second, the pathogenicity of the organism 
requires working in a biosafety level three laboratory, which can also be cumbersome and time-
consuming. Researchers in this field often turn to other mycobacterial species that are easier to 
manipulate, such as the fast-growing, non-pathogenic strain M. smegmatis, or the avirulent 
vaccine strain Mycobacterium bovis BCG.  
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While both slow growth and pathogenicity limit the ease and speed with which 
researchers can manipulate M. tuberculosis, there are more specific issues that complicate 
genetic assays. Because of their waxy coats, mycobacterial cells have a tendency to grow in 
aggregates or ‘clumps’ making isolation of single cells for genetic analyses difficult [41]. 
Additionally, generalized transducing bacteriophages that infect M. tuberculosis have not been 
isolated, and therefore mutations cannot be simply moved to different strain backgrounds as can 
be done in M. smegmatis [111,183].  
 In the past, the small cache of available antibiotic resistance markers was also a 
limitation, but this is slowly being overcome [3,19]. Many mycobacterial species encode -
lactamases, which therefore eliminates ampicillin-resistance genes as usable markers, and the 
instability of tetracycline over time in culture makes it impractical for use with the slow-growing 
mycobacteria [19]. Other antibiotics, such as chloramphenicol, have been used, but high 
background resistance make them less desirable [210].  The first demonstration of a selectable 
marker for the mycobacteria was a kanamycin resistance gene (aph; kanR) used in E. coli-
mycobacterial shuttle phasmids and on replicating plasmids that enabled stable introduction of 
foreign genes [62,87,107,210]. Later, hygromycin [59], apramycin [153], streptomycin [78], and 
gentamicin [121,155] were also successfully utilized. Currently, the kanamycin-resistance (kanR) 
and hygromycin-resistance (hygR) genes are still the selective markers of choice, although high 
levels of spontaneous KanR colonies are reportedly a problem when using kanR in some assays 
[139].  Another method for selection uses the mycobacteriophage L5 gene 71 that confers 
superinfection immunity such that no antibiotic markers are required, and this is a huge benefit 
for construction of recombinant vaccine strains [49].  Other selectable markers developed for the 
mycobacteria include auxotrophic complementation [21] and mercury resistance [16]. 
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Specifically, complementation of strains deleted for auxotrophic genes can be used as a form of 
selection, which was recently demonstrated with a leuD M. bovis BCG strain [21]. Great 
potential for other selective markers exists from sources, such as mycobacteriophages [70] and 
mutant alleles isolated from drug-resistant strains.  
A low rate of DNA uptake in the mycobacteria has also been troublesome; even the use 
of electroporation [210] – an improved strategy over spheroplasting [86] – still yields relatively 
low numbers of transformants of replicating or integrating plasmids in mycobacterial cells. 
Although protocols for DNA transformation have been optimized repeatedly, typical 
transformation rates average 105 – 106 transformed cells per microgram of DNA out of 109 
viable cells [155,235], even though some have claimed up to 107 [139]. The most effective 
strategy for improving transformation efficiency in M. tuberculosis is utilizing warmer 
temperatures (up to 37°C) during incubations of cells prior to preparation for electroporation. In 
contrast, lower temperatures (incubating on ice) are preferential for M. smegmatis [235]. Further, 
in comparison to cells that are stored at -80°C prior to use, freshly prepared cells tend to have 
higher transformation efficiencies [80]. Adding sub-lethal amounts of chemical agents that affect 
cell wall integrity – such as glycine or ethionamide – can also moderately improve the efficiency 
of transformation [3,235]. Others have treated the DNA substrates used for allelic replacements 
with ultra-violet light (UV), alkali, or boiling to increase transformant recovery [80]. Overall, 
while improvements can be made, transformation of mycobacterial cells will likely never reach 
the high efficiencies of 10 % (transformants/viable cells) routinely seen in other bacteria such as 
E. coli. 
   Despite the difficulties described above, the primary obstacle to simple genetics in M. 
tuberculosis is the relatively high level of illegitimate recombination compared to homologous 
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recombination observed in these bacteria [3,91,125]. During attempts to make targeted gene 
knockouts in M. tuberculosis and M. bovis BCG, it was seen that, instead of undergoing 
homologous recombination with the target locus, linear AESs were incorporated into the genome 
at seemingly random loci. This occurs at such high frequencies that it prevents simple isolation 
of a colony that has undergone targeted gene replacement [3,91]. Clearly, illegitimate 
recombination is a huge impediment to simple genetics in M. tuberculosis, and a variety of 
techniques have been developed to overcome this (see section 1.1.5); the available information 
on the molecular basis of illegitimate recombination will be examined in section 1.1.3. 
1.1.2 Genetics in other mycobacteria  
While M. tuberculosis is a central focus of research because of the health impact of the disease, 
other mycobacteria are also commonly studied. There are over 130 species of mycobacteria that 
have been classified, and these can be characterized broadly as either ‘fast-growing’ or ‘slow-
growing,’ the latter of which includes the pathogenic species. Many of these are grouped in two 
classes: the M. tuberculosis complex and the Mycobacterium avium complex [226]. These are 
the causative agents of tuberculosis and other diseases in animals and humans, especially in 
AIDS patients. In addition, although most of the fast-growers are not generally pathogenic, some 
can cause disease in immunocompromised individuals. Therefore, many mycobacteria are 
studied as either model systems or as pathogens in their own right. There are inherent 
characteristics of mycobacteria that make genetic manipulations of these organisms difficult, 
such as the propensity for cell-clumping and inefficient DNA uptake discussed above. The 
additional difficulties geneticists encounter with M. tuberculosis are also present in other slow-
growers: biosafety level three requirements and illegitimate recombination. While there are 
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innumerable specific differences in manipulations of mycobacterial species, some of the more 
common model mycobacteria are briefly described below. 
 The vaccine strain M. bovis Bacille Calmette-Guerin (BCG; a member of the M. 
tuberculosis complex) is often used to model M. tuberculosis because, even though it is a slow-
grower, it is relatively non-pathogenic and can be used in biosafety level two containment. M. 
bovis was passaged 230 times, and the resulting strain has lost the ability to cause disease in 
several animal models [26]. Experimental evidence has shown that deletion of the Region of 
Difference 1 (RD1) largely contributes to its attenuation (reviewed in [24]). M. bovis BCG 
exhibits many of the molecular characteristics of M. tuberculosis, including limited allelic 
exchange due to illegitimate recombination [91].  
 Members of the M. avium complex are also frequently studied, including Mycobacterium 
intracellulare and numerous subspecies of M. avium  [121,226]. Unfortunately, DNA 
transformation frequencies are particularly low in these organisms, compounded by relatively 
high levels of inherent antibiotic resistance. However, gene replacement mutants are readily 
obtained in M. intracellulare by homologous recombination, which is unique among the slow-
growers [121]. 
 One of the most intractable mycobacterial species is Mycobacterium leprae, the causative 
agent of leprosy, which has never been grown in artificial media and thus is not amenable to 
classic genetics. However, growth in animal models such as the armadillo and in mouse footpads 
facilitates metabolic and clinical study of this pathogen [202]. Also, recent sequencing of the M. 
leprae genome has yielded new insights into its genomics and proteomics, enabling better 
comparisons with more tractable mycobacterial species.  
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 Arguably, M. smegmatis is one of the best model mycobacterial species: it grows 
relatively fast (doubling time of approximately two hours), is non-pathogenic, and is amenable to 
genetic manipulations [80,82]. Generalized transducing phages that infect M. smegmatis have 
been isolated [111,183], as well as numerous plasmids – both replicating and integrating – and 
promoter systems that can be used for cloning and gene expression [95,110,126,160,170]. A 
significant advance to M. smegmatis genetics was the isolation of a transformation-proficient 
strain, mc2155 [211], with which DNA transformation rates of up to 107 colonies per microgram 
DNA are obtained [139]. The M. smegmatis mc2155 genome has also been sequenced, making 
this widely-used strain a particularly ideal system. 
1.1.3 Recombination in mycobacteria 
Attempts at allelic gene replacement in M. tuberculosis were unsuccessful initially due to the  
prevalence of ‘illegitimate recombination’: recombination between unrelated DNA sequences 
with very short or no regions of homology [84,125,139]. This type of recombination is observed 
broadly in prokaryotes and eukaryotes and causes genome rearrangements by two main 
mechanisms, which are either dependent on, or occur independently, of short homology 
[50,84,106].  Illegitimate recombination is thought be involved in repair of chromosomal breaks 
as a mechanism of recombinational repair [106], is induced in response to DNA damage, and is 
spontaneously induced at lower frequencies [205]. Although it is not surprising that illegitimate 
recombination occurs in bacteria, the high levels of this found in some mycobacterial species 
compared to homologous recombination is striking. Illegitimate recombination is troublesome 
for mycobacterial researchers because it is a barrier to straight-forward genetics. 
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The relative frequencies of illegitimate and homologous recombination (as assayed by 
allelic exchange) vary among the mycobacterial species. Although low levels of illegitimate 
recombination have been reported in M. smegmatis [80], sufficient levels of homologous 
recombination occur, such that gene knockouts are easily obtained [82,125]. In M. tuberculosis 
and M. bovis BCG, illegitimate recombination rates are unusually high compared to homologous 
recombination, making gene replacements difficult to isolate. However, this is not common to all 
slow-growing mycobacteria, and single homologous recombinants are readily obtained in M. 
intracellulare and Mycobacterium marinum.  No double crossover events were observed in these 
studies [80,121,184], indicating that while illegitimate recombination is not frequent in these 
bacteria, homologous recombination occurs less frequently than in M. smegmatis [82]. Overall, 
genetic manipulation is difficult in most slow-growing pathogenic mycobacteria; some of the 
initial experiments illustrating this are discussed below. 
1.1.3.1 Gene replacement by homologous recombination in M. smegmatis 
 The first report of successful targeted gene replacement in M. smegmatis was 
accomplished by using a ‘suicide vector’ [82], which is a plasmid that replicates in E. coli for 
propagation but lacks a mycobacterial origin of replication and relies on a homologous 
recombination event to integrate into the mycobacterial chromosome (see section 1.1.5). The 
plasmid was constructed with a kanR gene flanked by DNA segments with homology to the M. 
smegmatis pyrF gene. This locus was chosen because strains with a wild type pyrF gene can 
grow in media without uracil but are inviable in the presence of 5-fluroorotic acid (5-FOA), 
while pyrF strains are uracil auxotrophs and 5-FOA resistant. These characteristics, therefore, 
provide both positive and negative selection, and single versus double homologous 
recombination events can be distinguished (Figure 1). Using this approach, single and double 
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crossovers occurred at similar frequencies in M. smegmatis (60% and 40%, respectively), 
although these frequencies vary in other reports [168,196]. Gene replacement also occurs when a 
second crossover event loops out the remaining vector sequence from the first single crossover. 
These mutants can be identified by selection with 5-FOA and arise at a frequency of 10-4 (Figure 
1B). Other groups have developed similar strategies for constructing gene replacements in M. 
smegmatis, some of which include the use of other counter-selectable markers that make double 
crossover allele identification easier [168,196]. Compiling data from multiple studies, 
frequencies of homologous recombination resulting in plasmid integration (single crossovers) 
average 10-3 – 10-4 cfu per microgram DNA, with respect to the number of colonies that arise 
from transformation with a replicating control plasmid [168,196]. Gene replacement events 
(double crossovers) are less frequent but still occur at a frequency of 10-4 – 10-6, which makes M. 
smegmatis an ideal model system for mycobacterial genetics [125]. 
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Figure 1. Homologous recombination in M. smegmatis. 
 
 
 
Figure 1. Schematic representing the classic allelic gene replacement experiments targeting the pyrF gene 
performed by Husson et al. [82] using a circular suicide vector. (A) Class I transformants: a single homologous 
recombination event yields an integration of the entire plasmid; transformants are KanR, uracil prototrophs, 5-FOA 
sensitive. (B) Following a single crossover, the sequences that are in duplicate can be removed by a second 
recombination event. (C) Class II transformants: a double homologous recombination event yields integration only 
of the kanR gene into the pyrF gene; transformants are KanR, uracil auxotrophs, 5-FOA resistant. 
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1.1.3.2  Evidence of illegitimate recombination in M. tuberculosis  
 In the first report of illegitimate recombination in the mycobacteria, Kalpana et al. were 
unable to replace either the M. bovis BCG or M. tuberculosis strain H37Rv met genes with a 
kanR gene [91]. No correctly targeted gene replacements were identified out of more than 200 
KanR colonies screened (Table 1). Linear double-stranded DNA (dsDNA) AESs were used in an 
attempt to exclusively isolate mutants from double crossovers, and this resulted in an ~10-fold 
increase in colonies. However, KanR recombinants were recovered irrespective of the presence of 
homologous mycobacterial DNA sequences in the AES (pBR322::Tn5, Table 1), clearly 
showing that integration of the kanR gene was not dependent on homologous DNA sequences. 
The illegitimate recombinants were obtained at a relatively high frequency (i.e. 10-4 to 10-5 
relative to plasmid transformants), such that they masked the presence of colonies (if any) arising 
from correctly targeted recombination events. In the same study, M. smegmatis met mutants were 
readily obtained using either linear or circular AESs, as expected from previous studies [82], and 
recovery of recombinants was dependent on the presence of mycobacterial sequences in the AES 
(Table 1).  Subsequently, other groups successfully isolated mutant alleles that were generated 
by homologous recombination in M. tuberculosis, but the frequencies of single crossovers were 
low (<20%) and were lower for double crossovers (<5%) [3,8,147,168,188].  
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Table 1. Isolation of illegitimate recombinants in M. tuberculosis and M. bovis BCG. 
Plasmid DNA typed M. smegmatis M. bovis BCG M. tuberculosis 
No DNA controla – 0 12 7 
pYUB53 control (per 
g DNA)b 
CCC      
(replicating) 10
6 1-3 x 105 3 x 104 
pBR322::Tn5c  CCC 0 13 – 
 Linear 0 140 26 
M. smeg met::Tn5 CCC 332 – – 
 Linear 196 – – 
M. bovis met::Tn5-a CCC – 16 – 
 Linear – 130 – 
M. bovis met::Tn5-b CCC – 18 14 
 Linear – 148 27 
 
Summary of data from DNA transformations performed by Kalpana et al. targeting the met genes of M. smegmatis, 
M. bovis BCG, and M. tuberculosis [91].  
a. The ‘no DNA control’ determined background KanR. 
b. pYUB53 is an episomally replicating plasmid used to determine overall transformation proficiency (per g).  
c. Plasmid pBR322::Tn5 contains no mycobacterial sequences and is a control for illegitimate recombination. 
d. Cells were transformed with 2-4 g AES DNA, either covalently closed circular (CCC) or linearized, containing a 
Tn5 seq1 inactivated met gene; transformants were selected on Kan and the number of colonies are reported.  
1.1.3.3 The recombination genes of M. tuberculosis 
The complete genome sequence of M. tuberculosis has made comparative genomic 
studies possible [35], which revealed genes predicted to encode homologous recombination 
proteins [130]. The M. tuberculosis predicted open reading frames (ORFs) were searched for 
homologues of the E. coli recombination (rec) proteins, and a number of predicted rec proteins 
were identified including RecA, RecBCD, RecF, RecR, as well as Holliday junction resolvases 
[130]. Strikingly, several rec proteins were not identified in this initial analysis, such as RecO, 
RecJ, ExoI, RecQ, SbcCD, and RecET.  
However, closer analysis indicates that identification of mycobacterial recombination 
proteins cannot be identified merely through the presence of E. coli rec homologues. In fact, 
many mycobacterial species, including M. tuberculosis, do have ORFs that encode proteins with 
similarity to these ‘missing’ rec proteins [35]. The M. tuberculosis RecO protein is easily 
identifiable by BLAST analysis but is only distantly related to the E. coli RecO. In addition, M. 
 12 
tuberculosis Rv2837c is a member of the DHH protein family, which includes RecJ proteins 
from several bacteria including E. coli. Another M. tuberculosis ORF, Rv3198c, is predicted to 
encode a protein that has both a UvrD2 helicase domain and a fragment of the RecQ domain, and 
is therefore described as a putative RecQ helicase. Finally, since the RecET proteins are encoded 
by a cryptic prophage in E. coli, it is not surprising that these are absent in M. tuberculosis. 
Therefore, this bacterium has a number of recognizable recombinational repair pathway 
components.  
Arguably, a comparison of the known recombination genes of more closely related 
bacteria may provide better insights into the recombinational repair system of M. tuberculosis. 
Comparative analysis of the B. subtilis and mycobacterial genomes revealed the presence of 
multiple genes encoding B. subtilis AddA homologues (at least two) in several mycobacterial 
species, including M. smegmatis and M. tuberculosis (D. Ennis and G. Cromie, personal 
communication; see Appendix A and Figure 34). The AddAB proteins function similarly to 
RecBCD for processing and repair of dsDNA lesions and are most commonly found in Gram-
positive bacteria, whereas RecBCD are typically encoded by Gram-negative bacteria [32,245]. 
The specific activities of RecBCD have not been fully characterized in mycobacteria for general 
recombinational repair, and these have only been examined with regard to their role (or lack 
thereof) in conjugation and non-homologous end-joining, respectively [120,234]. It is therefore 
possible that both sets of recombination proteins – RecBCD and the two AddA homologues – are 
active and perhaps redundant in mycobacteria. Alternatively, it may be that only one set of 
proteins is expressed and/or active in vivo.  
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1.1.3.4 The debate over homologous and illegitimate recombination in mycobacteria 
It was not clear from the initial studies discussed above if levels of homologous 
recombination are actually decreased or if the levels of illegitimate recombination are merely 
increased – or perhaps both – in slow-growing mycobacteria such as M. tuberculosis. One 
hypothesis is that the presence of an intein in the M. tuberculosis recA gene reduces the activity 
of this pivotal recombination enzyme, thereby decreasing overall levels of homologous 
recombination (reviewed in McFadden, 1996).  
In M. tuberculosis, the conserved RecA sequences are situated at the N- and C-termini of 
the ORF and are interrupted by 440 amino acids that are not conserved in other RecA proteins 
[45]. Splicing of the full-length protein is essential to remove this “spacer protein,” and the N- 
and C-terminal regions are ligated to produce the mature active protein [46]. The recA gene of 
M. leprae also includes an intein that is spliced in vivo [57], but the recA gene of M. smegmatis 
does not [47], which further suggests that the abnormal gene structure of the M. tuberculosis 
recA may correlate to low levels of homologous recombination. In vitro experiments with 
purified M. tuberculosis RecA proteins – both full-length and mature – have shown that the 
unspliced protein is defective in ATPase activity and strand exchange, whereas the mature 
protein is active [103]. It is therefore possible that RecA activity in vivo is regulated by 
conditional splicing of the full-length inactive protein.  
In addition, expression of recA in M. tuberculosis is controlled by multiple transcriptional 
regulatory elements, which adds to the complexity of regulation. Two promoters upstream of 
recA are regulated in response to DNA damage, one by LexA and RecA in the classical 
mechanism through an SOS box, while the other is independent of LexA and RecA (discussed 
below)  [48,65,127]. Additionally, RecA activity is negatively regulated by a co-transcribed 
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protein RecX in mycobacteria [154,155,230]. It is also intriguing that recA expression is much 
more delayed in response to DNA damaging agents in M. tuberculosis as compared to M. 
smegmatis [127,156]. It was suggested, therefore, that the genetic and biochemical 
characteristics of M. tuberculosis RecA may result in reduced levels of homologous 
recombination in this bacterium.  
Subsequent experiments, however, suggested that the intein does not affect the function 
of RecA in recombination or other activities. Expression of the M. tuberculosis RecA – with or 
without the intein – in an M. smegmatis recA strain was sufficient to promote levels of 
homologous recombination similar to wild type M. smegmatis, and no illegitimate recombination 
was observed [56,155]. These data support two conclusions: 1) the M. tuberculosis RecA protein 
inteins does not reduce the levels of homologous recombination in M. smegmatis, and 2) the 
expression of M. tuberculosis RecA in M. smegmatis is not sufficient to introduce levels of 
illegitimate recombination similar to those in M. tuberculosis. However, similar experiments 
expressing the M. smegmatis recA in an M. tuberculosis recA strain would be required to 
determine the specific role of RecA in illegitimate recombination. It is also possible that there are 
factors regulating RecA splicing in M. tuberculosis that modulate its recombination activity 
levels, and perhaps this does not occur in M. smegmatis. 
There is evidence that suggests that the levels of homologous recombination are not 
decreased in M. tuberculosis. Experiments by Pavelka et al. showed that similar numbers of 
homologous transformants were obtained  in M. smegmatis, M. tuberculosis, and M. bovis BCG 
using circular suicide vectors, suggesting that illegitimate recombination likely occurs 
predominantly with linear DNA substrates [163]. These data imply that homologous 
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recombination frequencies in mycobacteria are similar, and the increased level of illegitimate 
recombination is likely what is different between the fast- and slow-growing mycobacteria.  
It has also been speculated that the slow induction of recA expression in M. tuberculosis 
may result in deficiencies in DNA repair and decreased SOS response, leading to high rates of 
illegitimate recombination. Since recA expression is induced slowly (compared to M. smegmatis) 
in response to DNA damage, this could result in reduced RecA-dependent autocatalytic cleavage 
of LexA and decreased activation of downstream genes involved in the SOS response. In this 
situation, it is conceivable that chromosomal breaks would be more prevalent, perhaps leading to 
higher rates of illegitimate recombination for repair of these lesions. The LexA protein of M. 
tuberculosis has been characterized and shown to bind an SOS box (as is typically seen with this 
repressor [127,128]), and one SOS box is present in one of the promoter regions at recA. 
However, it was found that two mechanisms for DNA damage response exist in M. tuberculosis, 
one that is classically dependent on RecA and LexA and one that is independent of this process; 
each mechanism controls a different set of genes [48,127,186]. Therefore it seems that even 
though induction of recA expression is slow, other mechanisms for DNA repair and SOS 
response are in place, perhaps negating the argument that recA expression kinetics play a role in 
illegitimate recombination. Thus, the molecular basis of the relatively high frequencies of 
illegitimate recombination in M. tuberculosis and other slow-growing mycobacteria remains an 
open question. 
1.1.4 Mycobacteriophage-derived genetic tools 
Bacteriophages have long demonstrated their utility as sources for genetic tools in bacterial 
model systems, especially those that are genetically intractable. Over fifty mycobacteriophages 
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have been isolated and sequenced to date ([73,165] and unpublished data), from which a plethora 
of genetic information has been gathered, enabling the study of numerous phage genes [71,72]. 
For the mycobacteria, phage-derived vectors have proven extremely useful for expression of 
foreign genes.  Several integration-proficient vectors containing phage integration cassettes have 
been developed and can be used simultaneously for stable introduction of multiple genetic 
elements in a single cell [95,111,126,170]. Also of great use are shuttle phasmids, which are 
chimeric cosmid molecules containing mycobacteriophage and E. coli plasmid DNA [86]. These 
replicate as plasmids in E. coli and as phages in mycobacteria and are used as delivery vehicles; 
their use for delivering AESs will be discussed in further detail in section 1.1.5.5 [14]. Shuttle 
phasmids have also been used to deliver transposons for genetic assays [13] and as reporter 
phages in clinical studies to assay for live mycobacterial cells and drug susceptibility 
[10,27,88,164,189,197]. 
Phages have also been isolated that infect M. smegmatis and facilitate generalized 
transduction, enabling transfer of mutations to other strains [111,183]. Generalized transduction 
would be particularly useful for studying mutations conferring drug-resistance. However, no 
generalized transducing phages that infect the slow-growing mycobacteria, such as M. 
tuberculosis, have been isolated. Also of use in M. tuberculosis are phage-derived methods for 
selection that can be used in place of antibiotic markers, which are not desireable in potential 
vaccine strains. The mycobacteriophage L5 repressor gene product gp71 confers immunity to 
superinfection. Thus, when gene 71 is expressed as a selective marker on plasmids, cells are 
resistant to infection by a homo-immune phage [49]. Phage promoters have also been used for 
gene expression in mycobacteria as an alternative to constitutive strong promoters such as the M. 
bovis BCG hsp60 promoter [18,72]. It is clear that mycobacteriophages have contributed greatly 
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to the study of genetics in mycobacteria and will likely continue to do so as we learn more 
through isolation and characterization [73]. 
1.1.5 Genetic techniques for allelic replacement 
Characterization of isogenic mutants is a powerful method for the study of gene function, and 
targeted gene replacement is a standard way to construct these defined mutants. Other techniques 
such as transposon mutagenesis and random mutagenesis are extremely valuable but do not offer 
the same precision or control over the type of mutations made. In many organisms, allelic gene 
replacement is simple and fast, requiring little DNA manipulation and screening [38]; however, 
this is not the case for the mycobacteria. Canonical substrates for targeted gene replacement 
(AESs) contain a selectable genetic marker flanked by long (>1000 bp) regions of homology to 
the gene locus being targeted. These substrates are introduced into the cell and homologous 
recombination leads to single or double crossovers to yield a marked allelic replacement mutant. 
While this strategy is successful in M. smegmatis, the prevalence of illegitimate recombination in 
some of the slow-growing mycobacteria prevents this from being an efficient method for gene 
replacement. Null mutations in genes resulting in an auxotrophic or otherwise identifiable 
phenotype were the first constructed because they facilitated differentiation of double versus 
single crossovers [3,8,9,80,158,188]. Clearly not all gene mutants would have screenable 
phenotypes, and therefore even the limited success of these early methods suggested a need for 
improvement. 
A number of attempts have been made to improve the recovery of mutant alleles from 
double homologous recombination events and reduce the need for screening. Figure 2 
summarizes the multitude of techniques that were developed for the mycobacteria in a timeline 
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style and also shows the first gene replacements made in some of the more commonly studied 
mycobacteria. The majority of mycobacterial genetic tools developed were aimed at modifying 
the AES to make it more recombinogenic: altering the structure, treatments prior to 
transformation, and delivery method. The preferred genetic techniques are successful because 
they either utilize a selection for double crossovers or drastically reduce or eliminate illegitimate 
recombination events. It is worth noting, however, that none of the strategies developed thus far 
have successfully increased the levels of homologous recombination in M. tuberculosis. This 
may be due to the complexity of recombination in the mycobacteria, or perhaps this was 
attempted and never accomplished. Yet this still represents another potential method for 
improving recovery of allelic replacement mutants. 
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Figure 2. Development of allelic gene replacement techniques in the mycobacteria: 1990-present. 
 
 
 
 
Figure 2. The first gene replacements made in M. smegmatis, M. bovis BCG (BCG), M. tuberculosis (TB), M. 
intracellulare, M. marinum, and M. avium are indicated by red boxes.  The first publications that studied illegitimate 
recombination (IR) through gene replacement are shown in orange. New techniques are shown in purple boxes. 
Abbreviations: TB: M. tuberculosis; KO: gene knockout, x-over: crossover; STORE: selection technique of 
recombination events.  
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Arguably, there were two techniques that were most successful: (1) the use of suicide 
vectors with counter-selectable markers, which aid in the selection of the desired double-
crossover events, and (2) the delivery of the AES by mycobacteriophages (referred to as 
‘specialized transduction’). This section will discuss the numerous genetic tools developed for 
the mycobacteria over the last 18 years. 
1.1.5.1 AES structural modifications 
Numerous AES designs were explored to optimize allelic exchange frequencies: linear 
versus circular DNA substrates, the length of sequence identity, the presence of nonhomologous 
DNA flanking the homologous regions, and the selectable marker. The initial experiments 
performed by Kalpana et al. used both a linear and circular dsDNA AES [91], while Aldovini et 
al. used a circular suicide vector as an AES [3]. Using a linearized AES yielded up to ten-fold 
more colonies than the circular substrate and resulted in mostly illegitimate events in multiple 
studies [91,163]. It therefore appears from these experiments that: (1) using a circular AES yields 
lower numbers of recombinants compared to a linear AES, but these result from predominantly 
illegitimate recombination and single crossover events in M. bovis BCG and M. tuberculosis 
[3,91], (2) using linear AESs did not result in any identified homologous recombination events 
(single or double crossovers), only illegitimate events [91] in M. tuberculosis and M. bovis BCG, 
and (3) using circular AESs in M. smegmatis can facilitate both single and double homologous 
recombination events [82] with low amounts of illegitimate recombination [80]. Later 
experiments with linearized AESs were somewhat successful in M. tuberculosis and M. bovis 
BCG for making double crossover mutants, although at low frequencies (~4%) [8,188]. 
Balasubramanian et al. succeeded in making gene replacements in leucine biosynthetic 
genes using long (40-50 kbp) linear AESs [9]. Genomic cosmid libraries of M. tuberculosis 
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H3Rv and M. bovis BCG were constructed, and interplasmid recombination in E. coli was used 
to make the kanR-marked disrupted leuD allele. In this case, transformants were obtained equally 
with linear or circular cosmid AESs, but leucine auxotrophs were only found with the linear 
AES; 6% double crossover mutants were identified. While this was a successful method, it was 
time-consuming, and another group demonstrated similar frequencies (4%) of double crossover 
using linear AESs with short (>1 kbp) homologies [188], albeit at a different locus. 
Since low levels of spontaneous resistance to kanamycin occur in slow-growers [91], 
others have used different antibiotic resistance genes such as hygR, gentamicin resistance (gentR), 
streptomycin resistance (strR) and even mercury resistance as markers [14,15,82,147,159,161]. 
However, these methods did not generally improve the recovery of double crossover mutants. It 
was also suggested that the presence of nonhomologous sequences flanking the homology 
targeting the gene might increase the propensity for the AES to undergo illegitimate 
recombination [3,91], although this has not been tested rigorously.  
1.1.5.2 Treatment of the AES 
Neil Stoker’s group has shown that treating the DNA substrate with agents that promote 
the formation of single-stranded DNA (ssDNA) improves the frequency of homologous 
recombination in M. smegmatis, M. intracellulare, and M. tuberculosis [80,158]. The most 
effective experiments utilized treatments with alkali or by boiling to denature the DNA, or 
merely used ssDNA derived from phagemids. In experiments with ssDNA AESs, not only were 
transformant numbers typically increased, but also the proportion that had undergone double 
crossovers. Importantly, the use of phagemid DNA eliminated the recovery of illegitimate 
transformants.  
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1.1.5.3 Plasmid delivery of the AES 
Numerous groups have also made allelic exchange mutants in mycobacteria using either a 
circular or linearized suicide vector [3,8,121,159,184,188]. These are plasmids that rely on 
integration via homologous recombination for maintenance in the mycobacteria, either through a 
single crossover (in which the entire plasmid is integrated) or double crossover (in which the 
targeted chromosomal gene is replaced by the disrupted gene) (see Figure 1). Despite the high 
frequency of illegitimate recombination in the slow-growers, homologous recombination using 
these substrates is still relatively successful. Further, although single crossovers occur at a higher 
frequency than double crossovers, single crossover mutants can be propagated and screened for a 
second recombination event between the duplicate sequences to loop out the excess vector 
(Figure 1); however, this does not occur at a high frequency [91]. Plasmids with multiple cloning 
sites flanking different antibiotic markers were constructed to simplify synthesis of the AES 
suicide plasmid [159], but the screening was still labor-intensive. The development of a two-step 
counter-selection strategy (discussed below) greatly improved this by reducing the number of 
transformants screened. 
Since the frequency of homologous recombination is lower than the transformation rate 
in mycobacteria, large quantities of DNA are required for transformations (up to 4 g). The use 
of a replicating vector for delivery of the AES could arguably work better than a suicide vector, 
since extended survival of the plasmid would likely improve the frequency of recombination 
with the target. A replicating plasmid was used in one study, but did not result in a stable mutant 
allele of the targeted gene accBC in M. bovis BCG. However, the reason for this is unknown 
since PCR and Southern blot analysis confirmed that homologous recombination with the AES 
had occurred [147]. Another group developed a technique called STORE (selection technique of 
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recombination events) that uses a replicating plasmid with a promoter-less kanR gene targeted to 
the M. bovis BCG hsp60 locus for replacement of the hsp60 gene [15]. Selection for KanR 
therefore yielded recombinants that had undergone homologous recombination at the hsp60 
locus, which placed the kanR gene under control of the constitutive hsp60 promoter. However, 
extension of this technology for targeting other loci would require that the gene is expressed.  
One concern with replicating vectors is removing the plasmid; temperature-sensitive 
plasmids offer an advantage here, but for best results in the slow-growing mycobacteria these are 
combined with SacB counter-selection (examined in more detail below) [169]. Pashley et al. 
made use of incompatible plasmids to facilitate removal of the plasmid following gene 
replacement [161]. This technique uses a pair of plasmids that replicate co-dependently and are 
lost in the absence of selection. The plasmid carrying the AES can therefore undergo targeted 
gene replacement.  However, this method like many others requires multiple rounds of selection, 
growth, and plating, making it less efficient than other techniques. 
1.1.5.4 The counter-selection strategy 
Husson et al. was the first to use counter-selection for allelic exchange in the 
mycobacteria (discussed in section 1.1.3.1). In this study, the pyrF gene in M. smegmatis was 
replaced with a kanR gene through a double crossover event. The mutant was selected by plating 
on 5-FOA, since loss of wild type pyrF confers resistance [82]. This technique was extended 
later by Knipfer et al. who used the pyrF gene as a selective marker in a pyrF strain for 
unmarked introduction of genes [97]. Since this is therefore limited to the pyrF locus, broader 
strategies were developed. Another useful counter-selection strategy is the introduction of the 
wild type rpsL gene (rpsL+) in a strain with a specific rpsL mutation that confers streptomycin 
resistance (StrR) [196]. Plating a strain that contains both wild type and mutant alleles on 
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streptomycin selects for loss of the wild type rpsL gene. Therefore when rpsL+ is placed on a 
suicide AES, double selection on streptomycin and kanamycin (e.g., if kanR is the disrupting 
genetic marker) results in generation of predominantly double crossover gene replacement 
mutants in M. bovis BCG. However, this requires the use of a StrR resistant strain background, 
which is not ideal for vaccine development. 
The B. subtilits sacB gene has been extremely useful as a counter-selective marker in 
mycobacterial genetics. The presence of the sacB gene causes sensitivity to sucrose, and 
therefore plating on sucrose selects for loss or mutation of the gene (Figure 3) [166-168]. Allelic 
exchange mutants that are the products of double homologous recombination events can be 
obtained in a single step by dual positive and negative selection with antibiotics and sucrose at 
100% efficiency. Alternatively, if this is unsuccessful, allelic exchange can be performed in two 
steps, in which single crossover mutants are selected by antibiotic resistance, followed by 
removal of the vector sequence by a second crossover event, selected by plating on sucrose (this 
occurs in ~two-thirds of the colonies screened). This strategy can also be used to make unmarked 
mutants; in this case, γδ resolvase sites are placed flanking the antibiotic marker and sacB, and 
recombinants from expression of the resolvase can be selected by sucrose resistance (Figure 3). 
The sacB gene has also been used for very effective gene replacement (100%) on replicating 
temperature-sensitive plasmids as AES delivery vehicles: it ensures loss of the plasmid by 
shifting to high temperature and plating on media with sucrose [169]. 
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Figure 3. Gene replacement by counter-selection with sacB. 
 
 
Figure 3. Genes (yfg: your favorite gene) targeted by using sacB on the vector DNA result first in a (A) single 
crossover and then loop out the vector, or a (B) double crossover in vectors which contain the sacB gene on the 
backbone. Simultaneous selection for antibiotic resistance (e.g. KanR) and sucrose resistance can yield either (C) 
removal of the vector containing sacB or (D) mutation of sacB. (E) Unmarked mutations can also be generated by 
using γδ resolvase: res sites are placed flanking the antibiotic resistance gene (e.g. kanR) and sacB (instead of it 
being on the vector backbone). 
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1.1.5.5 Specialized transduction 
Delivery of the AES by phage infection, a method called ‘specialized transduction,’ has 
proven to be a successful method for targeted gene replacement [14]. This was accomplished by 
the development of shuttle phasmids, which are chimeric DNA molecules that replicate as 
plasmids in E. coli and phages in mycobacteria [86]. Phasmids contain phage genomic DNA 
with an E. coli plasmid inserted in a non-essential region of the genome (Figure 4). They can 
therefore replicate as plasmids in E. coli and as phages in mycobacteria. This technology was 
developed by Jacobs et al. using mycobacteriophage TM4, and later mycobacteriophages D29 
and L1 [86,164,210]. The most commonly used shuttle phasmid is phAE87, which is a TM4 
shuttle phasmid containing a temperature-sensitive mutation that allows phage propagation at 
30°C but not at 37°C [13]. Shuttle phasmids have been used not only for delivery of transposons 
and expression of reporter genes, but also for delivery of AES for targeted gene replacement in 
both the fast- and slow-growing mycobacteria [13,14,88,164].  
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Figure 4. Construction of TM4 shuttle phasmids. 
 
 
 
Figure 4. Construction of the parent shuttle phasmid. Phage DNA is ligated together via the sticky ends of the 
genome to form concatemers, and these are partially digested with a frequently-cutting restriction enzyme (such as 
Sau3AI) to cut minimally in the genome. Fragments ~45 kbp in length are ligated to an E. coli vector (digested with 
an enzyme leaving a compatible site) that contains a phage λ cos site for packaging and an ampicillin resistance gene 
(ampR). These molecules are packaged into λ phage heads in vitro, E. coli cells transduced, and colonies are selected 
on ampicillin. Pools of E. coli colonies are made and DNA isolated; this is transformed into mycobacteria and cells 
are plated as top agar lawns. DNA constructs that form plaques and retain the E. coli plasmid are true shuttle 
phasmids. 
 28 
For gene replacements, a canonical AES is constructed by cloning ~1000 bp of upstream 
and downstream homology to the target gene flanking an antibiotic marker (typically kanR or 
hygR). This can be directly cloned into a parent shuttle phasmid such as phAE87 to replace the 
existing E. coli plasmid sequences, and shuttle phasmid molecules containing the AES are 
prepared. A mycobacterial culture is then infected with mycobacteriophage-packaged shuttle 
phasmids at a non-permissive temperature for phasmid replication, and this facilitates delivery of 
the AES and targeted gene replacement (Figure 5). This method has been used to make more 
than 300 gene mutants in M. tuberculosis (W.R. Jacobs, Jr., personal communication). 
Specialized transduction has also been used to construct a strain of M. tuberculosis containing a 
single defined point mutation in the inhA gene [232]. This was the first experiment in which a 
point mutation was placed in an endogenous gene in a wild type background, and is an example 
of the power of specialized transduction. 
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Figure 5. Targeted gene replacement by specialized transduction. 
 
 
 
 
 
Figure 5. Upstream and downstream regions of the target gene are cloned flanking an antibiotic resistance gene (e.g. 
hygR).  Shuttle phasmids for gene replacements are then constructed by using the parent shuttle phasmid (such as 
phAE87) and inserting the AES vector by restriction digest with Pac I and ligation. These are packaged into λ heads, 
E. coli infected and HygR colonies selected. The shuttle phasmid DNA is prepared and transformed into 
mycobacteria at permissive temperature (30°C) and resulting plaques are picked and lysates of phage prepared. 
Mycobacteria are then transduced with the phage at a non-permissive temperature (37°C) and the AES will undergo 
homologous recombination with the target in the genome yielding a gene replacement mutant. 
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In conclusion, a variety of techniques have been developed for gene replacement 
mutagenesis of M. tuberculosis with varying success. Each method has drawbacks that include 
time-consuming AES constructions or screening of large numbers of recombinant colonies. In 
other organisms, technologies for mutagenesis have been greatly improved through the use of 
phage-encoded recombination proteins. In particular, genetics in E. coli and related Gram-
negative bacteria have benefited enormously by exploiting these recombination proteins in a 
genetic system called recombineering. The following sections will discuss the recombination 
proteins of bacteriophages that promote single strand annealing homologous recombination and 
their use for development of host genetic tools. 
1.2 SINGLE STRAND ANNEALING PROTEINS 
Homologous and non-homologous recombinational repair of DNA is an extremely well-studied 
field that is exemplified by research in E. coli and bacteriophage λ [106]. Homologous 
recombination – the pairing and exchange of complementary strands – can be divided into two 
mechanisms: strand invasion and single strand annealing. The two classically defined 
mechanisms of RecA-dependent strand invasion are: the ‘daughter strand gap repair pathway’ 
involving the RecF ‘machine,’ and the ‘double-strand end repair pathway’ mediated by the 
RecBC complex (reviewed in Kuzminov 1999). Although alternative repair pathways exist that 
involve different combinations of the Rec proteins, it is clear that RecA plays a central role in 
recombinational repair of chromosomal lesions that occur during replication and DNA damage. 
The second major recombination pathway that appears to be conserved through 
eukaryotes is called the ‘single strand annealing pathway.’ As the name implies, single strand 
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annealing involves pairing of complementary single strands via a RecA-independent mechanism 
that is initiated at double strand breaks (Figure 6) [220]. These recombination proteins, called 
single strand annealing proteins (SSAPs), promote strand pairing, strand exchange, and strand 
invasion [17,69,114,129,145,193]. SSAPs are found predominantly in bacteriophages and in 
bacterial genomes in prophages, although they have also been identified in eukaryotes, including 
yeast and humans. The SSAPs comprise three superfamilies based on sequence conservation: (1) 
the Red /RecT family, (2) the Erf family, and (3) the Rad52 family [85]. It appears that these all 
have bacteriophage origins and are typically found adjacent to other DNA recombination or 
repair proteins, such as exonucleases. These groups of proteins and their biochemical 
characteristics will be explored in this section. 
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Figure 6. Single strand annealing pathways. 
 
 
 
 
 
 
 
 
 
 
Figure 6. SSAPs can catalyze recombination by three basic mechanisms: (A) strand pairing, (B) strand exchange, 
and (C) strand invasion. The partner exonuclease (RecE or Exo) degrades a dsDNA end 5-3 leaving behind a 3 
ssDNA tail. This is bound by the SSAP (RecT or Beta) and recombined with its homologous target sequence. 
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1.2.1 Single strand annealing protein families 
The founding members of the SSAP superfamilies – λ Beta, Rac RecT, P22 Erf, and yeast Rad52 
– have been extensively characterized genetically, biochemically, and structurally, leading to the 
general concept that these proteins are functional analogues and ‘structural homologues’ [162]. 
These ‘recombinases’ form ring structures, bind ssDNA and dsDNA, and catalyze pairing, strand 
exchange, and strand invasion [162,174,204,224]. Although no sequence similarity was initially 
observed between any of the founding members, they were shown to fall into three 
evolutionarily defined superfamilies [85].  The ‘Red /RecT superfamily’ is comprised of the 
bacteriophage λ Beta (Red ) and the E. coli Rac prophage RecT proteins. RecT and Beta have 
no apparent sequence similarity but function analogously such that RecET can substitute for 
Exo/Beta for phage λ recombination [66]. PSI-BLAST analysis with Beta homologues from 
numerous other lambdoid phages retrieves the RecT protein and its homologues. Sequence 
analyses further revealed several conserved residues as well as secondary structure predictions 
that correlate well with some of their biochemical properties, such as Mg2+-dependent ssDNA-
pairing and dsDNA binding activities [96,145]. Further, λ Beta homologues are present in 
numerous diverse bacteria and phages, while RecT-like proteins appear predominantly in low 
G+C% Gram-positive bacteria and phages. Two proteins found in this superfamily – E. coli 
EHAP1 and Borrelia hermsii PF161 – have an unusual domain structure; the N-terminal domain 
is similar to the Beta/RecT family, while the C-terminus is similar to the Erf family. 
The bacteriophage P22 Erf protein has also been described as a SSAP and defines another 
superfamily [85,178]. Conserved motifs have been identified in these proteins, and much like the 
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Beta/RecT family, they seem to have originated in bacteriophages and subsequently appeared in 
bacterial genomes as prophages. P22 Erf can also substitute functionally for λ Beta [175].  
The third small superfamily of both eukaryotic and bacterial SSAPs was identified by 
database searches with eukaryotic Rad52 proteins. Rad52 from yeast and humans has been 
shown to act as a SSAP in conjunction with the RecA ortholog Rad51 [17]. Sequence alignments 
and structural predictions detect a conservation of two large motifs and other structural elements 
(including two putative helix-hairpin-helix folds) in both eukaryotic and bacterial Rad52s, 
indicating that they all belong to a single superfamily [85]. Although these proteins have been 
characterized biochemically, the following sections will focus on the bacteriophage systems of 
phage λ, E. coli Rac prophage, and P22. 
The genes adjacent to the SSAPs are commonly predicted to be DNA recombination or 
repair proteins [85]. These include single-strand-binding protein (SSB), Holliday junction 
resolvases, and nucleases, specifically exonucleases like λ Exo and RecE, which are found with λ 
Beta and RecT, respectively. Most of the exonucleases fall in two families, the type II restriction 
enzyme fold (e.g. λ Exo) and the type EndoVII fold. This suggests that SSAPs work in 
conjunction with their partner proteins in recombination and recombinational DNA repair. 
However, in some phages, the SSAPs and exonucleases are mixed, which is unexpected given 
the apparent specificity of the exonuclease-SSAP protein interaction observed with the λ Red 
and RecET systems [142]. For example, in several phages, a gene encoding a λ Exo-like protein 
is located next to a RecT-like gene. Additionally, SbcC-like genes are adjacent to both RecT- 
and λ Beta-like genes. In one unique case, a Beta-like gene was fused to a C-terminal fragment 
of the P22 Erf gene (Borrelia hermsii circular plasmid pf161 gene). Also, the order of the genes 
within the operon differs between phages such that either the SSAP or its partner gene may be 
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transcribed first [43,85]. Collectively, the organization of these phage-encoded recombination 
genes reflects the modular structure that is characteristic of phage genomes. 
1.2.2 The Red recombination proteins 
The Red recombination system of bacteriophage λ was identified by the observation that 
bacteriophage λ could replicate in the absence of RecA [23]. Red- mutants (recombination-
deficient) were found to map to genes encoding the Exo and Beta proteins [181,207], which were 
shown to be required for the RecA-independent recombination observed in λ [206,207]. Red-
mediated recombination is stimulated by the presence of double-strand breaks that act as the 
substrates for Exo.  Exo is an ATP-dependent dsDNA exonuclease that degrades DNA in the 5 
to 3 direction at approximately 1000 bases per second [29,63,116,124] and leaves behind long 3 
ssDNA ends [79]. The enzyme requires a dsDNA end for activity and cannot degrade at nicks in 
DNA [28,29]. The structure of the active enzyme is a trimer that forms a toroid through which 
the dsDNA passes at one end and the resulting ssDNA substrate through the other [100]. 
The λ Beta protein is a SSAP that binds ssDNA substrates of lengths greater than 35 
nucleotides [144] that protects ssDNA from nuclease attack prior to synapsis [92,114,129]. Beta 
promotes renaturation of complementary ssDNAs [96,129], strand exchange (displacement) 
[114], and strand invasion [193] all of which have been studied as recombination mechanisms of 
the single strand annealing pathway. Following pairing of ssDNAs, Beta binds tightly to the 
dsDNA complex [114]. Electron microscopic analyses show that Beta – like RecT and P22 Erf – 
forms circular structures in the absence of DNA which increase in size and monomer 
composition in the presence of ssDNA. Beta also forms helical filaments in the presence of 
dsDNA [162]. The data from structural studies suggest that ssDNA molecules are actually 
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wrapped around the Beta toroid, perhaps to prevent ssDNA from forming secondary structure 
and maintaining a conformation such that the bases are exposed for strand pairing. Beta also 
interacts with other proteins as determined by co-purification which precipitate λ Exo [129,182], 
host ribosomal protein S1 [129], and RNA polymerase subunit NusA [231].  Beta interacts 
specifically with Exo [129], functioning to modulate its activity as it degrades linear dsDNA 
substrates [225], and this interaction cannot be mimicked with other functionally analogous 
exonucleases [142]. Another attractive idea is that Beta also functions to interact with 
transcription and translation factors, perhaps to remove these complexes in front of the 
exonuclease [106]. 
The third protein that acts with the Red system in λ, Gam, binds the RecB subunit of the 
RecBCD nuclease in E. coli, preventing it from binding to dsDNA ends and thereby inhibiting 
all known enzymatic activities of this complex [39,93,122,133,138,176]. It has also been shown 
to interact genetically with the gene product of sbcC, though this is less-well characterized [102]. 
Although Gam is not required for recombination activities of Exo and Beta in phage λ [53], it 
increases recombination by limiting host nuclease attack on linear dsDNA substrates 
[38,106,142,240,241]. Alternatively, strains of E. coli that are recBC sbcBC or recD (which 
are typically used for linear DNA transformation) show an increase in recombination of linear 
AESs, though not as high as observed using a Gam-expressing strain (20- to 800-fold increase) 
[135]. Numerous other bacteriophages are known to encode Gam functional analogues that 
inactivate or block host nucleases [195], and examples include the phage T4 protein gp2 
[6,115,208] and phage Mu Gam protein [2]. These proteins bind dsDNA ends and protect 
injected linear DNA from degradation by RecBCD. In addition, the phage P22 Abc1 and Abc2 
proteins work cooperatively to modulate RecBCD activity (discussed below). Therefore, 
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although the mechanisms of nuclease inhibition are different, the ultimate result is the protection 
of linear DNA ends from degradation by host nuclease.  
The Red genes exo and bet, along with gam, are expressed from the PL operon during 
early infection or upon induction of lysis of the prophage [38]. The Exo and Beta proteins are 
believed to play a role in phage λ infection during DNA replication by functioning to increase 
DNA synthesis [106], although this is still not well understood. Phage λ DNA molecules are 
replicated initially as circular molecules by theta replication, and this switches to rolling circle 
(sigma) replication and forms concatemers of linear DNA. Since initiation of DNA replication 
likely requires circular DNA (prior to concatemer formation), DNA synthesis could conceivably 
be increased through generation of additional circular genomes by Exo/Beta recombination 
[106]. Gam functions to inhibit the degradation of the linear concatemers of λ genomic DNA by 
the RecBCD nuclease [53]. Therefore the Red and Gam proteins are not essential for λ 
propagation but mutations in these genes result in fewer plaques [53]. The Red proteins also are 
involved in generalized transduction of λ, although at low levels compared to RecA [106]. 
Additionally, since the conditions that stimulate the lytic cycle of λ prophages may also cause 
DNA damage (such as ultraviolet light), the Red proteins could be important for repair of the 
resulting double-strand breaks [179]. Numerous studies have investigated the mechanism of 
recombination employed by phage λ [106], and it has been found that single strand annealing 
occurs in the absence of RecA, while strand invasion is favored in the presence of RecA [216].   
1.2.3 The Rac prophage RecET recombination proteins 
SSAPs were first described in E. coli as an alternative recombination pathway in a 
recBC strain [12].  Analysis of mutations that suppress recBC revealed a class of mutations that 
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map to the sbcA gene (suppressor of recBC) and activate expression of the recE and recT genes 
of the cryptic Rac prophage in the E. coli genome [34,68,105]. The RecE (ExoVIII) and RecT 
(RecET) proteins catalyze recombination independently of RecA similar to λ Exo and Beta and 
have been shown to be functional analogues. Specifically, mutants of λ deleted for the Red 
recombination genes were able to recombine only in E. coli strains that expressed the Rac 
prophage recE and recT genes (i.e. sbcA-) [63,66]. Although the two systems function similarly, 
recombination does not proceed when the paired proteins are mixed heterologously (e.g. λ Exo 
and RecT), and only RecE binds RecT in vitro, indicating that there is a specific interaction 
between the cognate proteins required for recombination [142].   
 The RecE enzyme – like λ Exo – is a highly processive ATP-dependent exonuclease that 
degrades linear dsDNA 5 to 3, cannot act at nicks or gaps, and has low but detectable activity 
on ssDNA [89,90,105]. RecE is a member of the RecB nuclease family of proteins: the C-
terminus of RecE is similar to the nuclease domain in the C-terminus of RecB, and mutations in 
the conserved critical residues of RecE either abolish or decrease nuclease activity [31]. 
However, the N-terminal 587 amino acids (full-length RecE is 866 amino acids) are not required 
for its exonuclease activity or recombination [33,119,142]. The SSAP, RecT, acts to pair ssDNA 
substrates and promote strand exchange and invasion [68,69,145], and exhibits properties of 
homology-recognition with RecA [146]. It was also shown to bind dsDNA in the absence of 
magnesium, whereas ssDNA binding is only decreased slightly by the presence of magnesium 
[145]. RecT protein monomers form open and closed rings in the presence and absence of 
ssDNA as well as nucleoprotein filaments with RecE on dsDNA [224]. Finally, unlike phage λ, 
the Rac prophage does not encode a Gam-like protein.  
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1.2.4 The P22 Erf, Arf, and Abc recombination proteins 
Much like λ, bacteriophage P22 encodes a homologous recombination system that functions 
through the single strand annealing pathway. However, unlike λ, recombination-mediated 
circularization of the linear genomic DNA upon entry into the host cell is required for DNA 
replication [237,238], and the phage proteins are therefore absolutely essential in recA strains of 
Salmonella [218]. Recombination-deficient mutants of P22 can also be complemented by the λ 
Exo and Beta proteins and vice versa [175,178]. The P22 recombination system is composed of 
Erf (essential recombination function), Arf (accessory recombination function), and Abc1 and 
Abc2 (anti-recBCD) proteins. Erf, the SSAP in this system, binds and protects ssDNA [131,173], 
promotes strand annealing [136], and forms ring structures [162,174]. It has also been shown to 
bind dsDNA under certain conditions [173], and in general appears to be biochemically 
equivalent to λ Beta and RecT. Arf is less well-characterized, but it is known to be required 
along with Erf for the recombination activity of P22, and is located adjacent to erf in the PL 
operon [177,203].  
The Abc proteins function to modulate RecBCD activity: they are not essential but 
phages lacking these are decreased in burst size [132]. Null mutations in recB of the host restore 
progeny levels to wild type [54], suggesting that they prevent the degradation activity of 
RecBCD much like λ Gam. It appears that Abc2 functions similarly to Gam but with distinct 
differences: Gam inhibits all activities of RecBCD [133], while Abc2 inhibits RecBCD 
recombination (dsDNA-exonuclease, ATPase, and helicase activities) but retains its 5 ssDNA 
exonuclease activity [134]. It therefore appears that P22 uses Abc2 to modulate and exploit the 
ssDNA exonuclease activity of RecBCD to synthesize recombinogenic substrates for Erf. 
Through binding to the RecC subunit, this Abc2-modified RecBCD complex was shown to 
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interact with λ Beta and substitute for λ Exo in Red recombination [136]. Therefore the Abc2-
RecBCD complex appears to have activity similar to λ Exo, RecE, and other 5-3 exonucleases. 
It is not clear yet what role the Arf and Abc1 proteins play, although Abc1 is not required for 
Abc2-RecBCD/λ Beta recombination of phage λ [136]. Further, it is unknown if one of the P22 
recombination proteins or a host protein such as SSB functions to protect the 3 ssDNA tails 
following degradation by Abc2-RecBCD.  Finally, while the λ Red recombination proteins Exo 
and Beta can work independently of Gam, it is clear that the mechanism of recombination in P22 
is different and requires its ‘Gam analogue,’ Abc2, for recombination. In fact, it appears 
functionally equivalent to both λ Exo and Gam by simultaneously inhibiting deleterious effects 
of RecBCD and taking advantage of its exonucleolytic activity in single strand annealing 
recombination.  
1.2.5 SSAP mechanisms of recombination in vivo: single strand annealing versus strand 
exchange 
Recombination by phage λ can proceed effectively in the absence of RecA [23,206,207], and 
both strand annealing and strand invasion activities have been shown in numerous in vitro 
reactions with only λ Beta or RecT proteins [69,96,114,129,145,193]. Yet, in different reports, 
the question as to which mechanism of recombination occurs in vivo has been contested 
[55,142,206,207]. Experiments investigating phage λ recombination have further implicated a 
role for RecA in some SSAP-mediated recombination such as strand invasion [64,96,129,178]. 
In studies where λ DNA replication is blocked, Red-mediated recombination is drastically 
reduced in the absence of RecA [215]. Thaler et al. showed that DNA replication of the λ 
genome was required to produce populations of dsDNA ends as substrates for the Red proteins 
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[222], which provided an explanation for λ Red recombination dependence on either DNA 
replication or RecA. Stahl et al. therefore carefully tested the two proposed mechanisms of Red-
mediated recombination in λ: (1) strand invasion, and (2) strand annealing. They found that the 
strand annealing was the predominant type of recombination (with low levels of strand invasion) 
in the absence of RecA, whereas Red-mediated strand invasion occurred in the presence of RecA 
[216]. Strand annealing by the Red proteins was observed at a high frequency during λ DNA 
replication. However, λ Red dependence on DNA replication was eliminated by the introduction 
of dsDNA breaks on the λ genome, although this slowed strand annealing [216].  These data 
suggest that DNA undergoing replication is an optimal substrate for single strand annealing 
promoted by Red proteins, and likely other SSAPs.   
1.3 RECOMBINEERING IN ESCHERICHIA COLI 
Recent advances in E. coli genetics have illustrated the utility of bacteriophages through 
the development of a simple yet powerful technique called ‘recombineering’: genetic 
engineering in bacteria using phage recombination proteins [38,223]. Recombineering facilitates 
numerous types of mutagenesis in E. coli through expression of the potent recombination 
proteins of either the λ Red or Rac prophage systems. Single strand annealing recombination 
mediated by these proteins occurs with small lengths of homology (<50bp) and therefore allows 
simple synthesis of substrates for mutagenesis. This is reminiscent of genetic techniques that 
have long been available in yeast, in which the double-strand break repair system – that includes 
the SSAP Rad52p – promotes recombination between short regions of homology [152]. 
Recombineering in bacteria can be used to target chromosomes, plasmids, and phage genomes 
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and has been expanded for use in other Gram-negative bacteria such as Salmonella, Shigella, and 
Vibrio [42,185]. In addition, modifications of bacterial artificial chromosomes (BACs) by 
recomineering in E. coli has made a huge impact on functional genomic research 
[109,140,219,236]. This has simplified construction of mouse knockout constructs in BACs and 
high-throughput manipulation of genomic libraries by alleviating the time-consuming steps of 
traditional recombinant DNA cloning techniques [36,199].  Genetic engineering with ssDNA 
substrates has even been demonstrated in mammalian cells either expressing λ Beta or RecT 
[244] or in wild type cell lines [83,171]. Clearly this is a highly efficient system for genetics that 
is broadly applicable. 
1.3.1 Recombineering systems: λ Red and RecET 
E. coli recombineering systems have been successfully developed using both the λ Red/Gam 
proteins and the Rac prophage RecET proteins. This technique has far surpassed those previously 
available for targeted gene replacement by largely increasing the numbers of transformants that 
are recovered. Earlier methods used conventional AESs with large amounts of homology (>1 
kbp) that were typically transformed into recombination-proficient E. coli such as recBC 
sbcBC or recD strains [192], although this severely limited the strain background that could 
be utilized. In the first demonstration of recombineering, Murphy placed the λ exo bet genes in 
the chromosome of a recBCD strain background and showed a large increase (up to three 
orders of magnitude) in gene replacement frequencies, which was dependent on inducible 
expression of Exo and Beta [135]. It was also shown that a strain expressing Exo, Beta and Gam 
worked just as well as a recBCD strain expressing only Exo and Beta [135,137]; however, 
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expression of Exo and Beta in a wild type background was not sufficient to promote gene 
replacement without Gam or recBCD in this particular study [135]. Murphy’s ‘hyper-rec’ strain 
with the λ genes placed on the chromosome was more effective for recombination than strains 
containing the plasmid-encoded Exo/Beta, and therefore the decrease in copy number and level 
of protein expression in the chromosomally-encoded proteins was compensated [135]. One 
possible explanation for this was that perhaps the linear multimeric plasmids that undergo rolling 
circle replication compete with the linear AESs for Exo and Beta. 
Shortly following this study, Zhang et al. produced a similar tool for gene replacement in 
E. coli using the RecET proteins in combination with λ Gam on a plasmid [242]. This system 
was developed following the observation that gene replacements were obtained with short 
homologies (42 bp) only in sbcA E. coli strains, which express the RecET proteins from the 
Rac prophage.  The need for an easily transferable system was solved by expressing the recE and 
recT genes from a plasmid. Further, the λ gam gene was incorporated in place of using recBC 
strains.  
Numerous technical advances were applied to these two methods, but ultimately the 
system developed with λ Red by Donald Court and colleagues was preferable and is now the 
most commonly used. A modified λ prophage was used to tightly control expression of exo bet 
gam for short induction times while preventing cell death from prolonged expression [240]. 
Including Gam in the recombination system eliminated the need for recBCD strains and 
allowed high levels of recombineering in any strain background. These modifications eliminated 
problems with leaky expression that caused other undesirable recombination events and plasmid 
instability. While the λ prophage configuration is typically used, similar plasmid versions have 
been developed for use in E. coli and other bacterial systems [42], making the system more 
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mobile. The P22 system was also tested for its ability to promote recombineering in these assays 
but was found to be less efficient than the λ Red system [135], although this was not tested 
extensively. 
1.3.2 The recombineering strategy for mutagenesis 
Recombineering in E. coli has been successful for making several kinds of mutants: targeted 
gene replacements, point mutations, deletions, and small insertions [38,244]. The system can 
also be used for BAC modification, gene specific random mutagenesis, and in vivo cloning by 
gap repair [38,140,143,201,243]. Most applications of this system have been described in 
detailed protocols [7,38,42,201], though more are likely to appear in the future. Some of the 
more commonly used techniques such as targeted gene replacement and point mutagenesis will 
be discussed here in more detail.  
Several expression strategies were tested for optimal recombination activity. In one setup, 
RecT was placed under a constitutive promoter and RecE under an inducible promoter [242]. 
Stronger promoters (Ptac) increased expression five-fold but actually decreased recombination 
activity two-fold [137]. Observations such as this indicated that there is likely an optimal level of 
expression of the pair of recombination proteins, and it is suggested that a 5:1 ratio of Beta to 
Exo results in the highest level of recombination (K. Murphy, personal communication). Others 
have placed the exo bet genes under inducible control while keeping gam constitutively 
expressed [141]. However, the ideal configuration for the λ Red/Gam system was developed 
using a modified prophage that carefully controls expression through their native promoter for 
maximal recombination activity and minimal cell death [240]. This was accomplished by 
removing the lytic genes and using a temperature-sensitive allele of the λ cI repressor (cI857) 
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such that expression of the PL operon (including the λ exo bet gam genes) for less than 60 
minutes is tolerable. The strain is grown at 32°C then shifted to 42°C for 15 minutes to induce 
expression of the Red proteins, after which electrocompetent cells are prepared [201]. Although 
the protocols differ for each type of mutagenesis, the strain background is typically the cI857 λ 
defective prophage version, unless a plasmid encoding the λ Red genes is being used. 
1.3.2.1 Recombineering with dsDNA substrates 
Targeted gene replacement by recombineering eliminates the need for special 
recombination-proficient strains of E. coli and yields large numbers of colonies (>104) following 
transformation with an AES. Even the synthesis of the AES was made simpler by eliminating the 
need for cloning. Since the SSAPs can perform recombination with short substrates (>35 nt) 
[144], AESs can be made using PCR-generated substrates with short regions of homology 
flanking the antibiotic cassette (Figure 7) [242]. The distance between the homologies does not 
appear to affect recombination frequencies [242], while extending the length of homology from 
20 bp to 40 bp increases recombination by four orders of magnitude [240]. Extending the 
homology proportionally increases gene replacement frequencies mediated by RecET or λ 
Exo/Beta up through 1500 bp [142], though the difference between 40 bp and 1000 bp only 
increased Red recombineering frequencies 10-fold [240]. However, since small regions of 
homology are sufficient, substrates for targeted gene replacement typically include 50 bp of 
homology flanking a variety of antibiotic resistance genes [7]. Saturating amounts of the AES 
are reached at 100 ng, so this quantity of DNA is used in standard transformations [240].  
Counter-selection with sacB has also been used to generate unmarked deletions of genes 
following recombineering [137]. Further, this method for gene replacement can be used on either 
the chromosome or on plasmids [240]. 
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Figure 7. Strategy for targeted gene replacement by recombineering. 
 
 
 
 
 
 
Figure 7. (adapted from Court et al. [38]). Primers (75 nt) are designed such that 50 nt at the 5 end are homologous 
to the target gene (your favorite gene; YFG) and 20-25 nt at the 3 anneal to an antibiotic resistance gene. PCR 
performed with these primers yields a dsDNA AES product with 50bp homology flanking the antibiotic resistance 
gene. Transformation of this AES into recombineering cells induced for expression of λ exo bet gam yields targeted 
gene replacement mutants by homologous recombination.  
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 The dependence on host RecA, as well as on the individual Red proteins, was examined 
by measuring targeted gene replacement frequencies in strains missing any one of these 
[142,240].  A 10-fold drop was observed in recA strains, indicating only a modest role for 
RecA in λ Red-mediated recombination. Deletion of any one of the Red- or Gam-encoding genes 
results in zero transformants as compared to 4,000 in a strain with all three. The dependence on 
Gam or the requirement for a recBCD strain was observed in other studies [135,142]. However, 
a recent study showed that Gam is not required for recombineering of dsDNA substrates, 
although it increases recombineering frequencies ~10-fold [43]. 
1.3.2.2 Recombineering with ssDNA substrates 
Point mutagenesis by recombineering was an important development that requires the 
simplest of manipulations. The ability to construct single nucleotide changes has numerous 
applications, including the study of specific amino acid effects on protein function and structure. 
This has been accomplished in E. coli on the chromosome, plasmids, and BACs using short 
ssDNA substrates [52,219]. Since SSAPs – like λ Beta – can bind and recombine short segments 
of ssDNA, point mutations can be made with synthetic ssDNA substrates. Oligonucleotides are 
synthesized containing a point mutation and are transformed into electrocompetent 
recombineering cells induced for λ Red/Gam expression. Point mutations by ssDNA 
recombineering are incorporated at a sufficiently high frequency to eliminate the need for 
selection (as high as 6% of the total survivors of electroporation in some experiments [52]). 
However, this number seems to be achieved only rarely, and more typical frequencies are 0.1% - 
0.5%. Alternative strategies for introduction of point mutations have been developed that include 
a selection step [141]. The target gene is marked first with an antibiotic resistance gene and sacB 
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by targeted gene replacement. This allele is subsequently targeted by recombineering using a 
ssDNA that deletes the selection markers and simultaneously incorporates a point mutation; 
negative selection for cells that have lost sacB, which are able to grow on sucrose, identifies the 
mutant recombinant. Other strategies for identifying point mutants exist, such as the use of 
specialized PCR screens (mismatch amplification mutation assay; discussed in section 3.4.6) and 
inactivation of mismatch repair. 
Recombineering can also be used to make deletions and small insertions. Deletion of the 
galK gene using a ssDNA substrate was shown to be as efficient as making a point mutation 
[52]. These ssDNA substrates can also be used to delete larger regions; this is particularly useful 
for the removal of antibiotic resistance and sacB genes in mutant strains [223]. Small insertions 
can be made, although the frequency of recombination decreases as the length of the insertion 
increases (tested up to 60 nt) [244]. The recombineering technology can likely be used for 
numerous other applications, and more developments will probably arise in the future. 
The frequency of incorporation of point mutations is highly correlated with the activity of 
the E. coli methyl-directed mismatch repair (MMR) system [37]. Since the MMR proteins 
function to correct errors during DNA replication, repair of the recombineered point mutation 
back to wild type can occur at high frequencies by MMR. Elimination of MMR by mutation of 
mutH, mutL, mutS, uvrD results in an increase in ssDNA recombineering (25- to 60-fold). 
Recombineering frequencies with ssDNA were found to correlate with the pattern of MMR 
activity, such that certain mismatches are more frequently corrected than others. Ultimately, 
mutS strains are recommended for increasing ssDNA recombineering frequencies  for point 
mutagenesis in up to 25% of viable cells following transformation [37]. 
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The dependence of ssDNA recombineering on the length of the ssDNA substrate has also 
been tested. In one study, maximal numbers of point mutants were obtained in strains expressing 
Beta with a 70 nt substrate; shortening these to 60, 50, or 40 nt resulted in a large drop in 
recombination frequency (approximately four orders of magnitude), and lengths of 20 nt did not 
recombine [52].  The 10-fold decrease in recombination observed with oligonucleotides 
shortened from 40 nt to 30 nt [52] likely reflects the length requirement for Beta binding to 
ssDNA (36 nt) [144]. RecT was also found to recombine longer ssDNAs substrates more 
efficiently (>30 nt) [244]. In addition, homology was required on both sides of the point 
mutation, and placement of the point mutation at either the 3 or 5 end of the ssDNA substrate 
did not produce recombinants [244]. However, shifting the point mutation toward the 3 end such 
that more homology was present on the 5 side was more successful than the opposite scenario. 
These data suggest a requirement for binding of the SSAP on both sides of the substrate. It is 
also noteworthy that annealing two complementary oligonucleotides did increase recombineering 
frequencies slightly in some assays compared to using either oligonucleotide independently 
[244].  
A variety of mutant host strains were tested by Zhang et al. to determine the contribution 
of host recombination proteins, and it was found that strains with sbcBC mutations were more 
deficient for ssDNA recombineering than wild type [244]. In contrast to targeted gene 
replacements with dsDNA substrates, recombineering of a ssDNA substrate was not at all 
dependent on RecA [52,244].  
It has been demonstrated that only λ Beta (or RecT) is necessary and sufficient for 
ssDNA recombineering [52,241,244]. However, another study with RecET and λ Exo/Beta 
showed a slight increase in frequency when the cognate exonuclease was included with the 
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SSAP [244]. This is further evidence of a specific protein-protein interaction between these pairs 
of proteins [142].  Since SSAPs are found in a plethora of prokaryotes and eukaryotes, it was 
postulated that this type of recombination could be extended into other systems, and indeed it 
was shown that both λ Beta and RecT function in mouse ES cells to promote ssDNA 
recombineering [244]. The P22 Erf protein was also shown to function in ssDNA 
recombineering similar to λ Beta and RecT, although the P22 system was not found to support 
dsDNA recombineering [244]. In one study, deletion of gam resulted in approximately a five-
fold decrease in ssDNA recombination frequency [52]. It is not clear why Gam is required for 
maximal recombination since Beta binds and protects ssDNA from nuclease attack. Yu et al. 
hypothesized that perhaps the ssDNA nuclease activity of RecBCD still has a slight negative 
effect. This observation was contradicted by another study in which no difference in ssDNA 
recombineering was found in the presence or absence of RecBC or λ Gam [244].  
A strand bias was observed in correlation with ssDNA recombineering frequencies. 
Using oligonucleotides that anneal to both strands of the chromosome at six different loci, it was 
found that the oligonucleotide that annealed to the template for lagging strand (discontinuous) 
DNA replication (referred to as the ‘lagging strand’) was most efficient [52]. The biases toward 
ssDNAs targeting the lagging versus the leading strand ranged from 2- to 50-fold. This supports 
the hypothesis that the direction of DNA replication at the target locus directly influences the 
recombination frequency of ssDNAs, since the lagging strand likely has more single-stranded 
regions exposed to which a ssDNA substrate (bound by Beta) could anneal and recombine [38]. 
However, other cellular processes such as transcription, MMR, or other DNA repair systems that 
function with strand-specificity could conceivably generate exposed regions of ssDNA for 
pairing predominantly one strand at a particular locus, resulting in a strand bias. Numerous 
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reports that examined recombination with ssDNA substrates in yeast and mammalian cells 
present data that transcription plays a large role in the strand biases [83,117]. Therefore, Li and 
colleagues examined the effects of these different factors on ssDNA recombination [113].  They 
conclude that, in E. coli, MMR and DNA replication are the major contributors to the observed 
strand biases, with little to no influence from other cellular processes such as transcription.  
Therefore, the current model for ssDNA recombination in E. coli, the ‘annealing-
integration’ model, suggests that the ssDNA anneals to the lagging strand and DNA polymerase 
and ligase complete the reaction to join this ssDNA to the template (Figure 8A). Further, 
sequence-specific effects can be dominant to the role of DNA replication for mutations that are 
corrected by the MMR system. This model could also be extended to examine recombination of 
dsDNA substrates, in which the resected, SSAP-bound 3 ends could also anneal to the lagging 
strand during DNA replication [38]. Previously, it was thought that dsDNA substrates were 
recombined either by strand annealing or strand invasion [106], but these mechanisms imply an 
indirect role for DNA replication to provide exposed ssDNA surfaces for recombination. 
Alternatively, while recombineering of dsDNA substrates is likely different than that which 
occurs with λ phage DNA recombination, a direct role of DNA replication would connect 
observations made of the two processes.  
One model that has more experimental support is called the ‘replisome invasion and 
template switch’ mechanism (Figure 8B) [180]. This suggests that the SSAP-bound 3 ssDNA 
end that is annealed to the lagging strand actually becomes a template for continuous (leading) 
strand synthesis. Replication continues through this substrate, and the lagging strand portion of 
the fork is released. However, this leaves several subsequent details unresolved, such as the fate 
of the unreplicated lagging strand half of the fork. A more likely model suggests that replication 
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does not continue through the substrate, but terminates at the dsDNA junction, and is completed 
by ligation (not shown). Following this, recombination of the second resected end results in 
replacement of the wild type template with the dsDNA substrate (K. Murphy, personal 
communication). These models are both currently being further tested. 
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Figure 8. Models for the mechanism of ssDNA and dsDNA recombineering. 
 
 
Figure 8. Models for how recombineering substrates might be incorporated during DNA replication. (A) During 
ssDNA recombineering, the SSAP (e.g.Beta) forms a toroid around which the ssDNA substrate is wrapped, and Beta 
promotes strand pairing with the chromosome. This occurs preferentially with substrates that anneal to the lagging 
strand where an exposed ssDNA template may be more available. (B) The ‘replisome invasion and template switch’ 
model for dsDNA recombineering. dsDNA substrates are degraded by the 5’-3’ exonuclease (e.g. Exo), leaving 
behind a 3’ ssDNA tail bound by Beta. This anneals with the lagging strand, and is positioned in line with the 
replicating DNA fork. This becomes a template for leading strand synthesis, and the original chromosomal template 
is cleaved. This results in displacement of the lagging strand, and continuous replication proceeds through the 
dsDNA substrate. Presumably a similar reaction occurs at the second resected site. (adapted from Court et al. [38] 
and Poteete [180]) 
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1.4 SPECIFIC AIMS OF THIS STUDY 
The development of a simple and efficient system for genetics would greatly benefit the 
mycobacterial research community. Numerous factors inherent to mycobacterial cell growth and 
cell wall structure prevent simple handling and manipulation of the mycobacteria. However, the 
relatively high levels of illegitimate recombination compared to homologous recombination in 
M. tuberculosis and other slow-growers is the primary limiting factor to the application of 
conventional genetic techniques in these bacteria. The current methods for targeted gene 
replacement are designed to circumvent illegitimate recombination by modifying the AES or its 
delivery into the host cell. It is striking, however, that none of these have focused on increasing 
the levels of homologous recombination within the bacterial cell. The historical success of 
adapting mycobacteriophages and their proteins for manipulation of their mycobacterial hosts 
has led to the hypothesis that mycobacteriophage-encoded recombination proteins could be 
introduced into the mycobacterial cell to improve the efficiency of homologous recombination 
and thereby promote allelic exchange for mutagenesis purposes. The success of the λ Red 
recombination system for recombineering in E. coli further supported this notion and provided a 
basis for initial experimental design. Therefore the focus of my thesis research has been to utilize 
mycobacteriophage-encoded recombination proteins to develop a recombineering system for the 
mycobacteria. 
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1.4.1 Specific Aim 1: Bioinformatic and biochemical analysis of mycobacteriophage 
Che9c-encoded RecET homologues. 
Mycobacteriophage-encoded homologues of the E. coli Rac prophage RecET proteins are rare in 
mycobacteriophages; only Che9c was found to encode homologues of both. In vitro biochemical 
analysis of Che9c gp60 and gp61 demonstrates that they possess exonuclease activity and DNA 
binding activities, respectively, similar to RecET. These data are presented in Chapter 2, and 
some of the experiments have been published [227]. 
1.4.2 Specific Aim 2: Development of a mycobacterial recombineering system using 
mycobacteriophage Che9c-encoded recombination proteins. 
Che9c gp60 and gp61 have biochemical properties reminiscent of a coordinated recombination 
system that functions via the single strand annealing pathway. Expression of these proteins in 
mycobacterial strains yields a substantial increase in homologous recombination. This has 
provided an efficient genetic tool that has been successfully used to construct gene replacement 
mutants and point mutants in the genomes of both M. smegmatis and M. tuberculosis, and likely 
is applicable to other mycobacterial species. Chapter 3 describes the development of the 
mycobacterial recombineering system and the various technical applications, the majority of 
which have been published [227-229]. 
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1.4.3 Specific Aim 3: Identification of additional mycobacteriophage-encoded 
recombination systems. 
Sequencing of more than 50 mycobacteriophage genomes has revealed several additional gene 
candidates that may encode functional recombination proteins; these are present in the genomes 
of phages Giles, Halo, Wildcat, and also prophages in the genome of M. avium and 
Mycobacterium abscessus. In vivo analysis of several of the putative SSAPs, as well as λ Beta 
and RecT, demonstrate that the Che9c gp61 functions most efficiently in mycobacteria. 
Mycobacteriophage TM4 also appears to encode a recombination system, although the genes 
responsible have not thus far been identified by bioinformatic analysis. Experimental analysis of 
TM4 cosmid recombination sheds some light on the mechanism of TM4 recombination in vivo. 
These experiments and the implications of the results are discussed in Chapter 4. 
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2.0  MYCOBACTERIOPHAGE CHE9C ENCODES RecE AND RecT HOMOLOGUES 
2.1 INTRODUCTION 
Bacteriophages are an extremely diverse group of organisms, and at an estimated 1031 total 
phage particles, they are more abundant than any other life form in the biosphere [77].  Phages 
can be found in a variety of environments along with their bacterial hosts, and interactions 
between phages and bacterial populations foster copious amounts of genetic exchange. This 
contributes to a large pool of shared genetic elements [76] and has a significant impact on the 
evolution of bacteria, particularly on mechanisms of pathogenicity and acquisition of virulence 
genes [233]. Phages are often grouped based on their morphology, host-range, and other types of 
limited characteristics. However, it has become apparent that relationships among phages are 
better represented and understood through examination of their gene similarity and organization 
and by grouping them in ways that account for both their high level of diversity and the 
independent origin of their genes [108].   
Although the number of well-characterized phages is a miniscule fraction of the total 
population, more than 500 phage genomes have been sequenced to date [73]. A significant 
proportion of these include the group of phages that infect the mycobacteria: the 
mycobacteriophages. More than 50 mycobacteriophage genomes have been sequenced 
[73,126,165,170] (and G. Hatfull, unpublished data), revealing a mosaic architecture reminiscent 
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of that originally observed in the lamboid phages and in other phages [165]. In this way, when 
comparing phages, similar genes are often staggered amongst genes have been acquired in a 
different way, and are organized in a modular organization. The unique combination of genes 
and gene clusters in this manner – with little to no sequence homology at the gene boundaries – 
is evidence that illegitimate recombination plays an important role in genetic exchange of 
functional genetic elements [126]. An alternative hypothesis has been suggested in a recent study 
that homeologous recombination – recombination between sequences that are related but are 
divergent – contributed to genetic mosaicism in phage λ [123]. Further, Martinsohn et al. suggest 
that the λ Red recombination system contributes to this recombination substantially more than 
the host rec proteins. However, the contribution of this particular type of recombination may not 
be the common contributing factor in other phages, and the observations made in this article 
could be limited to a small number of phages. Since the presence and/or activity of these types of 
recombination systems has not been carefully examined in many phages, the effect and 
prevalence of homeologous recomibination is unclear.  
Bioinformatic analysis of mycobacteriophage genomes indicates that the genes encoding 
phage structural and assembly proteins are typically organized in similarly ordered operons, and 
therefore their function can often be inferred from previously characterized genes [165]. 
However, approximately half of the mycobacteriophage ORFs do not have detectable similarity 
to known genes from either phages or other organisms, and their function is unknown [71]. Of 
the mycobacteriophage genes that do have homologues, 90% of these are found in other 
mycobacteriophages, indicating that these organisms exchange DNA more frequently amongst 
themselves than with their bacterial hosts or other phages. A large proportion of the genes that 
have detectable similarity to known genes are found in multiple mycobacteriophages, while a 
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small number are homologues of genes from other organisms, including bacteria and other 
phages. Thus, sequencing of this relatively small number of phages has revealed a largely 
untapped reservoir of genetic information, suggesting that characterization of phage genomes is 
important not only to gain evolutionary perspectives, but also to explore and exploit the diversity 
of their gene pool. 
Phage-encoded SSAP genes are examples of the architectural modularity found in 
bacteriophage genomes [85]. Most SSAP genes in the phages of the λ Beta/RecT superfamily are 
situated adjacent to DNA recombination or repair genes, although the pairing and operon 
organization of these differ in each phage. Identification of E. coli Rac prophage RecET 
homologues in mycobacteriophages illustrates not only a mosaic architecture but also the 
relatively rare occurrence of these types of genes in mycobacteriophage genomes. Initially, out 
of 14 sequenced mycobacteriophage genomes [73], only Che9c was found to encode both RecE-
like and RecT-like gene products [165]. Further sequencing of mycobacteriophage genomes 
revealed additional ORFs with homology to proteins from known recombination systems, and 
these will be discussed in Chapter Four. Discovery of the Che9c recombination proteins 
suggested that these might be utilized to develop recombineering in the mycobacteria. Therefore, 
biochemical analysis was undertaken to examine the properties of the Che9c proteins to see if 
they function similarly to the RecET proteins.  
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2.2 BIOINFORMATIC ANALYSES OF MYCOBACTERIOPHAGES REVEALS A 
PUTATIVE RECOMBINATION SYSTEM 
 
Through BLAST analyses [4], it was observed that identifiable recombination systems are rare in 
the mycobacteriophages, and only one phage encodes proteins that are distantly related to RecE 
and RecT of the E. coli Rac prophage (Figure 9). Che9c gp60 shares 28% identity with the C-
terminal region of RecE. This encompasses a nuclease domain belonging to the RecB family, 
while the N-terminus of RecE is not necessary for its exonuclease activity [31]. The N-terminal 
two-thirds of gp61 (residues 28-237; Figure 9A) have 29% identity to RecT, whereas the C-
terminal third of gp61 (residues 238-353) only has detectable similarity to the corresponding 
region of a predicted M. avium RecT protein (discussed in Chapter Four) and no other known 
proteins. A multiple sequence alignment performed with Che9c gp61 and the proteins identified 
by Iyer et al. as members of the λ Beta/RecT superfamily shows conservation of a core domain 
(200 amino acids) and a similar predicted secondary structure (Figure 9B), indicating that gp61 
is indeed a member of this superfamily of SSAPs [85]. Much like the Rac prophage RecET 
system, no Gam homologues have thus far been identified in any of the sequenced 
mycobacteriophages. 
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Figure 9. Che9c gp60 and gp61 are RecET homologues. 
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Figure 9. (A) Che9c gp60 is a RecE homologue, while Che9c gp61 is a RecT homologue. Exonucleases are 
indicated in red, and SSAPs (recombinases) are indicated in green. E. coli Rac prophage genes and Che9c genes are 
transcribed from left to right, while the λ genes are transcribed right to left. (B) Multiple sequence alignments were 
performed with all protein sequences used by Iyer et al. [85], and conserved regions are shown. The T-coffee 
program was used to align Che9c gp61 (outlined in blue) with the λ Beta/RecT protein family members [148], and 
this was manually incorporated into the alignment made by Iyer et al. Secondary structure predictions (using JPred) 
for gp61 were also conserved (shown in blue at the top) [40]. Similar residues are highlighted that were found by 
Iyer et al. to be conserved greater than 85%: h, hydrophobic; l, aliphatic; a, aromatic; o, alcohol; c, charged; +. basic; 
-, acidic; p, polar; b, big; s, small; u, tiny. 
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2.3 PURIFICATION OF CHE9C GP60 AND GP61 PROTEINS 
To determine if the Che9c proteins function similarly to their RecET homologues, gp60 and 
gp61 proteins containing C-terminal 6x-histadine tags were over-expressed and purified from E. 
coli lysates by nickel-affinity chromatography. SDS-PAGE analysis indicated that purified 
samples of recombinant gp61 were nearly homogeneous, while recombinant gp60 samples 
retained small amounts of contaminating host proteins (Figure 10A). Therefore, a mock-
purification was performed with E. coli extracts from a strain containing an empty vector, and it 
was observed that these samples contained similar host proteins to the gp60 preparation (Figure 
10B). This mock-purified protein sample was used for biochemical assays alongside gp60 as a 
negative control. 
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Figure 10. SDS-PAGE analysis of purified Che9c gp60 and gp61 protein samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Recombinant gp60 and gp61 were over-expressed and purified from E. coli and samples analyzed by 
SDS-PAGE. Molecular weight (MW)  in kDa is indicated by the standard protein ladder. (A) Approximately 0.5 g 
of protein samples were loaded on this gel. Che9c gp60 (36 kDa) was purified to a concentration of 0.1 mg/ml (2.5 
M), although contaminating proteins were observed. Che9c gp61 (40 kDa) was purified to a concentration of 3.87 
mg/ml (96 M). (B) Eluates from mock-purified E. coli lysate from a strain containing an empty vector (control 
lysate) contains similar proteins that contaminate the preparation from E. coli lysates of strains expressing gp60 
(gp60 lysate). The mock-purified sample was used as a control for gp60 and was stored at a concentration of 4 
g/ml. Protein samples from the last two elutions from each lysate were dialyzed and stored. L, lysate; P, pellet; FT, 
flow-through; W, wash; E, elution. 
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2.4 CHE9C GP60 IS AN EXONUCLEASE 
Phage λ Exo and E. coli RecE are highly processive enzymes that degrade linear dsDNA in a 5 
to 3 direction [89,116]. To determine if gp60 has exonuclease activity, three in vitro assays were 
developed [227]. First, gp60 was observed to degrade short radiolabeled dsDNA substrates (100 
bp) similarly to λ Exo, while no degradation was seen in negative control reactions (Figure 11A). 
Notably, it was observed that serial dilutions of gp60 did not yield the expected step-wise 
decrease in activity, but rather even a 2-fold dilution resulted in very little degradation activity, 
which may be due to protein inactivation in dilution buffers. Because the observed activity of 
gp60 could conceivably also be attributed to a contaminating phosphatase that would remove the 
radioactive phosphate, a similar assay with linearized plasmid dsDNA substrates was used and 
visualized by agarose gel electrophoresis.  Incubation of gp60 with this dsDNA substrate also 
resulted in degradation, while negative control reactions with mock-purified protein did not 
(Figure 11B). Finally, the observed exonuclease activity was shown to be limited to substrates 
with dsDNA ends, since neither supercoiled or nicked open circle dsDNA substrates were 
degraded by gp60 (Figure 11C). These data demonstrate that Che9c gp60 has exonuclease 
activity similar to λ Exo and RecE. 
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Figure 11. In vitro assays demonstrate exonuclease activity of Che9c gp60. 
 
 
 
Figure 11. (A) Exonuclease activity was assayed by incubating Che9c gp60, λ Exo, or control protein extract with 
32P-labeled dsDNA (100 bp) for 5 minutes at room temperature, and the reactions analyzed by polyacrylamide gel 
electrophoresis. Reactions contained either no protein (–), or two-fold serial dilutions as indicated. Reactions with 
the highest protein concentrations contained Che9c gp60 at 0.2 μM or 5 U of λ Exo (NEB). The control protein 
extract was prepared from mock induced cells and the highest concentration corresponds to approximately 0.1 
μg/ml. (B) Exonuclease activity of Che9c gp60 (0.2 M), λ Exo (1 U/10 l), or control protein was assayed in 
reactions with a 3 kbp linearized plasmid DNA substrate (0.8 nM), incubated for increasing amounts of time (t = 0, 
2, 5, 7, or 10 minutes), and analyzed by agarose gel electrophoresis. The marker (M) indicates sizes in kbp. (C) 
Exonuclease activity of circular versus linear substrates was assayed. Che9c gp60 (final concentration 0.2 μM) or λ 
Exo (5 U) was incubated for increasing times (0, 5, and 10 min) similarly to (B) with a 3 kbp dsDNA substrate (2 
nM) that was either supercoiled closed circular or linear (as indicated) and the products analyzed by agarose gel 
electrophoresis. 
 68 
2.5 CHE9C GP61 BINDS ssDNA AND dsDNA 
The λ Beta and E. coli RecT proteins both have numerous biochemical characteristics that 
distinguish them as SSAPs, including the formation of multimeric structures and the ability to 
bind both ssDNA and dsDNA and perform strand pairing, exchange and invasion. Several of 
these attributes were tested with the gp61 protein to determine if it acts similarly to RecT [227]. 
First, the DNA binding activities of gp61 were measured using a double-filter binding assay 
[20,239], and these results were confirmed by electrophoretic gel mobility shift assays. Similarly 
to RecT [68], gp61 binds ssDNA with moderate affinity (Kd = 163 ± 12.5 nM) and is only 
slightly reduced in binding affinity in the presence of Mg2+ (Figure 12A,B). Che9c gp61 bound 
dsDNA with a slightly lower affinity (Kd = 211 ± 4.2 nM), but this is substantially reduced with 
Mg2+ (Figure 12C,D), much like what is observed with RecT [68,69,145]. It is also of interest 
that gp61 bound ssDNA substrates at lengths of 20, 44, 48, and 76 nucleotides (nt) with similar 
affinities (Figure 12E). This is different than what is observed with λ Beta; gel shift assays have 
shown that Beta does not bind substrates that are 17 nt or 27 nt long, although it can bind to a 
36mer [144]. Binding activity of gp61 was also observed by native polyacrylamide gel 
electrophoresis using both ssDNA and dsDNA substrates (Figure 12F), and quantification of the 
shifted bands reflects the binding affinities observed by filter binding analysis. 
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Figure 12. Che9c gp61 binds ssDNA and dsDNA. 
 
Figure 12. Purified gp61 protein at varying concentrations (0, 0.2, 0.3, 0.7, 1.3, 2.0, 2.7, 3.2 M) was incubated 
with 66.7 nM 32P-labeled ssDNA or dsDNA in binding assay buffer and analyzed either by double-filter binding 
assays (A-E) or native polyacrylamide gel electrophoresis (F). These experiments (without Mg2+) were repeated in 
triplicate for both ssDNA (A) and dsDNA (C) and the data analyzed on SigmaPlot to determine binding constants. 
Reactions were also assayed with ssDNA (B) or dsDNA (D) containing 0 mM MgCl2 (●), 5 mM MgCl2 (○), or 10 
mM MgCl2 (▼).  (E) ssDNA substrates of different lengths were tested (0 mM MgCl2) and are depicted in the 
legend. (F)  For gel shift assays, the same reactions from using either ssDNA (A) or dsDNA (C) were run on a 
native 8% polyacrylamide gel and analyzed. 
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It was observed that gp61-ssDNA complexes formed multiple distinct bands (at least 
four) in gel shift assays. These decreased in number as the concentration of protein was 
increased, and ultimately two large shifted bands were seen at a concentration of 2 M gp61. 
This suggested that gp61 might form a multimeric complex upon binding to ssDNA, and is of 
importance since the formation of toroidal multimers is a property exhibited by other SSAPs 
such as λ Beta and RecT [162,224]. Large ring structures composed of up to 18 subunits are 
formed by λ Beta in the presence of ssDNA, and smaller rings (~12 subunits) are observed even 
the absence of DNA.  Samples of gp61 were therefore prepared incubated with ssDNA substrates 
of several different lengths and analyzed these by electron microscopy. In the presence of even 
short ssDNAs (20 nt), gp61 formed small curved ‘c-shaped’ structures, although no structures 
were observed above background in the absence of DNA. As the length of the ssDNA increased, 
the size of the curved structures increased in diameter (Table 2), and many were circular in 
reactions with a 100 nt substrate (Figure 13A). The average diameter of the toroids formed by 
gp61 (14 – 16 nm) are similar to the diameter of the structures formed by λ Beta (18 - 21 nm) 
and RecT (18 nm) in the presence of ssDNA [162,224]. Both Beta and RecT also form helical 
filaments when bound to dsDNA [162,224], though this was not tested with gp61.  
 
Table 2. Size analysis of Che9c gp61 structures observed by electron microscopy. 
Length of ssDNA 
substrates (nt) 20 44 48 76 
Average diameter 
of particles (nm) 9.74  12.17 13.48 15.74 
Number of particles  
measured 10 14 13 11 
 
Che9c gp61 protein was incubated with ssDNA substrates of varying lengths (20, 44, 48, 76 nt), stained with uranyl 
acetate, and visualized by transmission electron microscopy. Measurements were taken across the diameter of 
multiple particles and averaged. 
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Like λ Beta, the E. coli RecT protein also forms multimers in the absence of DNA that 
are visible by electron microscopy, although no structures could be seen with gp61 using simple 
negative staining. Gel filtration analysis of RecT (originally called p33) indicates that it forms a 
tetramer [68]. Therefore, analytical gel filtration was used to determine the state of gp61 in 
solution. Three concentrations of recombinant gp61 protein were run on a Superdex gel filtration 
column that had been standardized with both low and high molecular weight proteins. As the 
concentration of gp61 was increased from 5 M to 25 M, the size of the complex increased. At 
5 M, gp61 eluted at a time corresponding to approximately 70 kDa, which is roughly twice the 
size of the predicted molecular weight of gp61 (40 kDa). At 10 M, it eluted at 102 kDa, and at 
25 M it eluted at 143 kDa. Although these data do not fit exactly with the predicted size of 
multimers of gp61 (e.g., 80 kDa, 120 kDa, or 160 kDa), the native molecular weight of the 
standards varied slightly on this column (±14 kDa) (Figure 13B). Thus, it appears that at the 
highest concentration tested, gp61 likely forms a tetramer, much like what has been observed for 
RecT (concentration not given for RecT experiment; [68]). Additionally, increasing the salt 
(NaCl) concentration in the buffer from 100 mM to 300 mM did not change the size of the gp61 
complexes eluted by gel filtration (data not shown). This indicates that the multimerization of 
gp61 in solution is not likely the result of non-specific protein-protein interactions; further 
anlaysis would be required to completely rule out this possibility. Reactions containing gp61 
incubated with ssDNA eluted in the void volume, indicating that they were larger than the pore 
size of this column, which is consistent with gp61-ssDNA complex formation (data not shown). 
Finally, while these data are not conclusive, they support the hypothesis that gp61 forms 
multimers in the absence of DNA. 
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Figure 13. Multimeric structures formed by gp61 in the presence and absence of DNA. 
 
Figure 13. (A) Electron micrograph depicting Che9c gp61 protein multimers in the presence of ssDNA. Reactions 
containing gp61 protein (1.2 M) incubated with ssDNA (100 nt; 1.9 M) were absorbed to copper grids, stained 
with 2% uranyl acetate and examined by transmission electron microscopy. Images were collected at a 
magnification of 140,000x; four examples of toroid structures are shown alongside a size bar for reference. (B) 
Protein standards (high and low molecular weight) were run on a Sephadex high-performance gel filtration column, 
elution times recorded, and the Kav value was determined for each standard. These were plotted against the 
molecular weight (on a logarithmic scale) and a trendline wasfit to the data; the equation and fit value are depicted 
on the graph. Using this equation, the elution times for each gp61 sample (5, 10, and 25 M) were calculated to 
determine the molecular weight of the native protein complex, and these were graphed on the trendline. 
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2.6 CONCLUSIONS 
The mosaic architecture commonly observed in bacteriophages is exemplified by phage-encoded 
SSAPs and their cognate exonucleases [85] in that there is no apparent consistency with the 
specific pairing of these proteins. Further, SSAP-exonuclease recombination systems are rare in 
sequenced mycobacteriophages. Bioinformatic analyses identified mycobacteriophage Che9c 
gp60 and gp61 as homologues of the E. coli Rac prophage RecE and RecT proteins. Finding 
these genes in mycobacteriophages was somewhat suprising; previous analyses found RecT-like 
proteins predominantly in the low GC% Gram-positive bacteria [85], while the mycobacteria 
have a high G+C% (~65-67%) [22]. However, the Che9c-encoded proteins were distantly related 
to the E. coli RecET proteins with less than 30% amino acid identity conserved. Similarly to the 
organization of these genes seen in other phages, the mycobacteriophage-encoded SSAP is 
located next to a predicted exonuclease.  
 Desite the weak identity observed for these proteins, the biochemical properties of Che9c 
gp60/gp61 support the finding that they are RecET homologues. Che9c gp60 has dsDNA 
exonuclease activity that does not act on circular substrates, which has been observed for RecE.  
Che9c gp61 binds ssDNA and dsDNA with affinities and Mg2+ dependencies similar to RecT, 
and it forms toroids in the presence of ssDNA. Interestingly, gp61 binds to ssDNA substrates as 
small as 20 nt with higher affinity than longer substrates. Although it is reported that Beta cannot 
bind substrates shorter than 36 nucleotides [144], more recent experiments indicate that it does 
indeed bind smaller lengths of ssDNA (D. Court, personal communication).  
 Numerous additional in vitro assays could be performed with each of these proteins to 
further characterize their activities, such as strand pairing and strand exchange assays for gp61. 
These assays were attempted but were not successful for control reactions. It would also be 
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helpful to analyze gp61 by native gradient gel electrohoresis to confirm the gel filtration data 
which suggest it is a trimer or tetramer in its native state. Also, RecT DNA binding is affected by 
salt (NaCl) concentrations greater than 50 M [145]. It was suggested that the varying salt and 
Mg2+ requirements for ssDNA and dsDNA binding may reflect different types of binding [145], 
which is supported by the observation that ssDNA- and dsDNA-gp61 complexes form toroids 
and helical filaments, respectively [224]. Additional experiments could therefore be performed 
with gp61 in buffers containing Mg2+ and/or NaCl to determine their effect on multimer 
formation. MgCl2 is absolutely required for formation of λ Beta multimers in the absence of 
DNA, and addition of Mg2+ to reactions with Beta and ssDNA appears to stabilize the formation 
of large rings [162]. However, Beta also requires Mg2+ for ssDNA binding [144], whereas RecT 
and gp61 do not [145]. In fact, RecT multimers are inhibited with high concentrations of MgCl2, 
though a low concentration (0.3 mM) is required for the formation of small circles but not rod-
like structures [224]. Therefore varying Mg2+ concentration or testing other cations might 
enhance gp61 multimerization, and this could be assayed in the future. 
 Collectively, the biochemical data clearly demonstrate that gp60 and gp61 function 
equivalently to the E. coli λ Red and RecET systems in all assays tested. Thus, these proteins 
have properties consistent with their utility as a means to develop a recombineering system in the 
mycobacteria using mycobacteriophage-encoded proteins.  
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3.0  DEVELOPMENT OF THE MYCOBACTERIAL RECOMBINEERING SYSTEM 
3.1 INTRODUCTION 
Recombineering is a widely used system for mutagenesis in E. coli [38], which has recently been 
extended to other Gram-negative bacteria, such as Salmonella and Shigella [42,185]. A variety of 
techniques can be performed with ease including gene replacements, point mutations, deletions, 
small insertions, in vivo cloning, and modifications of bacterial artificial chromosomes and 
genomic libraries [36,38,199]. Recombineering exploits the potent recombination activities of 
the λ Red proteins and is a simple means of increasing homologous recombination in the host 
bacterium with minimal DNA manipulations or screening.  
Recombineering is most commonly used for construction of allelic gene replacements 
and point mutations on either the bacterial chromosome or on BACs. Substrates for gene 
replacements contain an antiobiotic resistance gene of choice (and a sacB gene for counter-
selection if desired) with short lengths of homology to the gene target on either end (Figure 7) 
[223]. These strains can be easily unmarked with ssDNA substrates that have homology flanking 
the antibiotic and sacB cassettes with selection for sucrose resistance. Optimum numbers of 
recombinants (up to 105 out of 108 viable cells) are obtained with 100 – 300 ng of the AES. 
Recombination of the dsDNA AES substrates is dependent on Exo and Beta, and the addition of 
Gam increases recombineering efficiencies significantly [135,240].  
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Mutagenesis with ssDNA substrates is a particularly useful strategy that permits 
numerous types of mutations to be introduced into bacterial and phage genomes [52,151]. This 
recombination only requires the Beta protein, although some experiments have shown that the 
presence of Exo (even with ssDNA substrates) can slightly enhance recombination [244]. 
Maximal recombination frequencies are achieved with 70 nt ssDNAs [52], and these substrates 
are designed with the mutation(s) centered such that they anneal to the lagging strand for DNA 
replication, since these are more efficiently recombined [52].  
The E. coli recombineering strains that are typically used express the λ Red/Gam proteins 
under control of the temperature-sensitive repressor CI857 in a defective λ prophage. Following 
mutagenesis, the prophage can be removed or the mutation can be moved to a clean background 
by generalized transduction with phage P1 [223]. Alternatively, there are various versions of 
recombineering plasmids with temperature-senstive replicons that can be transferred into 
different strains and quickly removed [42]. These appear to work just as well as the prophage 
version, and can be used in other Gram-negative bacteria. Recombineering strains are induced at 
mid-logarithmic phase for 15 minutes and prepared for transformation; this expression time is 
optimal for recombineering but is short enough that cell death does not occur from the toxic 
effects of Gam [240].  
Clearly, the strategic use of the λ Red proteins to develop the widely-applicable 
recombineering technology in E. coli sets a precedent for improving genetic techniques in other 
bacterial systems. Mycobacterial researchers in particular would benefit enormously from a 
simple and efficient system for genetics – such as recombineering – that alleviates time-
consuming DNA manipulations and screening procedures. However, the λ Red proteins, while 
useful for E. coli and related Gram-negative organisms, reportedly are not functional in the 
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mycobacteria, which is not surprising considering the divergence between these two groups of 
bacteria. From the bioinformatic and biochemical data, the mycobacteriophage-encoded RecET 
homologues appeared to be the most likely candidates for developing a recombineering system 
for the mycobacteria. Accordingly, expression of the Che9c proteins gp60 and gp61 elevates 
homologous recombination in both fast- and slow-growing mycobacteria. This facilitates the use 
of recombineering-based strategies for mutagenesis of mycobacterial and mycobacteriophage 
genomes. This chapter will discuss the development of the Che9c-based mycobacterial 
recombineering system and its various applications. 
3.2 EXPRESSION OF CHE9C RECOMBINATION GENES IN VIVO 
In order to test the activity of Che9c gp60 and gp61 in vivo, various plasmids were constructed 
that express these genes in the mycobacteria (see Table 15) [227]. Although genes 59 and 62 
encode small proteins, it was possible that one of these might encode a Gam-like functional 
protein that is not identifiable by bioinformatic analysis. Therefore, this region of Che9c was 
cloned under the control of the M. smegmatis acetamidase promoter (Pacetamidase) [44,157] on an 
extrachromosomally-replicating parent vector (pLAM12) to create pJV24 (Figure 14). The 
acetamidase promoter is comprised of the upstream region of the M. smegmatis acetamidase 
gene regulon and terminates at the start codon of the acetamidase gene (amiE) [157,190]. 
Therefore, placing the start codon of a gene at this locus results in translation from the ribosome 
binding site (RBS) encoded by this cassette. Additional constructs were made in the parent 
vector pLAM12 containing only genes 60 and 61; in this case, gene 60 was under translational 
control from either its endogenous signals (pJV53; Figure 14) or those present in the acetamidase 
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promoter cassette (pJV63). Similar plasmids were constructed containing only gene 60 (pJV61 
and pJV55) or gene 61 (pJV52 and pJV62), either under their own translation signals or those of 
the acetamidase cassette, respectively. All of these plasmids were transformed into M. smegmatis 
for further assays. Genes 59-62 were also cloned under control of the constitutive M. bovis BCG 
hsp60 promoter (pJV23), but this plasmid did not produce transformants in M. smegmatis. It is 
also noted that M. smegmatis:pJV63 grows slowly and does not grow on plates in the presence of 
inducer (data not shown). This may be due to the somewhat toxic effects of gp60, since strains 
expressing only this protein (even in the absence of induction) grow slowly compared to empty 
vector control strains (data not shown). 
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Figure 14. Mycobacterial plasmids expressing Che9c genes. 
 
 
Figure 14. Plasmid pLAM12 is an extrachromosomally-replicating plasmid that contains a kanamycin-resistance 
gene and the acetamidase expression cassette (Pacetamidase), which has an inducible promoter and translation signals 
(ribosome binding site: RBS); placing the start codon of a gene at site NdeI results in a translational fusion to this 
RBS. For the plasmids shown, Che9c genes 60 and 61 were cloned separately or together downstream of Pacetamidase  
into the HpaI site with their endogenous RBSs included. Plasmid pJV24 was constructed similarly but includes 
genes 59-62. Several plasmids were constructed similarly to those shown by placing the Che9c genes at the NdeI site 
for translational fusion; these are not depicted.  
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Protein expression was monitored by western blot analysis for several of these strains 
with polyclonal antibodies generated against purified gp61 protein (Figure 15) [227]. All strains 
in which gene 61 was under control of Pacetamidase had detectable expression of gp61 after three hr 
of induction with acetamide. It was seen that some strains expressed more gp61 than others, 
although there was no correlation between expression levels and whether the endogenous 
translation signals or signals from the acetamidase cassette were used (Figure 15 A,B; compare 
strains with pJV53 to pJV63, and pJV52 to pJV62, respectively). Specifically, a strain with 
pJV62 (Pacetamidase RBS) had three-fold less gp61 expression than pJV52 (endogenous RBS), 
whereas the opposite was true for pJV53 (endogenous RBS) and pJV63 (Pacetamidase RBS). The 
strain expressing gp59-gp62 (M. smegmatis:pJV24) consistently showed expression of gp61 in 
the absence of acetamide (Figure 15A,C), and this may be due to leaky expression sometimes 
observed with this promoter in succinate medium [157]. This level of protein expression was not 
observed with any other M. smegmatis strain, and further there is no expression observed in 
media containing ADC (see Materials and Methods) that is reported to be repressive of this 
promoter (Figure 15D). Strains of M. tuberculosis containing the same plasmids were also tested 
for protein expression, and it was observed that there was much more leaky expression of the 
promoter in the absence of induction (Figure 15E).  
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Figure 15. Western blot analysis of mycobacterial strains expressing Che9c proteins. 
 
 
 
 
 
 
 
Figure 15. Strains of either M. smegmatis (A-D) or M. tuberculosis (E) containing various plasmids were grown to 
mid-log phase and samples split; one culture was induced with 0.2% acetamide, and both were grown for 3 hours. 
Cell aliquots were normalized to OD600 and samples were run on SDS polyacylamide gels and analyzed by western 
blot with polyclonal anti-gp61 antibodies.  
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Cultures of M. smegmatis mc2155:pJV24 repeatedly showed a slight decrease in viability 
(assayed by colony counts) after four hours of induction with acetamide that continued to decline 
up to 24 hours, whereas mc2155:pJV53 did not (Figure 16A and data not shown). This may be 
due to the increased levels of protein expression in mc2155:pJV24, as seen by western blot 
(Figure 16B), or alternatively could result from the expression of Che9c gp59 and/or gp62. The 
strain containing the empty control vector (mc2155:pLAM12) surprisingly grows more slowly 
than strains expressing Che9c genes. Ultimately, three hours of induction appeared to give 
adequate levels of protein expression without any potential toxic effects, and this also is 
approximately the length of time required for M. smegmatis doubling in this media. Therefore, 
these strains were tested for recombination activity in vivo using this induction procedure.  
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Figure 16. Growth curves and expression profiles of strains expressing Che9c gp60 and gp61.  
 
 
 
Figure 16. M. smegmatis strains containing plasmids pLAM12 (empty vector control), pJV24 (Che9c gp59-62), and 
pJV53 (Che9c gp60-61) were grown to mid-log phase and induced with 0.2% acetmide (time point 0 hours). (A) 
Cells were plated to determine viability (cfu/ml) and absorbance (OD600) readings taken every two hours. (B) 
Aliquots of each culture were removed at each time point, normalized to OD600, and analyzed by western blot 
analysis with antibodies against gp61.  
 84 
3.3 ALLELIC REPLACEMENT MUTAGENESIS 
3.3.1 Che9c gp60 and gp61 promote homologous recombination in vivo 
To determine if Che9c gp60 and gp61 can function in vivo to promote elevated levels of 
homologous recombination, M. smegmatis strains expressing these genes were transformed with 
a linearized AES targeting the leuD gene. Deletion of this gene confers leucine auxotrophy 
[14,81] and therefore facilitates a phenotypic assay for correctly targeted genes; growth medium 
without leucine only supports growth of recombinant colonies that are not correctly targeted for 
gene replacement. The AES tested contained ~1000 bp of homology to the leuD locus flanking 
hygR and sacB genes (Figure 17A). Strains M. smegmatis mc2155:pJV24 (expressing Che9c 
gp59-62) and M. smegmatis mc2155:pLAM12 (empty vector control) were transformed with 100 
ng of the leuD AES, and the reaction was split onto media with or without leucine. HygR 
colonies (43) were recovered on media containing leucine and only in the strain strain expressing 
Che9c gp60 and gp61, while no colonies were obtained on media lacking leucine or in the 
control strain (Figure 17B). This indicates that expression of Che9c genes increases homologous 
recombination above background levels and that each recombinant colony obtained was the 
result of a correctly targeted allelic exchange [227]. 
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Figure 17. Allelic gene replacement of the M. smegmatis leuD gene.  
 
 
 
 
 
Figure 17. [227] (A) An AES targeting M. smegmatis leuD is depicted in this schematic; plasmid p0004S:leuD 
contains ~1000 bp of homology flanking a hygR and sacB gene, and this was linearized by restriction digest. (B) 
Strains M. smegmatis mc2155:pJV24 and M. smegmatis mc2155:pLAM12 were grown to mid-logarithmic phase, 
induced with acetamide for three hours, and electrocompetent cells prepared. 100 ng of the leuD AES were 
transformed into these strains, recovered for four hours, and the reaction split onto media in the presence or absence 
of leucine.  
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3.3.2 Recombineering requires both Che9c gp60 and gp61. 
A similar assay targeting the M. smegmatis leuB gene was used to dissect the genetic 
requirements for recombination, and this demonstrated that expression of both Che9c gp60 and 
gp61 is necessary and sufficient for recombineering (Table 3) [227]. The presence of genes 59 
and 62 in plasmid pJV24 repeatedly yielded similar recombineering frequencies to plasmid 
pJV53, which expresses only genes 60 and 61 (Table 3 and Figure 19), and these two strains 
gave the highest recombineering frequencies. Interestingly, although pJV63 produces higher 
levels of protein expression than pJV53 (Figure 15A), this strain was reduced for recombination 
activity. Based on these data, strain mc2155:pJV53 was used for most subsequent experiments 
because it does not exhibit a viability defect phenotype. 
 
Table 3. Recombineering requires both Che9c gp60 and gp61. 
 
Strain (proteins encoded)a 
Recovered colonies 
w/leucine b 
Recovered colonies 
w/o leucinec 
Cell competencyd 
(cfu/g DNA) 
Recombineering frequencye 
(w/leucine) 
mc2155:pLAM12 (control strain) 0 1 5.8 x 105 0 
mc2155:pJV61 (gp60 only) 0 0 1.2 x 106 0 
mc2155:pJV52 (gp61 only) 0 0 6.0 x 105 0 
mc2155:pJV24 (gp59-62) 52 0 6.4 x 105 1.6 x 10-3 
mc2155:pJV53 (gp60-61) 57 1 1.4 x 106 8.3 x 10-4 
mc2155:pJV63 (gp60-61)f 7 0 4.8 x 105 2.9 x 10-4 
 
a. Each strain contains an extrachromosomally-replicating plasmid expressing varying combinations of Che9c gp60 
and gp61. 
b,c. Cells were transformed with 100 ng of an AES targeting leuB, and recovered cells were split on media with or 
without leucine supplement.  
d. Cell competency is determined as the cfu/g plasmid pPGA1, an integration-proficient vector providing 
hygromycin resistance, when 50 ng was transformed. 
e. Recombineering frequency (recombinant cfu/g DNA/cell competency) is shown for transformations with the 
leuB substrate (p0004S:leuB) and that are plated on leucine-supplemented media. 
f. mc2155:pJV63 expresses Che9c gp60/gp61 under control of the acetamidase promoter through a translational 
fusion to that cassette, in contrast to mc2155:pJV53 in which these genes are expressed from their endogenous 
signals. 
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3.3.3 Recombineering of the M. smegmatis groEL1 gene 
Recombineering of other loci had similar results to those obtained at the leuD and leuB loci, and 
genotypic analysis of the recombinants demonstrated that 90% or greater were correctly targeted 
[227]. First, the groEL1 gene was targeted using an AES with ~500 bp of homology on each end 
(Figure 18A), which was amplified by PCR using a circular AES as a template (see Figure 21A). 
Colony PCR analysis shows that each of the ten colonies tested in this example were allelic gene 
replacements of groEL1 (Figure 18B), and Southern blot analysis confirmed these results (Figure 
18C). Additionally, several groEL1 mutant strains constructed by recombineering exhibited the 
expected biofilm defects for this strain (data not shown) [149]. Shortening the homology lengths 
of the groEL1 AES resulted in a decrease in recombination, such that less than ten colonies were 
obtained with 50 bp homology regions (Figure 19), and only ~ 50% of these were correctly 
targeted (data not shown). Not surprisingly, there is a low level of recombination activity in the 
absence of induction due to leaky expression from the acetamidase promoter, which has been 
observed in these experiments and others (data not shown, and K. Derbyshire, personal 
communication). Extending the induction time from three hours up to ten hours only slightly 
increased recombineering frequencies (less than two-fold, data not shown); therefore a three-
hour induction was used for all subsequent experiments. This recombination activity is 
somewhat dependent on host RecA, since recombination frequencies were decreased five-fold in 
an M. smegmatis recA strain (Table 4); the effect of M. smegmatis RecA dependence was small 
compared to the 10-50 fold decrease observed in E. coli in recombineering assays [135,240].  
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Figure 18. Allelic gene replacement of the M. smegmatis groEL1 gene. 
 
Figure 18. [227] (A) The groEL1 AES was generated by cloning approximately 500 bp of homology flanking a 
hygR gene (plasmid pMsgroEL1KO; see Figure 21) and PCR amplifying the region shown. Homologous 
recombination of this AES with the groEL1 locus results in allelic exchange as shown. The locations of primers a, b, 
c, and d are shown (e and f are depicted for assays shown in Figure 21) [JCV67+68, JCV71+94, JCV72+172]. (B) 
Colony PCRs from recombinant colonies using primer pairs a and b (1.9 kbp wild type, 2.3 kbp mutant groEL1:res-
hyg-res), and c and d (no product for wild type, 1.5 kbp mutant groEL1:res-hyg-res) are shown; c and d are present 
in the chromosome of recombinants only. DNA from wild type M. smegmatis or groEL1 mutant strains were used 
as controls. (C) Southern blot analysis of DNA isolated from gene replacement mutants using either a probe to the 
downstream homologous region of the groEL1 locus, or a probe to the hygR gene. Expected band sizes: 2.3 kbp wild 
type, 3.3 kbp mutant groEL1:res-hyg-res; DNA from wild type M. smegmatis or groEL1 mutant strains were used 
as controls. 
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Figure 19. dsDNA recombineering dependence on homology length. 
 
 
 
 
 
 
Figure 19 [227]. Plasmid pMsgroEL1KO contains 556 bp and 500 bp of homology 5 and 3 of the groEL1 gene, 
respectively, flanking a hygR gene. Primer pairs were designed to amplify this region resulting in PCR products with 
homology lengths of 50 bp, 100 bp, 150 bp, 200 bp, and 500 bp. These substrates were transformed into M. 
smegmatis strains containing plasmids pLAM12 (●), pJV24 (○), and pJV53 (▼), and recombineering frequencies are 
shown on the y-axis.  
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Table 4. dsDNA recombineering dependence on host RecA. 
Strain 
Recovered colonies 
with groEL1 AESb 
Cell competency 
(cfu/g)c 
Recombineering 
frequencyd 
mc2155:pJV53 226 6.0 x 106 3.8 x 10-4 
mc2155:pJV53 recAa 99 1.3 x 107 7.6 x 10-5 
 
a. The M. smegmatis recA strain was constructed by allelic gene replacement by recombineering and unmarked 
using resolvase, as described in the Materials and Methods.  
b. Electrocompetent cells of the two strains were transformed with 100 ng of the groEL1 AES (see Figure 18), and 
HygR colonies were recovered; the data represent the average of two experiments. 
c. Cell competency is determined as the cfu/g plasmid pJV39, an integration-proficient vector providing 
hygromycin resistance, when 50 ng was transformed. 
d. Recombineering frequency is calculated as the number of recombinant cfu per g DNA divided by the cell 
competency. 
3.3.4 Recombineering frequencies are limited by DNA uptake efficiency. 
Using 100 ng of the dsDNA substrates for allelic exchange typically produced between 50 and 
200 recombinant colonies, and the number of colonies obtained by recombineering was directly 
proportional to the ability of the electrocompetent cells to productively take up DNA (referred to 
as ‘cell competency’). Control transformations with an integration-proficient plasmid were 
performed with 50 ng to determine cell competency, and these values are reported as 
transformants (colony forming units; cfu) per g DNA (Table 3, Table 4, and Table 5), which is 
typically ~106 cfu/g. Therefore a ‘recombineering frequency’ is used to compare experiments; 
this is calculated as the number of recombineering transformants per g DNA divided by the cell 
competency. When using 100 ng of the AES, recombineering frequencies averaged 1-5 x 10-4 
(Table 5). Increasing the amount of AES (up to one g) does not result in a higher 
recombineering frequency (data not shown), but rather this can be accomplished by increasing 
the competency of the cells by optimizing the protocol for electrocompetent cell preparation (see 
Materials and Methods). 
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3.3.5 Recombineering of other M. smegmatis genes 
Several additional M. smegmatis loci were also tested for targeted gene replacement and yielded 
similar recombineering frequencies to groEL1 [227]. The number of colonies recovered for each 
gene locus were comparable, and again more than 90% were correctly targeted (Table 5). 
Frequencies were observed to vary between 10-5 and 10-4, with even higher frequencies (10-3) 
from targeting the leuD and leuB genes (Table 3 and Table 5). This is likely a result of the longer 
homology lengths utilized in these experiments and this corroborates the observation that 
increasing homology length increases recombineering frequencies (Figure 19). Occasionally, 
recombination frequencies at these two loci were more similar to those for other loci such as 
groEL1 (compare leuB in Tables 3 and 5).  
 
Table 5. Recombineering of M. smegmatis loci. 
Gene targeteda,b Recovered 
coloniesc 
Recombination 
frequencyd 
Gene 
replacementse 
0651 478 4.8 x 10-5 >90% 
1583 (groEL1) 180 1.8 x 10-4 >90% 
2379 (leuB) 25 1.9 x 10-4 >90% 
2388 (leuD) 43 1.2 x 10-3 >90% 
2723 (recA) 128 1.3 x 10-4 90% 
4303 281 2.8 x 10-5 >90% 
6048 (cobW) 280 2.8 x 10-4 90% 
6065 – 6067 242 2.4 x 10-5 ND 
6067 - 6068  280 2.8 x 10-4 ND 
 
a. Genes were targeted using linearized plasmid DNA substrates (digested with two enzymes adjacent to the 
homologous sequences and oriE region removed; see text below) containing a HygR cassette flanked by ~500 bp 
homology to the locus.  
b. The gene locus number is the new locus tag (MSMEG_XXXX). 
c. M. smegmatis mc2155:pJV24 cells were transformed with 100 ng of each targeting substrate and HygR colonies 
recovered; cfu for leuB and leuD represent half of the transformation plated on leucine supplemented media. 
d. Recombination frequencies are represented as recombinant cfu per g divided by cell competency, in which the 
transformation efficiency is determined by using a HygR, integration-proficient vector. For all loci except leuD and 
leuB, the cell competency was 1 x 107 cfu/g; for leuB: 1.3 x 106 cfu/g; for leuD: 7.2 x 105 cfu/g. 
e. The number of correctly targeted gene replacements was determined by PCR or phenotypic analysis (leuB and 
leuD), with a minimum of 10 colonies each. 
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 3.3.6 Recombineering of the M. tuberculosis groEL1 gene 
Since recombineering was successful in M. smegmatis, the effectiveness of this system was 
tested in M. tuberculosis by targeting the groEL1 gene (Figure 20A) [227]. The results were 
similar to those seen in M. smegmatis; ~150 recombinant colonies were obtained in an M. 
tuberculosis H37Rv:pJV53 strain (Figure 20B and Table 6), yielding a recombineering 
frequency of 1.7 x 10-4. Out of 16 colonies examined by Southern blot analysis, at least 14 were 
correctly targeted to the groEL1 locus (Figure 20C). Although colonies were observed in a 
control strain (H37Rv:pLAM12), these grew slowly (Figure 20B), arose at a much lower 
frequency (8.1 x 10-6), and none were correctly targeted when examined by Southern blot 
analysis (Figure 20D). However, the M. tuberculosis H37Rv:pJV53 strain showed protein 
expression in the absence of acetamide induction (Figure 15E), which is not observed in M. 
smegmatis (Figure 15A). This is not surprising, since previous studies have shown that M. 
tuberculosis has a lower tolerance than M. smegmatis for plasmids containing the acetamidase 
promoter cassette [25]. Therefore, as an additional experiment, cultures were grown in OADC 
(see Materials and Methods), washed, and grown for 24 hours in media containing succinate and 
acetamide prior to harvesting for electrocompetent cells. Recombinants were also correctly 
targeted in these experiments (Figure 20C,D), and recombineering frequencies were similar; 
however, cell competency was overall lower for these strains. Although protocols for preparing 
electrocompetent cells of M. tuberculosis do not recommend storing cell aliquots at -80°C, this 
did not have an effect on the overall recombineering frequency. However, freezing cells did 
lower cell competency (Table 6), which has been observed previously [80]. Additionally, using a 
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PCR-generated groEL1 AES yielded approximately five-fold more recombinants than a 
pMtbgroEL1 plasmid AES linearized by restriction digest (Table 6), and a higher proportion of 
the PCR colonies were correctly targeted (Figure 20D). The incorrect targeting of the PacI-
digested groEL1 AES was likely due to targeting to the pJV53 plasmid via the homology at the 
oriE region (see below). Using PCR-generated substrates also reduced the background in the 
control strain (Table 6). 
 
Table 6. Recombineering frequencies from targeted gene replacement of the M. tuberculosis groEL1. 
 Recombineering frequencies with each AESb 
Strain and growth mediaa 
pYUB854  
PacI-digest 
pMtbgroEL1KO 
PacI-digest 
pMtbgroEL1KO 
PCR 
H37Rv:pLAM12, OADC 1.7 x 10-5 3.3 x 10-5 5.6 x 10-6 
H37Rv:pLAM12, succinate 1.3 x 10-5 1.2 x 10-5 8.1 x 10-6 
H37Rv:pJV53, OADC 3.3 x 10-5 3.3 x 10-5 2.1 x 10-4 
H37Rv:pJV53, succinate 2.7 x 10-5 3.7 x 10-5 1.7 x 10-4 
H37Rv:pJV53, frozen aliquotsc ND ND 4.3 x 10-4 
 
a. Strains were grown to mid-logarithmic phase in media and induced for 24 hours as follows: either grown initially 
to mid-logarithmic phase in media (1) containing OADC, washed, and induced in succinate and acetamide media, or 
(2) containing succinate, and subsequently acetamide added for induction. 
b. The AESs were prepared either by restriction digest with PacI of plasmids pYUB854 (no homology) or 
pMtbgroEL1KO (groEL1), or by PCR-amplification.  
c. Electrocompetent cell aliquots (cells grown in succinate media) were frozen at -80°C for two weeks, thawed, and 
transformed with the PCR-amplified groEL1 AES. 
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Figure 20. Allelic replacement of the M. tuberculosis groEL1 gene by recombineering. 
 
 
 
Figure 20 [227]. (A) Schmetic of the M. tuberculosis groEL1 gene locus and the groEL1 AES. (B) Pictures of the 
recovered colonies in M. tuberculosis strains from transformations with 100 ng of groEL1 AES. (C) Southern blot 
analysis of the M. tuberculosis groEL1 gene locus of DNA isolated from 16 recombinant strains made by 
recombineering with a PCR-generated groEL1 AES in a pJV53 strain. The probe anneals to the downstream 
homology region of the groEL1 AES; expected band sizes: 7.5 kbp wild type; 10.2 kbp mutant. DNA from wild type 
and groEL1 M. tuberculosis strains (mutant constructed by specialized transduction [14]) were used as controls. 
(D) Southern blot of DNA isolated from recombinants: pJV53 or pLAM12 cultures grown either in succinate and 
induced with acetamide, or in OADC and washed into succ./acet. The AES was generated by PacI digest or PCR.  
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3.3.7 Recombineering efficiently targets replicating plasmids. 
Throughout these experiments, the linearized AESs were generated by plasmid digest, with the 
exception of the groEL1 AES, which was typically generated by PCR amplification. In one case, 
the groEL1 AES plasmid was digested with an enzyme that cut near the E. coli origin of 
replication (oriE), and a large increase in the number of recombinant colonies (104) was 
observed (Figure 21A,B). This was not due to the presence of non-homologous regions at the 
ends of the substrate (data not shown), nor was it dependent on the presence of homologous 
sequences (pYUB854; Figure 21B). Recombinant colonies were analyzed by PCR with primers 
that anneal in the AES homologies and thus produced two PCR products (wild type and mutant) 
if the AES has been incorporated at a locus other than groEL1. These two PCR products were 
seen at a low frequency with either AflII- or NcoI-digested AESs (Figure 21C). Conversely, all 
colonies yielded two PCR products from transformations with PciI-digested plasmid AESs 
targeting the groEL1 or MSMEG4308 genes (pMsgroEL1KO and pMs4308KO; Figure 21C,D).  
 These observations are likely connected to the presence of a region encompassing the 
oriE that is homologous to the extrachromosomal pJV24 plasmid (Figure 21A). Digest in this 
region (with PciI) results in a linear AES with significant lengths of homology to pJV24 on each 
end. However, removal of the backbone of the plasmid produces colonies that are all correctly 
targeted to the chromosomal groEL1 locus instead of the plasmid (Figure 21E). Analysis of 
plasmids electroduced from PciI-generated colonies showed that 64% of the plasmids (originally 
KanR only) were KanR/HygR (Figure 21F), and restriction digests revealed the presence of 
additional DNA sequences in these plasmids (Figure 21G). These data clearly demonstrate that 
extrachromosomal plasmids can be targeted by dsDNA recombineering, and that the plasmid 
backbone of circular AES constructs must be removed if chromosomal targeting is desired [227].  
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Figure 21. Recombineering targets extrachromosomal plasmids efficiently. 
 
 
 
Figure 21. (A) The plasmid pMsgroEL1KO was constructed by cloning regions of homology to the M. smegmatis 
groEL1 gene flanking a hygR cassette into the parent vector pYUB854 (not shown) [14].  These plasmids contain a 
region of homology to all mycobacterial extrachromosomal recombineering plasmids near the E. coli origin of 
replication (oriE), depicted by the light grey bar. (B) Transformation of 100 ng linearized pMsgroEL1 or the parent 
cloning vector without any homology to groEL1 (pYUB854) digested with PciI into mc2155:pJV24 cells results in a 
large increase in recombinants. (C) Digestion of pMsgroEL1KO with either AflII, PciI, or NcoI results in two bands 
(mutant and wild type) by colony PCR with primers that anneal in the regions of homology. (D) Two bands are also 
seen in experiments targeting the M. smegmatis MSMEG4308 gene with an AES linearized by PciI digest 
(pMs4308KO). (E) The correct bands are observed when pMsgroEL1 is double-digested with AflII and NcoI, and all 
are correctly targeted using primers annealing either in (a+b) or outside (c+d, e+f) the homologous regions (see 
Figure 18 for primer locations).  (F) Plasmids were electroduced from colonies (B) into E. coli and patched onto 
plates containing Kan or Kan/Hyg. (G) Restriction digests of five KanR/HygR colonies shows multiple additional 
bands compared to pJV24 control. 
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The data presented in this chapter demonstrate that recombineering with dsDNA 
substrates is a simple and efficient method of constructing gene replacement mutants in both M. 
smegmatis and M. tuberculosis [227]. The success of this technique further suggested that other 
types of mutagenesis might be accomplished using recombineering, and these will be discussed 
in the following section. 
3.4 POINT MUTAGENESIS 
3.4.1 ssDNA recombineering of replicating plasmids requires only Che9c gp61. 
To determine if short ssDNA substrates (oligonucleotides) could be used to make point 
mutations on mycobacterial genomes, a simple assay was developed using extrachromosomally-
replicating plasmids as targets for recombination [228]. The chosen target gene was a mutated 
version of the hygR gene containing two consecutive amber mutations that inactivate its function 
(hygS); the assay therefore tests if a HygR phenotype could be restored by ssDNA recombineering 
at the mutated locus. The hygS gene was cloned into various plasmids expressing Che9c gp60, 
gp61, or both (Figure 22A, Table 7), and electrocompetent cells were prepared of M. smegmatis 
strains containing these plasmids. Complementary substrates were synthesized that were 100 nt 
long (Table 16; JCV198, JCV199) and were homologous to the mutated region of hygS, with the 
mutations that restore wild type sequence in the center. Transformation of M. smegmatis strains 
expressing gp61 or both gp60/gp61 with either of these oligonucleotides resulted in more than 
103 HygR colonies, whereas strains expressing only gp60 or containing an empty vector had only 
background numbers of colonies (<25) (Figure 22B, Table 7). Transformations with 
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oligonucleotide JCV199 consistently resulted in higher recombineering frequencies, which may 
result from a strand bias due to the direction of DNA replication on this plasmid or a sequence-
specific effect. Similar results were observed in M. tuberculosis strains expressing gp61 using 
this same assay, although at frequencies approximately 10-fold lower (Figure 22B, Table 7). 
Recovering transformations for three days (compared to one or two days) yielded the highest 
numbers of recombinants (data not shown). These data suggest that Che9c gp61 is sufficient for 
recombination with ssDNA substrates, and the number of recombinants generated by this method 
is 100- to 1000-fold greater than for what is obtained with dsDNA substrates. 
 
Table 7. ssDNA recombineering of plasmids in M. smegmatis and M. tuberculosis. 
Recombinants recovered 
(HygR)c 
Recombineering frequencyd  
Strain background, hygS a 
JCV198b JCV199b   JCV198 JCV199 Ratioe 
pJV73amber (control, Phsp60) 6 6 1.7 x 10-5 1.7 x 10-5 N/A 
pJV74amber (control, Pacetamidase) 23 0 7.1 x 10-6 0 N/A 
pJV75amber (gp61, Pacetamidase) 5,300 3,310 3.9 x 10-2 2.4 x 10-2 1.6 
pJV76amber (gp60/gp61, Pacetamidase) 294,000 67,000 2.9 x 10-2 6.6 x 10-3 4.3 
pJV77amber (gp60, Pacetamidase) 1 0 8.0 x 10-6 0 N/A 
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pJV78amber (gp61, Phsp60) 2,710 250 3.5 x 10-3 3.2 x 10-4 10.8 
pJV74amber (control, Pacetamidase) 3 3 9.4 x 10-7 9.4 x 10-7 N/A 
pJV75amber (gp61, Pacetamidase) 10,200 1,960 3.6 x 10-3 6.9 x 10-4 5.2 M
. 
tu
be
rc
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os
is
 
H
37
Rv
 
pJV76amber (gp60/gp61, Pacetamidase) 2,130 1,020 1.3 x 10-3 6.1 x 10-4 2.1 
 
a. Each plasmid (extrachromosomally-replicating; in strains of M. smegmatis or M. tuberculosis as indicated) 
contains a hygS gene with two codons mutated to early amber stop codons and various combinations of Che9c genes 
60 and 61 under control of either an inducible promoter (Pacetamidase) or constitutive promoter (Phsp60).  
b. JCV198 and JCV199 are ssDNA oligonucleotides (100 nt; listed in Table 16) that are complementary, correspond 
to the mutated locus of hygS, and contain wild type sequence. 
c. Number of HygR recombinants with 100 ng of either JCV198 or JCV199. 
d. Recombineering frequency is expressed as the number of recombinants per 100 ng ssDNA divided by the cell 
competency (expressed in cfu/g DNA).  
e. The ratio for each strain is calculated by dividing the recombineering frequency obtained from the ssDNA with 
the highest recombineering frequency by the other ssDNA. N/A: not applicable – background levels of 
recombinants. 
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Figure 22. ssDNA recombineering of plasmids in M. smegmatis and M. tuberculosiss. 
 
 
 
 
Figure 22 [228]. (A) Schematic of plasmid pJV75amber, an example of the plasmids constructed containing the 
hygS gene. (B) The number of HygR transformants with 100 ng of JCV198 (white bars) and JCV199 (grey bars) (100 
nt, complementary) are reported (left y-axis) for either M. smegmatis or M. tuberculosis strains containing plasmids 
pJV74amber (control), pJV75amber (expressing gp61 only), and pJV76amber (expressing both gp60/gp61). Cell 
competency is reported for each strain (black bars; right y-axis) as determined from control transformations with 50 
ng of plasmid pSJ25Hyg and reported as transformants per g plasmid DNA. 
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3.4.2 Introducing point mutations in the M. smegmatis chromosome by ssDNA 
recombineering 
To determine if ssDNA recombineering could be used to target the chromosome, the same hygS 
gene was inserted into the chromosome of M. smegmatis at two loci using L5 and Bxb1 
integration-proficient vectors [95,110]. The L5 and Bxb1 attB sites are located on different sides 
of the M. smegmatis chromosome and are approximately the same distance from the origin of 
replication (Figure 23A); Bxb1 is located 1.67 megabasepairs (mbp) 3 of the origin, and L5 is 
2.22 mbp 5 of the origin (at 4.76 mbp). The hygS cassette was also inserted in both orientations 
at each locus in order to examine the possible strand bias seen with plasmid targeting (Figure 
23B). Using these four strains, the same oligonucleotides (JCV198 and JCV199) were tested for 
ssDNA recombineering in an M. smegmatis mc2155:pJV62 background, which expresses Che9c 
gp61 with transcription and translation signals from the acetamidase cassette. HygR colonies 
were recovered using either oligonucleotide, although a strand bias was observed that, in some 
cases, was more than 1000-fold (Figure 23C, Table 8). This strand bias correlates with the 
direction of DNA replication at each locus, such that oligonucleotides that anneal to the lagging 
strand consistently generated higher recombination frequencies than those annealing to the 
leading strand. The dif site for replication termination is predicted to be at 3.41 mbp on the M. 
smegmatis chromosome [74,75], and bi-directional replication from the origin to the terminus 
correlates with the data from this assay (Figure 23). Interestingly, for each locus, one orientation 
resulted in a much smaller strand bias (<3-fold; Table 8, pJV89amber and pJV94amber); lower 
numbers of transformants were obtained with the oligonucleotide annealing to the lagging strand 
(JCV198), and higher numbers of transformants were found with the leading strand 
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oligonucleotide (JCV199) as compared to the other orientation. This effect was consistent in all 
strain backgrounds tested (Table 9) but was only seen with these particular integrated targets for 
ssDNA recombineering. This may be due either to the presence of additional genetic elements on 
the integrating plasmid that interfere with recombination or to a sequence-specific effect.  
 
Table 8. ssDNA recombineering of a hygS gene in the M. smegmatis chromosome. 
Recombinants recovered 
(HygR) Recombineering frequency
 c  Strain backgrounda 
pJV62 (gp61), hygS 
JCV198 b JCV199 b JCV198 JCV199 Ratio d 
pJV89amber 1,220 670 3.2 x 10-3 1.7 x 10-3 1.8 
pJV91amber 5 20,400 8.5 x 10-6 3.5 x 10-2 4,080 
pJV92amber 15 27,600 8.4 x 10-5 1.6 x 10-1 1,840 
pJV94amber 1,760 700 4.7 x 10-3 1.9 x 10-3 2.5 
 
a. Each strain contains a hygS gene integrated at either the Bxb1 attB locus (pJV89amber, pJV91amber) or the L5 
attB locus (pJV92amber, pJV94amber). 
b. JCV198 and JCV199 are ssDNA oligonucleotides (100 nt; listed in Table 16) that are complementary, correspond 
to the mutated locus of hygS, and contain wild type sequence. 
c. Recombineering frequency is expressed as the number of recombinants per 100 ng ssDNA divided by the cell 
competency (expressed in cfu/g DNA). 
d. The ratio for each strain is calculated by dividing the recombineering frequency obtained from the ssDNA with 
the highest recombineering frequency by the other ssDNA.  
 
Recombineering of the hygS gene at these two loci was compared in strain backgrounds 
containing plasmids expressing either Che9c gp60/gp61 (pJV53) or only gp61, either from its 
endogenous translation signals (pJV62) or those of the acetamidase cassette (pJV52). 
Recombineering frequencies were approximately 10-fold higher in a pJV62 strain than in a 
pJV52 strain (Table 9), and notably, pJV62 expresses slightly lower levels of gp61 compared to 
pJV52  (Figure 15B). Therefore, strains expressing Che9c gp61 from plasmid pJV62 were used 
in most ssDNA recombineering experiments. 
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Table 9. ssDNA recombineering frequencies of chromosomal mutations in strains expressing Che9c gp61. 
 Recomb. Freq.
c 
pJV89amberb 
Recomb. Freq.c 
pJV91amberb 
Recomb. Freq.c 
pJV92amberb 
Recomb. Freq.c 
pJV94amberb 
Strain 
backgrounda JCV198 JCV199 JCV198 JCV199 JCV198 JCV199 JCV198 JCV199 
mc2155:pLAM12 
(control strain) 0 0 ND ND 0 0 0 0 
mc2155:pJV52 
(gp61) ND ND ND ND 0 6.9 x 10
-2 4.1 x 10-4 1.8 x 10-4 
mc2155:pJV53 
(gp60/gp61) ND ND ND ND 6.0 x 10
-5 1.9 x 10-2 2.9 x 10-4 7.7 x 10-5 
mc2155:pJV62 
(gp61*) 3.2 x 10
-3 1.7 x 10-3 8.5 x 10-6 3.5 x 10-2 8.4 x 10-5 1.6 x 10-1 4.7 x 10-3 1.9 x 10-3 
 
a. Each strain contains an extrachromosomally replicating plasmid expressing Che9c gp60/gp61, only gp61, or is an 
empty vector. Plasmid pJV62 (*) expresses gene 61 from translational signals encoded by the acetamidase cassette. 
b. Recombineering frequency is expressed as the number of recombinants per 100 ng ssDNA divided by the cell 
competency (expressed in cfu/g DNA). 
c. Plasmids containing a hygS gene integrated at either the Bxb1 attB locus (pJV89amber, pJV91amber) or the L5 
attB locus (pJV92amber, pJV94amber) were integrated into the indicated strain backgrounds (a). 
 
3.4.3 Recombineering chromosomal mutations that confer antibiotic resistance 
Recombineering with ssDNA was also tested for the ability to introduce point mutations that 
confer resistance to antibiotics in the M. smegmatis chromosome [228]. These experiments were 
utilized to further characterize the strand bias observed with the hygS and to determine the 
advantages of using ssDNA recombineering for assessing the effect of a particular point 
mutation on antibiotic-resistance. Four well-characterized mutations were chosen: inhA S94A 
[11], rpsL K43R [94,212], rpoB H442R [94], and gyrA A91V [187], which are expected to 
confer resistance to isoniazid and ethionamide (INH/Eth), streptomycin (Str), rifampicin (Rif), 
and ofloxacin (Ofx), respectively. Each of these genes is located on one side of the chromosome 
(Figure 23C). Complementary oligonucleotides were designed to construct these specific 
mutations (Table 16), and these were transformed into M. smegmatis mc2155:pJV62 cells. 
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Recombinant drug-resistant colonies were recovered at similar frequencies to those 
observed with hygS experiments (Figure 23B, Table 10); background levels of drug-resistance 
were similar to those reported in previous studies [11,94,187].  Targeting the lagging strand was 
most efficient for each gene (~105 colonies), which is consistent with the data from hygS 
targeting experiments and implicates a role for DNA replication in ssDNA recombination. 
Interestingly, the strand biases varied in size; the gene most proximal to the origin of replication 
(gyrA) had a strand bias of 36,000-fold, whereas the gene closest to dif (inhA) had a bias of 5-
fold. Overall numbers of recombinants from targeting the rpsL gene were 10-fold lower than for 
other loci, although the strand bias (7,800-fold) was intermittent between gyrA and inhA. The 
bias for rpoB could not be determined accurately because the background level of spontaneous 
RIF-resistance masked the level of recombineering with the leading strand oligonucleotide 
(Figure 23C, Table 10). In addition, not only was the strand bias small at inhA, but this did not 
result from a decrease in colonies from the oligonucleotide targeting the lagging strand. Rather, 
there was an increase in recombinants with a leading strand oligonucleotide at this locus as 
compared to the others. 
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Table 10. Recombineering point mutations that confer drug-resistance in mycobacteria. 
   Recombineering Freq. (mc2155:pLAM12)c 
Recombineering Freq. 
(mc2155:pJV62)c  
Gene target a Mutationb leading strand oligo 
lagging 
strand oligo 
Leading 
strand oligo 
lagging 
strand oligo Ratio
 
gyrA    [MSMEG_0006] 
(JCV259, lead; JCV260, lag) A91V 1.4 x 10
-6 4.0 x 10-6 8.5 x 10-7 3.1 x 10-2 36,000 
rpoB    [MSMEG_1367] 
(JCV253, lead; JCV254, lag) H442R 1.5 x 10
-4 1.0 x 10-4 5.7 x 10-5 2.2 x 10-2 382 
rpsL    [MSMEG_1398] 
(JCV218§, lead;  JCV219§, lag) K43R 0 0 6.4 x 10
-7 5.0 x 10-3 7,833 
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inhA    [MSMEG_3151] 
(JCV216§, lead; JCV217§, lag) S94A 6.6 x 10
-4 1.5 x 10-3 6.5 x 10-3 3.2 x 10-2 4.9 
rpoB   [Rv0667] 
(JCV325, lead; JCV326 lag) H451R ND 2.1 x 10
-5 ND 3.6 x 10-3 ND 
rpoB   [Rv0667] 
(JCV327, lead; JCV328, lag) S456L 8.8 x 10
-6 1.0 x 10-5 2.1 x 10-6 1.0 x 10-3 480 
rpsL   [Rv0682] 
(JCV329, lead; JCV330, lag) K43R 1.5 x 10
-6 7.4 x 10-7 3.6 x 10-7 3.5 x 10-3 9,722 
M
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katG [Rv1908c] 
(JCV324, lead; JCV269, lag) H108* 1.5 x 10
-3 1.4 x 10-3 2.2 x 10-3 5.7 x 10-4 0.3 
 
a. Specific drug-resistance mutations in M. smegmatis [MSMEG_X] or M. tuberculosis [RvX] genes were 
introduced by transformation with 100 ng of oligonucleotides that anneal to either the leading strand (lead) or 
lagging strand (lag) and are either 71 nt or 101 nt (§) in length.  
b. The specific mutation introduced by the oligonucleotide (oligo) is indicated; *, amber. 
c. Recombineering frequency is determine by the number of drug-resistant transformants for either empty vector 
control strain (pLAM12) or strain expressing gp61 (pJV62) divided by the cell competency. ND; not determined. 
d. Comparison of the oligonucleotides: lagging strand divided by leading strand. 
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Figure 23. ssDNA recombineering of the M. smegmatis chromosome. 
 
Figure 23.  (A) Schematic of the location of genes targeted by recombineering on the M. smegmatis chromosome. 
The direction of DNA replication is predicted based on the location of the origin (ori) and terminus (dif) of DNA 
replication, which are indicated by solid (leading strand) and dashed (lagging strand) lines, as well as the size of the 
chromosome in mbp. The hygS gene is integrated at either the L5 or Bxb1 attB sites (blue); other gene targets are 
shown in green.  (B) Illustration depicting the orientation of the hygS genes integrated at the L5 and Bxb1 loci. (C) 
The number of drug-resistant colonies obtained from transformations of a pJV62 strain (expressing Che9c gp61) 
with 100 ng of each oligonucleotide that anneal to either the leading strand (white bars) or lagging strand (grey bars) 
are shown in the graph (cfu). Background levels of spontaneous mutants for each drug are shown as determined 
from transformations of a control strain that does not express Che9c gp61 (hatched bars); background is zero for 
hygS and rpsL. The M. smegmatis chromosome is illustrated below the graph in a linear representation. The 
predicted strands for either leading strand synthesis (solid line) or lagging strand synthesis (dashed line) are shown. 
Arrows show the orientation of transcription for each gene. Drug-resistant colonies were selected with Ofx (gyrA), 
Str (rpsL), Rif (rpoB), INH/Eth (inhA), and Hyg (hygS). W: Watson strand; C: Crick strand. 
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Colonies from inhA targeting experiments were analyzed by PCR-amplification and 
sequencing of the inhA gene; all contained the S94A mutation, whereas colonies from negative 
control transformations did not (data not shown). An oligonucleotide that incorporates a 
synonymous third-base change at the same locus (inhA S94 codon) did not yield INHR 
transformants above background levels. Recombination with ssDNA appears to be independent 
of host RecA (Table 11), unlike recombination with dsDNA substrates (Table 4). Collectively, 
these data indicate that introduction of the inhA S94A and other mutations arose from 
specifically-targeted recombination events that are dependent on Che9c gp61 and not general 
mutagenesis. 
Table 11. ssDNA recombineering dependence on host RecA. 
Strain background Target: inhAb Target: rpsLb Recombineering frequency inhA 
Recombineering 
frequency rpsL 
mc2155:pLAM12 (control) 1,630 1 3.2 x 10-4 2.0 x 10-7 
mc2155:pJV62 (gp61) 115,000 6,600 1.4 x 10-1 8.1 x 10-3 
mc2155:pJV62 recAa (gp61) 362,000 29,800 9.1 x 10-2 7.5 x 10-3 
 
a. This M. smegmatis recA strain was constructed by K.G. Papavinasasundaram and colleagues [155] and is HygR .  
b. Oligonucleotides (100 ng) targeting the lagging strand containing either the inhA S94A (JCV217) or rpsL K43R 
(JCV219) point mutations were transformed into the M. smegmatis strains listed and either INHR or StrR 
transformants were selected, respectively. The number of transformants and recombineering frequencies for each 
target are shown. 
 
Similar results were obtained in M. tuberculosis in which ssDNAs were designed to 
introduce point mutations in rpoB (S456L and H451R), rpsL (K43R), and katG (H108amber; 
INHR [191,209]) (Figure 24, Table 10). Drug-resistant colonies (up to 104) were obtained with 
oligonucleotides that anneal to the lagging strand, with large strand biases up to ~9,700-fold; the 
background of katG prevented an accurate comparison of leading and lagging strand efficiencies. 
However, the recombineering frequencies were 5- to 30-fold lower as compared to those 
observed in M. smegmatis (Table 10), consistent with the plasmid-targeting results. 
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Figure 24. ssDNA recombineering of the M. tuberculosis chromosome. 
 
 
 
Figure 24. Similar to Figure 23 for the M. smegmatis chromosome, the locations of the M. tuberculosis genes 
targeted by ssDNA recombineering are depicted. (A) The location of the rpsL, rpoB, and katG genes on the M. 
tuberculosis chromosome, as well as ori and dif are shown on this schematic. Predicted leading (solid line) and 
lagging (dashed line) strands are indicated. (B) The number of drug-resistant colonies obtained from transformations 
of a pJV62 strain (expressing Che9c gp61) with 100 ng of each oligonucleotide that anneals to either the leading 
strand (white bars) or lagging strand (grey bars) are shown in the graph (cfu). Background levels of drug-resistant 
mutants are determined from transformations of a control strain that does not express Che9c gp61 (hatched bars). 
The rpoB mutation in this graph is S456L. Drug-resistant colonies were selected on Str (rpsL), RIF (rpoB), and INH 
(katG). 
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3.4.4 Optimizing ssDNA recombineering conditions 
Several modifications to the ssDNA substrates were tested in order to optimize recombineering 
frequencies. First, to determine the effect of ssDNA length, the same assay described above 
using an integrated hygS gene was used [228]. Oligonucleotides of varying lengths (20 nt to 76 
nt) were designed with the mutations that restore HygR centrally located, and these were 
transformed into an M. smegmatis mc2155:pJV62:pJV92amber strain. Maximal recombineering 
frequencies were achieved with oligonucleotides at lengths of 48 nt or greater, although low 
numbers of colonies were obtained above background at lengths as small as 32 nt (Figure 25). 
Since Che9c gp61 can bind a 20 nt oligonucleotide with similar affinity to a 44 nt 
oligonucleotide (Figure 12E), it is not clear why recombinants were not observed with 
oligonucleotides shorter than 32 nucleotides. The effect of ssDNA length is similar to what is 
observed with λ Beta, which works optimally with oligonucleotides 70 nt in length [52].  
The effect of using dsDNA substrates was also examined at the inhA locus using 100 bp 
or 200 bp substrates (with a centered S94A mutation) in M. smegmatis cells expressing Che9c 
gp60 and gp61. This did not improve recombineering frequencies, and only slight increases in 
recombineering were observed in a similar assay using dsDNA substrates in E. coli [244]. Co-
transformation of a StrR ssDNA substrate with a plasmid that consitutively expresses Che9c gp61 
into wild type cells did not result in recombinant StrR colonies (data not shown), suggesting that 
gp61 must be expressed in the cell prior to transformation with the oligonucleotide. Similarly, 
pre-incubation of the ssDNA with gp61 prior to transformation into wild type cells did not yield 
recombinant colonies, an observation also made of λ Beta in the E. coli system [38]. Finally, the 
length of induction is optimal since the number of recombinants recovered is greatly increased at 
three hours compared to cultures without induction (up to 5,000-fold; data not shown). 
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Figure 25. ssDNA recombineering dependence on oligonucleotide length. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 [228]. ssDNAs of varying lengths at four base intervals from 20 nt to 76 nt (and 100 nt as a positive 
control; JCV199) were tested for the ability to target the hygS gene integrated at the L5 attB site and restore HygR. 
Lengths shorter than 32 nucleotides produced colonies at background levels. The error bars represent data from three 
independent experiments. 
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3.4.5 Development of a co-transformation strategy to select against non-transformable 
cells 
The recombineering experiments performed with ssDNA substrates demonstrated that selectable 
point mutations could be made on either the chromosome or on extrachromosomal plasmid in M. 
smegmatis and M. tuberculosis [228]. However, most point mutations are not selectable by drug-
resistance or other phenotypes, and instead require genotypic analysis to identify the mutant 
allele. Although recombination of ssDNA substrates is very efficient, approximately only one 
point mutant is recovered out of 1,000 viable cells. However, this frequency is similar to that 
observed in a standard plasmid transformation. Since the limiting factor appeared to be the 
competency of the cells, and not the frequency of recombination, it was reasoned that non-
selectable point mutants could be recovered if the non-transformed cells could be removed from 
the population to be screened.  
A co-transformation strategy was therefore tested in which a HygR plasmid and an INHR 
(inhA S94A) oligonucleotide were electroporated into M. smegmatis cells expressing Che9c gp61 
and selected on media containing Hyg, INH, or both. Notably, INHR/HygR mutants were 
identified from colonies selected only on Hyg at a ~10% frequency (Figure 26A). This frequency 
was obtained using saturating amounts (500 ng) of either the plasmid or oligonucleotide, and 100 
ng of the other substrate (Figure 26B). Similar co-selection frequencies were also obtained 
regardless of the type of HygR plasmid, either integrating (Bxb1, L5, Giles) or replicating. This 
tactic was also successful using a double-oligonucleotide transformation: one oligonucleotide to 
introduce the desired point mutation (e.g. inhA S94A; JCV217; INHR) and the other to repair a 
hygS mutation (JCV198) present on the extrachromosomal plasmid (pJV75amber). This resulted 
in a slightly lower co-selection frequency (~3-5%) but did not require the introduction of an 
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additional plasmid  Optimal levels of co-selection were obtained with 200-500 ng of the INHR 
oligonucleotide and 50-100 ng of the HygR oligonucleotide (Figure 26C); increasing the HygR 
oligonucleotide to 500 ng dropped frequencies ~10-fold. Finally, four hours recovery yielded 
optimal co-selection frequencies (7.2%), whereas shortening the time (1 hour, 1.2%) or 
lengthening the time more than 8 hours (overnight, 2.8%) did not improve recovery of doubly-
resistant INH/Hyg colonies. 
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Figure 26. Optimizing recovery of point mutations by co-transformation of a HygR substrate. 
 
 
Figure 26 [228]. (A) Colonies from transformations with a HygR plasmid (pSJ25Hyg) and an INHR oligonucleotide 
(JCV217) were selected only on Hyg and patched onto INH/Hyg media. (B) Varying amounts of the HygR plasmid 
and the INHR oligonucleotide (10, 25, 50, 100, 250, or 500 ng) were co-transformed and plated on Hyg, INH, or 
Hyg/INH. The key indicates the substrate held constant at 500 ng (while the other substrate quantity was varied) and 
the type of antibiotic selection for each reaction. (C) Co-transformations with varying amounts of the HygR 
oligonucleotide (JCV198) and INHR oligonucleotide (JCV217) were plated on Hyg, INH, or Hyg/INH. The key 
indicates the substrate and quantity held constant, and the antibiotic selection for each reaction. 
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3.4.6 Point mutagenesis in the absence of selection 
The results of the co-selection experiments suggested that mutant alleles could be easily 
identified at a high frequency when selection for plasmid transformants eliminates the non-
transformable majority of the cell population. To test this idea, the same experiment was 
performed in which the INHR oligonucleotide and HygR plasmid were co-transformed, but the 
inhA mutation was not selected. Rather, the cells were diluted multiple times in liquid media 
containing Hyg in a culture block. Each culture well was plated to determine the number of 
starting cells; in this experiment, each well contained ~70 HygR cells at the time of dilution. 
Culture wells were then grown to saturation, and the inhA locus examined for each well by 
mismatch amplification mutation assay PCR (MAMA-PCR) [30,219]. Mutant alleles (even a 
single base change) are identified in a large wild type population by this technique (Figure 27A), 
in which the primers and PCR conditions are optimized such that only mutant alleles are 
amplified. Using this method, at least one mutant inhA allele was identified in each culture well 
(Figure 27B).  Homogenous mutant colonies were identified at a frequency of 3-4% from these 
culture wells by plating for single colonies and selecting for INHR (Figure 27C). It is noted that 
this is slightly decreased from experiments in which colonies are selected directly following 
transformation on solid media (5-10%). However, this is likely due to variation between 
experiments, since Hyg/INHR colonies were recovered at similar frequencies before and after 
outgrowth in culture wells in a different experiment (5% and 4.7%, respectively). 
This technique was also tested with an additional gene locus, the blaS gene in M. 
smegmatis. The oligonucleotide, which was designed to introduce two consecutive amber 
mutations in blaS, was co-transformed with a HygR plasmid, and the cells were diluted into 
liquid Hyg media as described above. MAMA-PCR identified a mutant allele in each culture 
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well (out of ~50 HygR cells) (Figure 27D), and subsequent MAMA-PCR analysis identified pure 
mutant strains that arose from the plating of a positive culture well (Figure 27E). This 
experiment corroborated the previous experiments with inhA, in that mutant cells were present at 
~3% out of HygR cells. Only two rounds of PCR were required to identify three blaS mutants (43 
PCR reactions). Alternatively, the experiment could likely be altered such that the transformed 
cells are diluted in Hyg media, grown to saturation, and plated for single colonies for MAMA-
PCR analysis. Interestingly, the early amber mutations did not confer the expected ampicillin-
sensitive phenotype for any of the three strains constructed; the blaS locus was analyzed by PCR 
and sequencing and the correct mutations were present (data not shown).  
In addition, an M. smegmatis pyrF point mutant that introduces an early stop codon 
(Q61amber) was also constructed using co-transformation. Since inactivation of pyrF results in 
5-FOA resistance and uracil auxotrophy, this mutant strain could also be used for co-selection in 
which uracil prototrophy acts as a positive selection, confirmed by 5-FOA sensitivity. The strain 
was constructed by double-oligonucleotide co-transformation, and three mutants were identified 
as UraS and 5-FOAR out of 100 HygR colonies. Two of these were confirmed by PCR and 
sequencing of the pyrF gene (data not shown).  
Experiments targeting two additional non-selectable loci (M. smegmatis groEL1 and 
leuD) were also attempted but were unsuccessful (data not shown). Several modifications were 
tested, including using oligonucleotides targeting both DNA strands, dsDNA substrates (100 and 
200 bp), increasing the recovery time of the transformation or the amount of substrate, but no 
mutants were found by MAMA-PCR in any of the examined samples. A similar result was found 
during attempts to make a selectable point mutation in M. smegmatis embB (I289M) that should 
confer ethambutol resistance [112,214], although recombinant colonies were never obtained 
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above background levels. This may be due to sequence-specific effects, and experiments 
introducing different mutations at the same or different nucleotides could be performed to 
examine this possibility. 
Finally, this strategy was tested on the M. tuberculosis leuD gene using co-transformation 
with a HygR plasmid, and mutants were identified by MAMA-PCR (Figure 27F). The co-
selection frequency in M. tuberculosis, estimated at 0.5% - 1%, is lower than that observed for 
most M. smegmatis loci. However, it should be noted that co-selection frequencies for the M. 
smegmatis rpsL locus are ~0.3 – 0.5%, since overall numbers of recombinants are ~10-fold lower 
at this target. Therefore, the low frequencies at the M. tuberculosis leuD target might be due to 
generally lower co-transformation or recombination frequencies, or sequence-specific effects. 
These data jointly demonstrate that both selectable and non-selectable point mutations can be 
constructed in M. smegmatis and M. tuberculosis. 
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Figure 27. Construction of non-selectable point mutations. 
 
 
Figure 27. (A) Schematic of the strategy used to identify non-selectable point mutations by MAMA-PCR. 
Electrocompetent recombineering cells (expressing Che9c gp61) are co-transformed with a HygR substrate (plasmid 
or ssDNA) and the ssDNA designed to introduce the desired mutation. Cells are recovered for four hours in media 
without antibiotics and diluted into culture wells (at multiple dilutions) in liquid media containing Hyg. MAMA-
PCR primers are designed in which the penultimate base does not match either a wild type or mutant allele, but the 
ultimate base pairs only with the mutant allele. Using high fidelity Taq polymerase, PCR preferentially amplifies 
DNA from mutant alleles. (B-E) MAMA-PCR analyses using wild type or mutant primers of the M. smegmatis inhA 
and blaS loci after co-transformations. (F) MAMA-PCR analysis of the M. tuberculosis leuD locus after co-
transformation. (B) Culture wells (12; A1-A12) from co-transformations with an oligonucleotide introducing an 
inhA S94A mutation and a HygR plasmid show the presence of wild type (upper panel) or mutant (lower panel) 
alleles; positive (inhA S94A mutant) and negative (wild type DNA) controls are shown. (C) Analysis of the inhA 
locus of INHR and INHS single colonies isolated from culture well A1 show pure mutant alleles only for INHR 
colonies. (D) Culture wells (12; A1-A12) from co-transformations with an oligonucleotide introducing two amber 
mutations (*) in blaS and a HygR plasmid show the presence of wild type (upper panel) or mutant (lower panel) 
alleles; positive (mutant DNA made by PCR) and negative (wild type DNA) controls are shown. (E) Analysis of the 
blaS locus of single colonies isolated from culture well A1 shows a positive pure mutant allele. (F) Culture wells 
from co-transformations in M. tuberculosis with an oligonucleotide introducing two amber mutations (*) in leuD 
and a HygR plasmid show the presence of mutant alleles. A1-A4: ~560 cells per well; B1-B7: ~56 cells per well. 
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3.5 OTHER APPLICATIONS OF RECOMBINEERING 
An additional attractive use of recombineering is the construction of unmarked, in-frame deletion 
mutants, and this can also be used for removing antibiotic resistance markers from gene 
replacement mutants. To determine if mycobacterial recombineering could be used to make 
deletions, the M. smegmatis leuD gene was targeted with substrates that delete the same region 
as previous allelic replacement experiments at this locus (Figure 17A). However, in this case, 
short ssDNA (100 nt) or dsDNA (100 bp or 200 bp) substrates were used that did not contain an 
antibiotic marker for selection. In addition, dsDNA substrates were tested because previous 
experiments targeting mycobacteriophage genomes indicated that these substrates were more 
efficient for deletion construction than ssDNAs (L. Marinelli, manuscript in preparation). The 
co-transformation strategy was used for this experiment since it had been successful for 
constructing point mutations. Colonies were analyzed by two methods, either by plating directly 
following transformation recovery, or by diluting cells in liquid media containing Hyg. In one 
experiment, colonies plated directly following transformation (with a 100 bp leuD substrate and 
HygR oligonucleotide) were replica plated onto media lacking leucine to identify leucine 
auxotrophs, and a single mutant was identified at a frequency of ~0.5% (Figure 28B).  
 In other experiments, culture wells were screened for the presence of the leuD deletion 
mutant. Mutants from experiments with an oligonucleotide that anneals to the lagging strand 
could be identified by MAMA-PCR at a low frequency (~0.2%), while no mutants were 
observed using a leading strand oligonucleotide (Figure 28C). Conversely, mutants were easily 
identified from transformations with 100 bp and 200 bp substrates using MAMA-PCR analysis, 
which indicated the presence of the mutant allele at a high frequency (Figure 28C). However, 
mutants can still be identified using a less sensitive PCR technique (with primers that anneal 
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outside the deletion locus). For example, in one experiment in which a HygR plasmid was co-
transformed with a 200 bp susbtrate, at least one mutant was identified out of eight culture wells 
(~10 cells per well; Figure 28D). Upon plating these colonies from the positive culture well, two 
mutants were identified and confirmed out of ten tested (Figure 28E). It should be noted that the 
frequencies observed by MAMA-PCR and standard PCR were inconsistent, which likely reflects 
the detection of much smaller quantities of the mutant allele by MAMA-PCR. Futher, mutant 
identification was simplified at this particular locus by screening for leucine auxotrophy. 
However, mutants were readily identified by using co-transformation and PCR screening 
techniques, and this technique is likely applicable to other genes. Additionally, it appears that 
using 200 bp substrates gives the highest recombineering frequencies, much like what is 
observed for mycobacteriophage recombineering (L. Marinelli, manuscript in preparation).   
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Figure 28. Construction of an M. smegmatis leuD unmarked deletion by recombineering. 
 
 
Figure 28. Recombineering of the M. smegmatis leuD gene to construct an unmarked deletion mutant. (A) A leucine 
auxotroph mutant was identified by replica plating following co-transformation with a 100 bp leuD deletion 
substrate and a HygR oligonucleotide. Primers for standard PCR (Std.) anneal out side the targeted region (blue), 
whereas the MAMA-PCR primer anneals over the deletion junction (red). (B) A pure leuD mutant constructed with 
a 100 bp substrate and HygR oligonucleotide selection is shown by standard PCR. (C) MAMA-PCR analysis of co-
transformations (experiment [A]) with 100 nt ssDNA substrates (leading or lagging strand), a 100 bp and a 200 bp 
substrate, with a HygR plasmid. The number of cells present in each well at the time of dilution (following 
transformation) are indicated. (D) Standard and MAMA-PCR analyses of culture wells from transformations 
(experiment [B]) with 200 bp substrate and a HygR plasmid. (E) MAMA-PCR analysis of 10 single colonies from 
culture well #1 [B] of (D). 
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3.6 CONCLUSIONS 
The Che9c recombineering system has successfully been used to construct gene replacements, 
point mutations, and gene deletions in the genomes of both M. smegmatis and M. tuberculosis. It 
is an efficient method for mutagenesis that is generally applicable to chromosomal and plasmid 
loci and is likely to be useful in other mycobacterial species. The Che9c proteins function 
similarly to the λ Red and RecET proteins in E. coli both in vitro and for recombineering in vivo. 
In fact, overall recombineering frequencies are similar between the two systems once differences 
in DNA uptake efficiencies are taken into account [52,240]. 
3.6.1 Recombineering: a powerful technique for constructing gene replacement mutants 
in the mycobacteria 
Targeted gene knockouts can be made simply with linear AESs generated from circular plasmid 
constructs containing ~500 bp or more of homology to the target gene flanking an antibiotic 
resistance gene. These can be linearized either by PCR-amplification or double-restriction digest, 
ensuring removal of the plasmid backbone (Figure 29). Using 100 ng of these substrates 
generates a sufficient number of mutant colonies at every non-essential gene locus tested thus 
far, with more than 90% the desired mutants. Although gene knockouts were obtained using 50 
bp of homology, this is not a recommended strategy due to the large decrease in recombineering 
frequency observed with these substrates. It is clear that the competency of the cells to take up 
DNA is an important criterion, and cells must be prepared with care. However, sufficiently 
competent cells were routinely made using a simple protocol without addition of glycine or other 
suggested supplements. As expected, the recovery of the desired gene replacement mutants is 
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dependent on expression of Che9c gp60 and gp61, and this sufficiently increased homologous 
recombination in M. tuberculosis, such that few recombinants arose from illegitimate 
recombination in these experiments.  
Targeted gene replacement mutagenesis has obvious benefits for the potential of making 
large-scale ordered gene deletion mutants in the genomes of M. tuberculosis and M. smegmatis. 
Not only would this provide mutant strains for various experimental purposes, but it would also 
supplement the data regarding gene essentiality from previous genome-wide studies [200]. 
Additionally, nonsense mutations could be introduced into putative essential genes by ssDNA 
recombineering to confirm essentiality and to avoid the polar effects of gene replacements or 
transposon insertions.  
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Figure 29. Construction of a recombieering AES for allelic gene replacement mutagenesis. 
 
 
 
 
 
 
 
Figure 29. Diagram of the recommended procedure for generating recombineering AESs. The regions at the 5 and 
3 ends of the targeted gene locus are amplified by PCR, such that the final products contain unique restriction sites 
(A, B, C, and D) for directional cloning flanking an antibiotic resistance gene (e.g. HygR). The PCR products and the 
cloning vector are digested with all four enzymes and simultaneously ligated together. Selection of HygR E. coli 
transformants generally yields a sufficient number of clones (albeit less than a standard two-way ligation), from 
which DNA is prepared and analyzed. Correctly cloned plasmids are digested with the two enzymes whose unique 
sites are at the distal ends of the homologous regions (A and D). Reactions are cleaned-up (removal of the plasmid 
backbone is unnecessary) and transformed into mycobacterial cells. 
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3.6.2 Recombineering of selectable and non-selectable point mutations 
The mycobacterial ssDNA recombineering technology enables the construction of isogenic 
strains that differ by a single point mutation without direct selection, a technique that is 
unparalleled by any other approach. Point mutations can be introduced in mycobacterial 
chromosomes, replicating plasmids, and lytically-replicating mycobacteriophage genomes at 
high frequencies. Since only Che9c gp61 is required for ssDNA recombination, point mutants 
can be constructed without the potential toxic effects of expressing gp60. Because ssDNA 
substrates can be synthesized commercially, these experiments merely require design and 
purchase of ssDNAs of a minimum recommended length of 48 nucleotides, which eliminates the 
requirement for plasmid construction or other complex DNA manipulations. In addition, the 
double-oligonucleotide co-transformation strategy enables the construction of non-selectable 
point mutations, such that strains are completely unmarked following removal of the 
recombineering plasmid. Remarkably, the E. coli and mycobacterial recombineering systems 
perform comparably under optimal conditions for each system – MMR-defective, Gam-
expressing strains and co-selective transformation, respectively – such that point mutants can be 
identified in the absence of direct selection at a high frequency (10-25%, respectively) 
[37,52,228].  
 The ssDNA recombineering technology could be specifically applied for determining the 
role of mutations that confer drug-resistance, particularly in regard to clinical research on the 
origins of XDR M. tuberculosis strains. Since most mutations are identified in combination with 
other mutations in M. tuberculosis strains, it is necessary to re-introduce each single mutation 
into a clean genetic background to determine its specific contribution to the strain’s drug-
susceptibility profile. However, this was previously not feasible due to the lack of generalized 
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transducing phages for M. tuberculosis. Only recently was the inhA S94A mutant strain 
constructed alongside an isogenic wild type strain by specialized transduction [232]. Similarly, 
the current study used ssDNA recombineering to test four characterized mutations for their 
ability to confer antibiotic resistance as reported, especially in genes such as inhA that have high 
levels of spontaneous mutagenesis and drug-resistance. For example, the gyrA A91V mutation 
had previously been identified in vitro along with other mutations in the gyrA gene, and this was 
not transduced into a clean genetic background [187]. The results of this study confirmed that 
this mutation is sufficient for generating resistance to ofloxacin. It is anticipated that similar 
experiments utilizing this technology will contribute to drug studies as a counterpart to detection 
and characterization of mutations conferring drug-resistance in M. tuberculosis clinical isolates. 
3.6.3 Unique attributes of the mycobacterial recombineering system 
Che9c gp61 functions similarly to λ Beta for ssDNA recombineering such that only the SSAP is 
required, recombination is independent of host RecA, and it is affected by the direction of DNA 
replication at the targeted locus. In both systems, ssDNA substrates that target (anneal to) the 
lagging strand DNA are more efficient than those that target the leading strand [52]. However, 
the strand biases in mycobacterial ssDNA recombineering assays at certain chromosomal loci are 
surprisingly quite sizeable (greater than 1000-fold in some cases), which is in stark contrast to 
the 2- to 50-fold bias in E. coli with λ Red recombineering [52]. It is clear that ssDNAs can 
recombine with the leading strand – since this was observed when targeting plasmids – but this is 
not consistently observed above background mutational frequencies or the limitations of DNA 
transformation. It is noted that experiments targeting plasmids in mycobacteria produce more 
modest strand biases, and this may be related to the mechanism of replication on the plasmid-
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encoded origin of replication. Furthermore, the size of the strand bias decreased from the origin 
to the terminus, suggesting that regions near the replication terminus are replicated by forks 
traveling in both directions. Overall, the dissimilarity in strand bias magnitude observed in 
mycobacteria and E. coli may relect with fundamental differences in DNA replication, which is 
not well-characterized in the mycobacteria. Specifically, this could be related to availability of 
ssDNA regions near replication forks for ssDNA recombineering substrates, or alternatively, the 
interaction of the SSAP-bound ssDNA with host proteins involved in DNA replication. 
 Mycobacteria do not encode homologues of the mutLS MMR, nor do they appear to have 
a functional MMR system [213], which otherwise might influence the efficiency of generating 
certain basepair mismatches [113]. Thus, DNA replication appears to be the major factor 
contributing to the frequency of ssDNA recombineering in mycobacteria. However, 
transformation efficiency has a limiting effect on mycobacterial recombineering, and it is not 
clear if this masks any other contributing factors. For instance, there were several attempts to 
make chromosomal point mutations that were unsuccessful, and this may be due to undetermined 
sequence-specific effects at those loci. Also, it is not clear why the highest observed co-selection 
frequency is 10%. Although the frequency was not expected to surpass 50% since only one 
strand of the chromosome is targeted, it is surprising that it is as low as 5-10%, and the reason 
for this is not known. 
An interesting difference between the E. coli and mycobacterial recombineering systems 
is the structure of the substrates required for making deletions. Experiments targeting both the 
mycobacterial chromosome and mycobacteriophage genomes for deletions demonstrated that 
dsDNA substrates yield better recombineering frequencies than ssDNA substrates, contrary to 
what is recommended in E. coli protocols for this type of mutagenesis [223]. In E. coli, ssDNA 
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substrates are clearly sufficient for making deletions at a high frequency [52,223], although the 
efficiency of dsDNA substrates for the same mutations has not been rigorously studied. 
Ultimately, 200 bp dsDNA substrates are recommended for constructing deletion mutants since 
these were more efficient than 100 bp substrates for both mycobacterial and mycobacteriophage 
genomes (see below). This is less suprising, however, since it reflects the correlation between an 
increase in homology length and an increase in recombineering frequency, which has been 
observed previously with both mycobacterial and E. coli recombineering systems [142,229,240]. 
3.6.4 Other uses for mycobacterial recombineering 
An ideal use of recombineering is to unmark allelic gene replacement mutants, which would also 
be useful in the mycobacteria. This is accomplished in E. coli by using a ssDNA substrate with 
homology to the regions to be deleted, typically flanking an antibiotic resistance gene (used to 
select the gene knockout) and a SacB cassette for negative selection. Interestingly, as described 
above, short dsDNA substrates were more efficient than either ssDNA for making an unmarked 
deletion mutant in M. smegmatis.  In-frame internal deletions and insertion of small tags for 
protein purification would also be useful strategies for assessing protein function. Although the 
ability to make these types of mutations in mycobacterial genomes has not been tested, it is 
likely that this will be successful, given the techniques that have been performed with the 
mycobacterial recombineering system on phages. 
 Experiments performed by Laura Marinelli have demonstrated that the mycobacterial 
recombineering system could also be used to target lytically-replicating mycobacteriophage 
genomes (manuscript in preparation). Phage mutagenesis is accomplished using a co-
transformation strategy (similar to experiments described above) in which the phage DNA is 
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transformed into recombineering-proficient cells along with the substrate to make the mutation. 
Several types of mutations have been constructed in different phages, including point mutations, 
unmarked deletions, and small insertions, and even a mutation that introduced a deletion and 
point mutation simultaneously. The ability to make mutants in virtually any mycobacteriophage 
will facilitate the study of uncharacterized phage genes and systematic analysis of genes essential 
for phage propagation, among other uses. 
3.6.5 Potential for optimizing the Che9c recombineering system 
As with any newly developed system, there are a number of parameters that could be tested to 
further optimize the conditions and increase the number of recombinants recovered. It is clear 
that the level of protein expression plays a role in recombineering frequencies; however, higher 
levels of gp61 expression did not necessarily correlate with an increase in recombineering. This 
is observed in the E. coli system as well [135,137,244], and using a 5:1 ratio of Beta:Exo 
produces the best results (K. Murphy, personal communication). An approximation of this with 
the mycobacterial recombineering system was roughly attempted by placing Che9c 60 under 
control of the Pacetamidase and 61 under the Phsp60. This setup did not increase dsDNA 
recombineering frequencies, which is not surprising since constitutive expression of gp61 did not 
increase ssDNA recombineering. It is likely that testing other promoter combinations would 
produce better results. For example, using another inducible promoter such as the Tet 
operator/UV15 promoter system [51,67] to control expression might work well. Alternatively, 
the current induction conditions could be modified, such as by altering the concentration of 
acetamide. 
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Another attractive approach for potential improvement to the mycobacterial system is to 
determine if the λ Gam or another functional analogue (T4 gp2, P22 Abc1/2) might function in 
mycobacteria to block host nuclease degradation. However, due to the specific protein-protein 
interactions of Gam or Abc1/2 with RecBCD that are required for activity, these particular 
proteins may not be the ideal solution. Instead, it might be more beneficial to co-opt a system in 
which the proteins block degradation by a different mechanism, such as T4 gp2 or Mu Gam 
which bind and protect the ends of dsDNAs [2,6].  Alternatively, recombineering could be tested 
in recBCD mutant strains, although this limits the strain background. It is also not known if other 
mycobacterial nucleases act on dsDNA substrates (such as AddA), and therefore, mutation of 
host genes is not preferred. However, to ascertain the effect of nuclease mutations, as well as to 
begin to characterize the role of RecBCD and AddA in mycobacteria, some of these experiments 
have been performed and are described in the Appendix. Briefly, deletion of recB  only modestly 
improved recombination frequencies (3- to 5-fold), and one assay with λ Gam did not improve 
recombineering frequencies. However, the recB strain holds potential for certain 
recombineering methods in which the genetic background is of less importance, such as with 
recombineering of phage genomes. This strain could therefore improve the frequency of mutant 
allele recovery in these assays, making mutant isolation easier and more efficient. 
Importantly, even though the Che9c recombineering system does not encode a Gam-like 
protein, it has worked sufficiently well for making gene replacement mutants at every non-
essential locus thus far tested in the Hatfull lab (>20 genes). This is striking in that inhibition of 
RecBCD (either with Gam or using a recBCD strain background) increases recombineering 
with the λ Red system at least 10-fold [43], and in some studies was found to be required 
[135,240,242]. This appears to be similar for RecET, such that Gam is not required but merely 
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enhances recombination efficiency [242]. It would therefore be interesting to examine the effect 
of Gam (or an analogous protein) on Che9c-mediated recombineering. 
One concern is the potential for genetic rearrangements due to leaky expression of the 
Che9c genes in M. tuberculosis, when these cells are grown in succinate media without 
acetamide. This expression pattern has been observed previously in mycobacterial strains 
expressing proteins from this promoter cassette, but importantly, expression was repressed in 
media containing ADC [157]. Although Che9c gp60/gp61 expression has not been monitored in 
M. tuberculosis recombineering strains grown in ADC, it is likely that expression is decreased (if 
not repressed completely) in ADC media as compared to succinate media. Recombinants were 
obtained at similar frequencies when M. tuberculosis recombineering cells were grown in ADC, 
washed, and incubated in succinate/acetamide media, albeit the cell competency dropped for 
both strains tested. This therefore represents an alternative approach to possibly eliminate 
expression of the Che9c proteins prior to the required 24 hour induction. 
Finally, other mycobacteriophage-encoded recombination systems were identified from 
sequencing and characterization. Although the Che9c proteins work sufficiently well for the 
types of mutagenesis thus far tested, other phages might encode recombination proteins with 
higher levels of activity. Therefore, the following chapter will examine the activity of phage-
encoded recombination proteins in the mycobacteria. 
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4.0  IDENTIFICATION AND CHARACTERIZATION OF OTHER 
BACTERIOPHAGE RECOMBINASES 
4.1 INTRODUCTION 
Recombinases that function in the single strand annealing recombination pathway are found in 
many bacteriophages, although only a few have been well-studied. SSAPs are typically identified 
in operons adjacent to an exonuclease similarly to λ Red and E. coli RecET. These genes exhibit 
the mosaic pattern broadly observed in phage genomes, such that different genes encoding 
SSAPs and exonucleases are mixed [85]. For example, in phages SPP1 (of B. subtilis) and A118 
(of Listeria monocytogenes), an Exo-like gene is found with a RecT-like gene. Several different 
exonucleases have been found in these systems, including proteins of the type II restriction 
enzyme fold (like λ Exo) and the type EndoVII fold [85]. Further, the gene order within the 
operon is not consistent, such that either the SSAP or the exonuclease can be transcribed first 
[43]. In some cases, like phage SPP1, other ORFs are predicted to lie between the genes 
encoding the exonuclease and recombinase [85]. Therefore, it appears that the organization of 
these recombination genes does not follow a particular pattern, but these can typically be 
identified based on similarity to other phage-encoded systems. 
 The apparent species-specificity of these recombination proteins is of particular interest 
with regard to the development and optimization of recombineering systems for bacteria other 
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than E. coli. A recent study by Datta and colleagues examined several putative SSAPs from 
phages that infect various bacterial hosts for activity in E. coli [43]. Using ssDNA 
recombineering as an assay, they observed that several SSAPs function with similar efficiency to 
λ Beta (~107 colonies), and not surprisingly, these proteins are predominantly from phages of 
Gram-negative bacteria. Several SSAPs from other phages that infect Gram-positive bacteria are 
able to introduce point mutations with moderate success (105 to 106 colonies). Notably, B. 
subtilis phage SPP1 gp35 and mycobacteriophage Che9c gp61 had the lowest recombination 
efficiencies (103 and 104 colonies, respectively). Also, a direct comparison of λ Beta and E. coli 
Rac prophage RecT showed that RecT functions ~30-fold worse in this assay. These data 
collectively suggest that there is a correlation between protein activity and organism relatedness, 
such that these phage-encoded proteins do not function as well in more distantly-related bacteria.  
Although the basis of this is unclear, it is possibly due to the ability of these proteins to interact 
specifically with host proteins during recombination, such as the components of the DNA 
replication machinery. 
In the same study, it was also observed that the B. subtilis phage SPP1 gp34.1 and gp35 
proteins, which are λ Exo and RecT homologues, respectively [85], promote dsDNA 
recombineering in E. coli [43]. Conversely, the L. monocytogenes phage A118 gp47 and gp48 
proteins (also λ Exo and RecT homologues, respectively [85]) did not have dsDNA activity, 
although the gp47 had ssDNA recombineering activity [43]. Interestingly, the genes encoding 
SPP1 gp34.1 and gp35 are separated by three predicted ORFs, whereas A118 gp47 and gp48 are 
adjacent. These data suggest that different pairs of recombination proteins can be identified in 
phages, although they may not be located together and not all are necessarily active in this type 
of assay.  
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 The finding that SSAPs from the same bacterial hosts – specifically, λ Beta and E. coli 
RecT – have different levels of activity has emphasized the need to examine other 
mycobacteriophage candidates for recombination activity. Mycobacteriophages are extremely 
diverse, and a large proportion of ORFs (~50%) do not have recognizable sequence similarity to 
known genes and are therefore of unknown function [165]. Currently, more than 50 
mycobacteriophages have been sequenced, contributing to a vast reservoir of genetic information 
in which to search for SSAP-like genes. The Che9c-encoded recombinase and exonuclease were 
identified out of the first 14 sequenced mycobacteriophages. However, analysis of the more 
recently sequenced phages has revealed additional putative homologous recombination systems, 
and these will be discussed and characterized in this chapter.   
Another approach to identifying phage-encoded recombinases is to assay directly for 
recombination activity, particularly with phages in which recombination proteins cannot be 
readily identified bioinformatically. During the construction of the first shuttle phasmids, Jacobs 
and colleagues observed that mycobacteriophage TM4 cosmid libraries recombined at a high 
frequency in vivo [86]. These TM4 cosmids are chimeric constructs in which an E. coli plasmid 
is randomly ligated to large fragments of the phage TM4 genome. These typically contain a 
nearly complete phage genomic molecule (containing an E. coli plasmid) with a small deletion of 
a portion of the phage DNA (see Figure 4).  Most of these cosmids cannot be propagated 
individually as phages and are non-infectious (as assayed by plaque formation); however, those 
that can were further utilized as shuttle phasmids [13,14,86]. Strikingly, when plaques resulting 
from transformation with a pool of cosmids were analyzed, it was found that only one plaque out 
of 400 still contained the E. coli plasmid; the rest contained intact wild type TM4 genomic DNA. 
This suggested that TM4 encodes a recombination system, although none of the ORFs have 
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similarity to known recombination proteins [165]. Therefore, the same assay utilizing TM4 
cosmid libraries was used to characterize the putative recombination system of this phage.   
4.2 BIOINFORMATIC ANALYSIS OF OTHER MYCOBACTERIOPHAGE 
RECOMBINATION SYSTEMS 
The results of BLAST analyses [4] using known recombination proteins as queries suggest that 
mycobacteriophages Halo, Giles, and BPs encode putative recombination systems that include 
recombinases in the λ Beta/RecT SSAP superfamily (Figure 30). Since Halo and BPs are 100% 
identical in the region containing these genes (99% overall), this analysis focused on the Halo 
proteins. Halo gp42 is 46% identical to Che9c gp60 and 30% identical to the C-terminus of 
RecE. However, analyses with Halo gp43 indicate that it is much more distantly related to other 
phage-encoded RecT proteins (~13% identity), and this was only identified after two rounds of 
PSI-BLAST. Additionally, the Halo gp43 protein was purified in a similar manner to Che9c 
gp61, and its DNA binding properties were analyzed by filter binding assays. Preliminary results 
indicated that gp43 does bind ssDNA (data not shown), although these experiments need to be 
repeated to determine the binding constant.  
Unlike Halo, BPs, and Che9c, mycobacteriophage Giles does not have a RecE-like 
homologue; instead, gp52 contains a domain from the YqaJ family of phage-encoded 
exonucleases. The putative SSAP in Giles, gp53, is also not easily identifiable, but it has 30% 
amino acid identity to Halo gp43. These two proteins do appear to be members of the λ 
Beta/RecT SSAP family (Figure 30B), although more distantly related than Che9c gp61. 
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In the process of studying genes related to Che9c 60 and 61, it was observed that M. 
avium contains a prophage that encodes similar proteins (Figure 30A). M. avium MAV_0829 
shares 29% amino acid identity with Che9c gp61; it is annotated as a ‘RecT/YqaK’ protein and 
has 40% identity to E. coli RecT. Not surprisingly, the gene adjacent to this (MAV_0830) is 
predicted to encode an exonuclease; it is 41% identical to Che9c gp60 and 23% identical to 
RecE. Further BLAST analysis also identified an Erf-like protein, gp64, encoded by 
mycobacteriophages Wildcat and Cjw1; Wildcat gp64 is 21% identical to P22 Erf and Cjw1 
gp70 is 15% identical to Erf (not shown). However, none of their adjacent genes has similarity to 
known recombination proteins. A prophage in M. abscessus is also predicted to encode a protein 
that is a distant relative of Erf (MAB_1744; 18% identity; not shown). Collectively, these data 
provided additional candidates to test for recombination activity in mycobacteria. 
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Figure 30. Mycobacteriophage-encoded recombination systems. 
 
 
 
Figure 30. Mycobacteriophages Giles and Halo, and an M. avium prophage encode putative recombination systems. 
(A) Che9c gp60, Halo gp42, and M. avium MAV_0830 are RecE homologues, while Giles gp52 has identity to a 
domain from the YqaJ-like exonuclease family. Che9c gp61, Halo gp43, Giles gp53 and M. avium MAV_0829 are 
RecT homologues. Proteins that share more than 20% amino acid identity are connected by shaded boxes and 
percent identity indicated. Exonucleases are indicated in red, and SSAPs (recombinases) are indicated in green. E. 
coli Rac prophage genes, Halo genes, Giles genes, M. avium genes, and Che9c genes are transcribed from left to 
right, while the λ genes are transcribed right to left. (B) Multiple sequence alignments were constructed with Che9c 
gp61, Halo gp43, Giles gp53, λ Beta, E. coli RecT, Shigella dysenteriae Beta, and Listeria innocua Lin1755; the last 
two were removed following alignment for simplicity. The alignment was performed similarly to Iyer et al. [85] 
using T-coffee [148], and secondary structure predictions (using JPred) were also conserved [40]. Similar residues 
are highlighted that were found by Iyer et al. to be conserved greater than 85%. 
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4.3 COMPARISON OF SSAP ACTIVITY IN M. SMEGMATIS 
Recombineering with ssDNA substrates provides a simple assay for recombination activity in 
vivo. In particular, drug-resistance mutations that give low background can be introduced in the 
M. smegmatis chromosome (discussed in section 3.4.3). Several SSAPs were tested for activity, 
including Halo gp43 and Giles gp53. In addition, E. coli RecT and λ Beta were analyzed in order 
to determine their activity in this distantly related bacterium, as well as to compare these results 
to those from a similar study by Datta et al. performed in E. coli [43]. The SSAP genes – Che9c 
61, Halo 43, Giles 53, E. coli recT, and λ bet – were under control of the Pacetamidase promoter 
cassette (plasmid pLAM12) such that translation was derived from either their endogenous 
signals (pJV52, pJV103, pJV145, pJV104, and pJV105) or from signals in the acetamidase 
promoter cassette (NdeI site; see Figure 14) (pJV62, pJV106, pJV116, pJV107, and pJV108).  
 M. smegmatis strains containing each of these plasmids were induced for expression the 
same way as all previous recombineering strains with the Che9c proteins. Reverse-transcription 
PCR (RT-PCR) analysis was used to examine expression from Pacetamidase for many of the 
constructs expressing genes from their endogenous translation signals (Figure 31A). Western 
blot analysis was performed on strains expressing Halo gp43 (Figure 31B), but was not suitable 
for some strains. Antibodies were not available for E. coli RecT, and the λ Beta antibodies (a gift 
from D. Court) had high background signal in M. smegmatis cells that masked any potential 
protein expression. Neither RT-PCR nor western blots were performed on Giles gp53 protein 
expressing strains. Strains expressing λ bet and E. coli recT both had detectable levels of RNA 
after induction with acetamide, indicating that at least transcription from this promoter is active 
in these constructs. However, this does not rule out any potential translation or protein instability 
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problems that could occur in this assay. Similar to Che9c gp61 (Figure 15), protein expression 
was also observed for the Halo gp43 (Figure 31B) by western blot.  
 Following these analyses, in order to test in vivo recombineering activity, each strain was 
transformed with oligonucleotides that introduced point mutations in the inhA, rpsL, and gyrA 
loci and recombinant colonies were selected. There were several surprising observations from 
these assays (Figure 31C, Table 12). First, Halo gp43 had a significant level of ssDNA 
recombineering activity, whereas Giles gp53 did not. This may be due to a lack of adequate 
expression, which can be tested in the future by RT-PCR and/or western blot analysis. Second, 
E. coli RecT had a high level of activity that was similar to Halo gp43, although not as high as 
Che9c gp61. Strains expressing λ Beta did not produce recombinant colonies above background, 
which is expected given anecdotal reports that the λ proteins are not active in mycobacteria. In 
addition, the strain that expressed RecT from the translation signals of the acetamidase promoter 
cassette had higher levels of activity (~10-fold) than the strain expressing RecT from its own 
translation signals (Figure 31C); this was also observed for Che9c gp61 in this and in previous 
assays (Table 9).  
 These data suggest that Che9c gp61 has the highest level of ssDNA recombineering 
activity in mycobacterial cells. Further, although Halo gp43 and Giles gp53 are 30% identical, 
strains expressing the Halo protein produced recombinants, whereas strains containing the Giles 
constructs did not. Finally, there is a substantial difference between the activities of E. coli phage 
SSAPs in the mycobacteria, such that λ Beta cannot recombine ssDNAs, while RecT is 
moderately efficient. 
 138 
Table 12. Comparison of SSAP recombination activities in M. smegmatis. 
    inhA rpsL gyrA 
 Strain 
(plasmid) Protein 
Cell 
Comp.a cfu
b Rec. Freq.c cfu
b Rec. Freq.c cfu
b Rec. Freq.c 
 pLAM12 [control] 2.7 x 106 ND ND 4 1.5 x 10-6 3 1.1 x 10-6 
pJV52 Che9c gp61 4.1 x 105 49,000 1.2 x 10-1 2,200 5.4 x 10-3 ND ND 
pJV103 Halo gp43 6.6 x 105 10,100 1.5 x 10-2 221 3.4 x 10-4 ND ND 
pJV145 Giles gp53 1.1 x 106 ND ND 4 3.7 x 10-6 9 8.3 x 10-6 
pJV104 E. coli RecT 7.8 x 105 3,190 4.1 x 10-3 101 1.3 x10-4 ND ND 
En
do
ge
no
us
 si
gn
al
s 
pJV105 λ Beta 3.6 x 105 1,740 4.8 x 10-3 2 5.6 x10-6 ND ND 
pJV62 Che9c gp61 6.2 x 105 ND ND 7,900 1.3 x 10-2 54,000 8.7 x 10-2 
pJV106 Halo gp43 5.6 x 105 ND ND 218 3.9 x 10-4 2,420 4.3 x 10-3 
pJV116 Giles gp53 1.6 x 105 ND ND 2 1.3 x 10-5 23 1.5 x 10-4 
pJV107 E. coli RecT 1.3 x 106 ND ND 1,400 1.0 x 10-3 9,700 7.2 x 10-3 
P a
ce
ta
m
id
as
e t
ra
ns
la
tio
n 
si
gn
al
s 
pJV108 λ Beta 8.6 x 105 ND ND 14 1.6 x 10-5 1 1.2 x 10-6 
 
a. Cell competency is determined by transformation with 50 ng of a control plasmid; expressed in cfu/g DNA. 
b. The number of drug-resistant transformants using 100 ng oligonucleotide to introduce the following mutations: 
inhA S94A (INHR), rpsL K43R (StrR), or gyrA A91V (OfxR). ND; not determined. 
c. Recombineering frequency is determined by dividing the number of recombinant colonies (b) by the cell 
competency (a). ND; not determined. 
 
 139 
Figure 31. Comparison of SSAP recombination activities in M. smegmatis. 
 
 
Figure 31. [228] (A) RT-PCR analysis of RNA extracted from M. smegmatis cultures in the presence or absence of 
induction with acetamide. RT-PCR products were analyzed with gene specific primers (Table 16) from strains 
containing the following plasmids: pLAM12 (empty vector), pJV52 (Che9c 61), pJV104 (E. coli recT), and pJV105 
(λ bet). Sizes of expected products: 482bp, 507 bp, and 642bp, respectively. PCR reactions without reverse 
transcriptase present were tested for the presence ofcontaminating DNA in the samples as a negative control. (B) 
Western blot analyses of strains expressing Halo gp43 in the presence or absence of inducer (0.2% acetamide) with 
polyclonal antibodies generated against purified gp43. (C) Recombineering frequencies of M. smegmatis strains 
expressing various SSAPs are shown from transformations with an oligonucleotide (JCV219) that confers StrR (rpsL 
K43R). The frequencies are represented on a log scale, and the frequencies are multiplied by 106 for presentation 
purposes. M. smegmatis strains contain plasmids that express SSAP genes from either their endogenous translation 
signals (RBS, pLAM12 HpaI site) or from translation signals present in the acetamidase promoter cassette (RBS, 
Pacetamidase; pLAM12 NdeI site); see Figure 14 for plasmid pLAM12 details. 
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4.4 CHARACTERIZATION OF A PUTATIVE RECOMBINATION SYSTEM IN 
MYCOBACTERIOPHAGE TM4 
Although the number of sequenced genomes continues to increase, recent PSI-BLAST analysis 
of the predicted gene products encoded by mycobacteriophage TM4 still did not reveal any clues 
as to which genes might provide the recombination activity. While some gene products had short 
regions of similarity to proteins with known recombination activity, they were not good 
candidates or were not located next to genes that were likely to be part of a recombination 
system. For example, gp54 (93 amino acids) has similarity to a region of the YqaJ-like 
exonuclease protein of Bacillus cereus. However, gp53 has only low levels of sequence 
similarity with hypothetical transpeptidase or dehydrogenase proteins, whereas the other adjacent 
gene, gp56, is predicted to encode a protein only 29 amino acids in length with no sequence 
similarity to known proteins. In another case, gp59 has only 17% sequence identity to a putative 
RecB family exonuclease from a Thermus phage. Again, the adjacent genes are not likely 
candidates; gp57 is predicted to encode a DinG helicase, gp58 has an esterase_lipase domain, 
and gp60 is a small protein (57 amino acids) without similarity to any proteins in the database. It 
is possible that there are different start sites for some of these genes that would alter the analysis. 
However, based on the annotated genes, these do not appear to encode bona fide recombinase or 
exonuclease homologues. 
 Therefore, to further examine the recombination phenotype observed for the TM4 cosmid 
molecules, a new TM4 cosmid library was constructed (as described [86] and in Figure 4, except 
a HygR plasmid was inserted instead of an AmpR plasmid). These molecules contained the E. coli 
plasmid inserted in a region of the TM4 genome that is either essential (non-viable phage = 
cosmid) or non-essential (true shuttle phasmid). TM4 cosmid DNA was isolated from individual 
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E. coli HygR colonies and examined by analytical restriction digest and sequencing to determine 
the structure of the cosmid. A set of cosmids was obtained by three rounds of screening, and the 
location of the E. coli plasmid and size of the TM4 deletion region were determined; these are 
illustrated in Figure 32. As a reference, four shuttle phasmids that were isolated by Jacobs and 
colleagues are also depicted in Figure 32 [13,14,86,87,210]. In addition, HygR colonies 
(~27,000) were pooled, and DNA was prepared in order to repeat the experiments performed by 
Jacobs et al. [86].  
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Figure 32. Diagram of the TM4 cosmid library. 
 
 
 
 
 
 
 
 
Figure 32. Each solid line on the schematic represents a TM4 cosmid (TM4cosX) or shuttle phasmid (phX). Dotted 
lines at the ends indicate that the molecule is connected at the termini; otherwise the E. coli plasmid connects the 
circle. The ‘blank’ spaces indicate the region deleted in the cosmid, as well as the location of the E. coli plasmid. A 
linear representation of the TM4 genome is depicted below (in kbp). Shuttle phasmids were made by Jacobs and 
colleagues [13,14,86]. The purple box indicates the region deleted in both TM4cos7 and TM4cos20 that renders 
them incapable of recombination. 
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Recombination experiments were performed in which cosmid pairs were co-transformed 
(500 g each) into wild type M. smegmatis, recovered for 30 minutes, and plated as top agar 
lawns with additional M. smegmatis cells. Plaque numbers were recorded for each 
transformation. It was observed that only cosmid pairs that represented the full genome between 
them (i.e., non-overlapping deletions) could produce plaques (Table 13), supporting the 
hypothesis that these molecules undergo recombination in vivo.  Since most cosmids had large 
deletions of their genome (~9 kbp), it is not surprising that the individual cosmids could not 
propagate as phages. Pairs of cosmids with overlapping deletions did not produce plaques, likely 
because the common deleted region was essential. As expected, plaques were also obtained from 
transformations with DNA of the ‘pooled’ cosmid library. Notably, two cosmids, TM4cos7 and 
TM4cos20, were not able to recombine with any other cosmids, even though the complete 
genome was represented in all pairs tested (Table 13). However, it is interesting that small 
numbers of plaques were obtained with these pairs, whereas zero plaques were consistently 
obtained with pairs that were not expected to recombine. This deficiency in recombination is 
likely due to the presence of a cis-acting element in this region that is required for recombination 
and/or DNA replication. The region encodes only one small gene in entirety, 71, but does also 
include the 3 half of gene 70, which is predicted to encode the DNA primase. Therefore, the cis-
acting element could be an origin of replication, which is often located in the region of the 
genome that encodes DNA replication proteins in other phages and in bacteria [58,99]. 
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Table 13. Recombination between TM4 cosmids as measured by plaque formation. 
Individual  Pairs w/  overlapping deletions  
Pairs w/ non-
overlapping deletions  
TM4Cos7 and 
TM4Cos20 pairs 
TM4Cos#a Pfu per g DNAb  TM4Cos#
a Pfu per 
g DNAb  TM4Cos#
a Pfu per 
g DNAb  TM4Cos#
a Pfu per g 
DNAb 
7 0  8 + 11 0  8 + 9 235  7 + 8 2 
8 0  9 + 49 0  9 + 11 353  7 + 9 3 
9 0  9 + 53 0  9 + 12 252  7 + 11 0 
11 0  14 + 13 0  9 + 42 263  7 + 14 2 
12 0     8 + 14 491  14 + 20 2 
13 0     11 + 49 248    
14 0          
20 0          
42 0          
49 0          
53 0          
TM4 DNA 
(pfu per g)c 1 x 10
4          
Pooled DNA 
(pfu per g) 320          
 
a. Each cosmid was assigned a number during screening: TM4cosX.  
b. The number of plaques (pfu) per g total DNA is shown from transformations with DNA from either single 
cosmids, pairs of cosmids, or a pooled library.  
c. Wild type TM4 DNA (200 ng) was used as a positive control and is represented as pfu/g. 
 
 Analysis of plaques resulting from transformations with pooled cosmid DNA or pairs of 
cosmids showed only the presence of wild type TM4 DNA (Figure 33A). These recombinant 
plaques did not show the presence of the E. coli plasmid (assayed by PCR), and DNA prepared 
from the plaques displayed a restriction pattern identical to wild type (Figure 33B). No true 
shuttle phasmids were identified out of 14 plaques screened from the pooled library, which is 
expected since these were recovered from the previous study at a very low frequency (~0.25%). 
Further, the average size of the deletions in the cosmids was ~9 kbp, which is much larger than 
the deletions found in shuttle phasmids, such as phAE87 (305 bp) and phAE159 (~5856 bp) [14], 
and is therefore more likely to have removed essential genes.  
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 Recombination between the TM4 cosmids could conceivably be derived from either host 
or phage recombination protein activity. Therefore, similar assays were performed in recA and 
recB M. smegmatis strains (gifts of K.G. Papavinasasundaram and K. Derbyshire, respectively) 
to determine the role of host recombination. Recombinant wild type plaques were obtained in 
both strains using pairs of cosmids to assess recombination (Figure 33C), but unpredictably, 
recombination levels were consistently higher in the recA and recB strains (~2-fold) 
compared to wild type. These data demonstrate that TM4 cosmid molecules recombine in vivo to 
yield wild type TM4 DNA independently of host RecA and RecB, which suggests that TM4 
encodes a recombination system. 
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Figure 33. TM4 cosmids recombine in vivo to yield wild type TM4, independently of host RecA and RecB. 
 
 
 
Figure 33. (A) Plaques from transformations with DNA from the pooled cosmid library were analyzed by PCR with 
two sets of primers that amplify TM4 DNA (880 bp) and pYUB854 DNA (584 bp). Controls included (from left to 
right): a plug from a lawn of M. smegmatis, a TM4 plaque, TM4 DNA, pYUB854 DNA, no DNA, and TM4cos11 
DNA. (B) DNA was prepared from two recombinant plaques and analyzed by BstEII restriction digest alongside 
wild type TM4 DNA as a control. (C) Cosmid pairs with non-overlapping deletions (e.g. TM4cos9 and TM4cos11) 
were co-transformed into wild type, recA, and recB M. smegmatis strains, and plaque numbers were recorded; 
TM4 DNA was transformed separately as a positive control. For each transformation, the number of plaques from 
cosmid transformations (per g) was divided by the number of TM4 plaques (per g) and represented as percent 
plaque formation. The data shown represent the average of eight independent experiments, with error bars calculated 
from standard deviations. 
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A number of other experimental approaches for identifying the TM4 recombination 
proteins were attempted without success. First, an M. smegmatis TM4 genomic library was 
constructed in which TM4 fragments were cloned in the pLAM12 vector under control of 
Pacetamidase, and a library of these were transformed into wild type M. smegmatis. These cells were 
induced for expression and prepared similarly to Che9c gp60/gp61-expressing cells. 
Recombination activity was assayed by ssDNA recombineering using oligonucleotides that 
introduce point mutations that confer drug-resistance. However, transformation of the pooled 
library cells did not produce recombinant colonies in duplicate experiments. Therefore, as a 
second approach, individual segments of the TM4 genome (~3 kbp, excluding known structural 
genes) were cloned in pLAM12. However, only two out of ten plasmids successfully 
transformed M. smegmatis. This suggests that even the leaky expression of the acetamidase 
promoter is sufficient to cause toxicity with some of these genes, and therefore a different 
promoter or vector may be required. A similar result that may be a result of leaky expression was 
observed in experiments with Halo genes 41-44 cloned under the acetamidase promoter. It was 
observed that constructs that expressed Halo gp41-44 on a replicating vector (pLAM12 parent) 
grew very slowly, while an integrated version was better tolerated (data not shown). These 
experiments – both the M. smegmatis library and the individual TM4 clones – could be repeated 
in a different vector background. 
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4.5 CONCLUSIONS 
4.5.1 Mycobacteriophage-encoded recombination systems  
Thus far, only seven known or putative recombination systems have been identified by 
bioinformatic analyses in mycobacteriophages and prophages out of 51 sequenced phages and all 
mycobacterial sequences in the NCBI database. However, more in-depth PSI-BLAST analysis 
using putative recombination proteins from phages of related bacteria as queries may uncover 
additional mycobacteriophage genes. The observation that TM4 likely encodes a recombination 
system that is not recognizable by sequence similarity suggests that these proteins are probably 
present in other phages but are, thus far, unidentified. The putative Giles recombination system 
could have easily been overlooked without careful scrutiny if not for the similarity between Giles 
gp53 and Halo gp43, and these genes were only recognized because the gene adjacent to Halo 
gp43 is a recognizable RecE homologue. Approximately 50% of the mycobacteriophage ORFs 
do not have sequence identity to proteins with known function from other organisms, but many 
are similar to other mycobacteriophage-encoded genes. Therefore, identification of additional 
phage-encoded recombination proteins – either by bioinformatic or experimental analyses – may 
reveal the presence of these in more mycobacteriophages.  
Among the mycobacteriophage-encoded SSAPs that were examined in vivo, Che9c gp61 
demonstrated the highest level of recombineering activity, and Halo gp43 functioned less well 
with an 8- to 30-fold reduction in activity. Surprisingly, however, Giles gp53 did not produce 
recombinant colonies above background levels, even though it shares 30% amino acid identity 
with Halo gp43. However, since protein expression was not confirmed, these results are not 
conclusive. It would therefore be interesting to examine the other putative SSAP proteins for 
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activity in mycobacteria.  These results are reminiscent of those from the study by Datta et al. in 
which λ Beta and E. coli RecT demonstrated a stark difference in recombineering efficiency 
[43], even though they both are encoded by E. coli phages. This further supports the notion that 
development of genetic tools such as this may require characterization of multiple 
bacteriophages to increase the available phage gene pool in which to search for recombination 
proteins.  
The role of these proteins in the mycobacteriophages is unknown, and the question of 
whether these proteins are essential in phages Che9c, Halo, and Giles is currently being tested in 
the Hatfull lab. Further, their role (if any) in phage propagation cannot necessarily be inferred 
based on data from other phages. The activities of these proteins vary in other phages, although it 
is common that recombination deficient phages are decreased in burst size [53,218]. For 
example, one function of the λ Red system is likely to increase DNA synthesis by generating 
additional circular genomes from linear concatemers [53,106], whereas the P22 system 
circularizes the genome upon entry into the host cell [237,238]. Further investigation of the 
prevalence of SSAP genes in mycobacteriophage genomes and their function in vivo will yield 
better insights into their biological relevance and diversity. 
4.5.2 SSAP species-specificity 
From this study and that performed by Datta and colleagues [43], it is apparent that there is a 
distinct difference in recombination activity when the same SSAPs are tested in M. smegmatis 
and E. coli.  Although this could be due to experimental variation, it is more likely a result of the 
inherent species-specific nature of these proteins. Recombination proteins encoded by Gram-
negative bacteria tended to have the highest activities in E. coli, whereas proteins from phages 
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infecting more distantly related hosts displayed decreased activity. In M. smegmatis, expression 
of Che9c gp61 facilitated the highest recombineering frequencies, with Halo gp43 and E. coli 
RecT moderately lower in activity (30- and 10-fold, respectively). Therefore, the finding that 
Che9c gp61 functions at a low level in E. coli is clearly not due to an inherently poor activity of 
this protein, which was suggested by Datta et al. [43], but instead is probably due to expression 
in a distantly-related organism. However, the data from the two studies correlated in the general 
observation that the SSAPs – specifically λ Beta and Che9c gp61 – displayed the highest 
activities above others tested in the native bacterial hosts of the phages from which they were 
derived. It is interesting to note that E. coli RecT had a high level of activity in M. smegmatis, 
whereas λ Beta was not active. This is in contrast to observations made in E. coli where λ Beta 
functioned substantially better than RecT in E. coli.   
 Overall, it appears that SSAP proteins function optimally in bacteria that are closely 
related to the hosts of their respective phages. This could be due to specific interactions with host 
proteins that occur during recombination. One plausible hypothesis is that the SSAP – and 
possibly the exonuclease – interacts with components of the DNA replication machinery, as 
replication is a process that has a direct effect on λ Red-, RecET-, and Che9c gp60/gp61-
mediated recombination efficiency [52,113,228,244]. A potential candidate for this interacting 
partner is the host SSB because it is associated with ssDNA during DNA synthesis, and this is 
therefore the suggested target for SSAP-ssDNA complex recombination. Therefore, extension of 
the recombineering technology to other organisms may require identification of a recombination 
system encoded by a host-specific phage in order to produce functional protein interactions for 
optimal activity. 
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 The SSAPs examined in this study have yet to be tested in other mycobacterial species, 
such as M. tuberculosis. Recombineering with ssDNA – though not with dsDNA – mediated by 
Che9c gp61 in M. tuberculosis is decreased 5- to 30-fold as compared to M. smegmatis in the 
same assays. This could also be due to slight differences between mycobacterial species in host 
protein-SSAP interactions that result in a decreased recombination efficiency. It is therefore 
possible that a different mycobacteriophage-encoded SSAP, such as Halo gp43, may improve 
recombineering frequencies in M. tuberculosis.  
4.5.3 The TM4 recombination system 
The in vivo recombination assay with TM4 cosmids observed by Jacobs et al. was repeated in 
this study, both with pools of the entire library of molecules and with pairs of cosmids [86]. No 
true shuttle phasmids were identified, though this is not surprising due to the average size of the 
deletions. Cosmid recombination was independent of the activities of the RecBCD complex, as 
well as the major host recombination protein, RecA. Therefore it appears that the activity is 
derived from phage-encoded proteins, although there may be other host proteins that are 
required. It is striking that an analysis of the TM4 genome does not reveal any pairs of proteins 
with sequence similarity to known recombination proteins. This suggests that the proteins 
required for recombination of the TM4 cosmids may be a new family of recombinases and/or 
exonucleases, and potentially these genes are located in separate regions of the genome. 
Experiments designed to screen for the recombination proteins were not initially successful, but 
the data provided a basis for altering the experimental setup. Further, a test screen should be 
performed with a phage genome – such as Che9c – that is known to encode recombination 
proteins. If the region of the Che9c genome that encodes gp61 can be identified in this type of 
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screen, this lends support to the utility of this experiment for other phages without recognizable 
recombination homologues. 
During the course of experiments with TM4 cosmids, a putative cis-acting element was 
discovered in the region of the genome between 42,796 bp and 44,854 bp. This is most likely the 
location of the origin of replication. Two pieces of evidence support this hypothesis; first, this 
region includes the putative DNA primase gene (70), and in other phages – such as λ – the origin 
of replication is present in the region encoding genes required for DNA replication [58]. Second, 
DNA replication plays a critical role in recombination in the single strand annealing pathway – 
such as with λ Red – by providing recombinogenic substrates [215,216,222]. Phage proteins 
required for DNA replication should be provided in trans by the other cosmid, but the deletion of 
the cosmid origin of replication cannot be compensated and may severely limit recombination. It 
is also possible that recombination still occurs at low levels, as evidenced by the small numbers 
of plaques observed in recombination assays with cosmids deleted for this region. Further 
experimentation would be required to clearly identify the TM4 origin of replication and/or this 
cis-acting element.  
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5.0  DISCUSSION 
5.1 MYCOBACTERIAL RECOMBINEERING 
Bacteriophages have long demonstrated their utility for advancing tools for genetics and 
molecular biology in their bacterial hosts. Some of the more well-known examples of this are 
DNA ligase, T4 polymerase, and various restriction enzymes. This is further exemplified by the 
use of phage-encoded recombination proteins for the recombineering technology originally 
developed in E. coli, and later extended for use in other Gram-negative bacteria. The 
mycobacteriophages are no exception; the sequencing and characterization of these phages has 
provided a vast reservoir of genes to study and exploit for materials such as integration-proficient 
plasmids, selectable markers, and most recently, the mycobacterial recombineering system.  The 
development of this system will allow members of the mycobacterial research community to 
perform genetic manipulations with an efficiency that is unparalleled by any other technique. 
Gene replacement mutagenesis by recombineering requires the same amount of DNA cloning 
and cell preparation as the minimum amount required for any other technique. Construction of 
the AES merely requires the standard synthesis of a linear substrate with ~500 bp homology 
flanking an antibiotic resistance cassette. No further manipulations of the AES are required, nor 
are the rounds of screening needed for some methods, since 90% of the mutants generated by 
recombineering are correctly targeted. Electrocompetent cell aliquots of the mycobacterial 
 154 
recombineering strain (containing plasmid pJV53 or a similar construct) can be prepared in 
advance and stored, which minimizes experimental preparation. Further, recombineering of point 
mutations does not require any plasmid construction, since the short ssDNA substrates can be 
synthesized commercially. Importantly, mutations that are not directly selectable can be made at 
a relatively high frequency (3-5%) by using a co-transformation technique. Removal of the 
recombineering plasmid can also be simplified by using a sacB gene for counter-selection. 
Another potential use of recombineering is the deletion of sequences, such as entire genes, 
internal domains, or the antibiotic resistance genes in marked gene replacement mutants. This 
has been demonstrated by deleting most of the M. smegmatis leuD gene, and likely can be used 
for other purposes. 
5.1.1 Future applications of mycobacterial recombineering 
The mycobacteriophage Che9c-encoded recombination system has provided a means for 
improving genetic techniques in mycobacteria, and it is likely that further extension of this 
technology will be made for other purposes. Targeted gene replacement mutagenesis has obvious 
potential for making complete gene deletion sets for M. tuberculosis and M. smegmatis, a feat 
that otherwise would be too time-consuming with available methods. Not only would this 
provide mutant strains for various experimental purposes, but it would also supplement the data 
pertaining to gene essentiality from previous genome-wide studies [200].  
 Additionally, nonsense mutations could be introduced into putative essential genes to 
assay essentiality and gene function. The initial experimental design to test this approach 
involved the use of a nonsense codon suppressor tRNA gene derived from mycobacteriophage 
L5, which has been shown previously to suppress amber mutations in mycobacteria [60]. The 
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amber suppressor gene has been cloned such that its expression should be controlled by the Tet 
inducible promoter [51], although suppression of amber mutations has thus far been 
unsuccessful. However, alternative expression systems could be tested that would provide tightly 
controlled induction or repression. Nonsense mutations could then be introduced into test genes 
by ssDNA recombineering, and the viability of the mutant strain could be assessed in the 
presence or absence of nonsense suppressor gene expression. Although this approach has yet to 
be tested, it offers the potential for analysis of gene essentiality at an individual locus or genome-
wide level. Finally, mutagenesis by ssDNA recombineering allows point mutations to be inserted 
in isogenic strains for direct and uncomplicated comparisons. This is more beneficial compared 
to previous methodologies that typically required gene deletion followed by complementation, 
and therefore analyses were not performed under endogenous conditions. This can be 
specifically applied for determining the role of mutations that confer drug-resistance, which may 
aid in research on the origins of XDR M. tuberculosis strains.   
 The extension of this technology for mutagenesis of mycobacteriophage genomes 
recently has provided a simple method for future genomic and proteomic study of phages (L. 
Marinelli, manuscript in preparation). For example, current experiments are testing if 
recombineering can be used to insert His-tags onto phage genes to facilitate simple purification 
of tagged proteins directly from infected cells. Several phages containing either point mutations 
or deletions have been constructed and are also currently being studied. In addition, gene 
essentiality can be tested, which has been demonstrated in a proof-of-principle experiment 
involving the deletion of the lysA gene of mycobacteriophage Giles.  
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5.2 MYCOBACTERIOPHAGE-ENCODED RECOMBINATION PROTEINS: A 
MODEL FOR DEVELOPMENT OF A RECOMBINEERING SYSTEM 
The mycobacteriophages are a fascinating group of organisms that have greatly contributed to 
our knowledge of evolution, morphologic and genetic diversity, biochemisty, and the biological 
consequences of phage-host interactions. Phage genome sequencing contributes to the expanding 
gene pool, a useful source for studies of gene function and the development of genetic tools. At 
the beginning of this project, the only sequenced mycobacteriophages encoding putative 
homologous recombination systems were Che9c and Halo, and therefore only these were 
available for study. Subsequently, phages BPs and Giles were sequenced, and similar proteins 
were identified, while careful PSI-BLAST analyses continue to reveal additional putative 
recombinases. Also of interest are the prophages that appear to be present in the genomes of M. 
avium and M. abscessus and encode SSAP recombinase homologues, as well as 
mycobacteriophages Wildcat and Cjw1. Although none of these proteins were examined any 
further in this study, they are also potential candidates for recombinase activity in vivo.  
 Interestingly, the mycobacteriophage-encoded recombinases that were tested had varying 
levels of activity in the M. smegmatis ssDNA recombineering assay. Fortuitously, the first 
recombinase used, Che9c gp61, exhibits the highest levels of recombination activity in vivo thus 
far. Halo gp43 is slightly less efficient, and Giles gp53 did not show any activity in these assays, 
although in this case expression was not confirmed. This first suggests that identification of only 
one phage-encoded recombination protein may not be sufficient for development of a 
recombineering system in other bacteria. Instead, these findings support the notion that 
identification and analysis of multiple phage-encoded proteins is preferable in order to optimize 
recombineering frequencies.  In light of the species-specificity observed for both the E. coli and 
 157 
mycobacterial phage-encoded recombination proteins, it is clear that optimal levels of 
recombineering can best be achieved through isolation and sequencing of host-specific 
bacteriophages. Therefore, it is likely that recombineering systems can be developed in virtually 
any genetically tractable bacterium for which at least basic genetic tools – such as plasmids and 
expression cassettes – have been described. 
 An important consideration is the question as to why the mycobacteriophage-encoded 
recombinases display varying levels of activity in M. smegmatis, particularly since they all 
appear to belong to the same SSAP superfamily. One attractive explanation is that they each 
function optimally in the preferred host bacterium of their respective phages. The species-
specific nature of these proteins – observed broadly between phage-encoded proteins of 
distantly-related host bacteria such as E. coli and M. smegmatis – likely affects activity even in 
closely related bacteria of the same genus. Che9c gp61, for example, shows decreased 
recombination efficiency in M. tuberculosis compared to M. smegmatis. The basis of the 
differing activity levels may be attributed to specific recombinase-host protein interactions – 
during processes such as DNA replication – that are required for optimal recombineering. The 
role of replication is particularly interesting to consider with regard to the fast- and slow-growing 
mycobacteria. Although this is not well-studied, the rate, processivity, and/or regulation of DNA 
replication in M. tuberculosis is probably dissimilar to M. smegmatis, which may have a 
profound effect on recombineering frequencies. Therefore, perhaps expression of another 
recombinase will be more suitable for recombineering in M. tuberculosis or other mycobacteria. 
Halo gp43 is a particularly interesting candidate because Halo can infect M. tuberculosis (T. 
Sampson, personal communication). This logic can also be applied to other bacteria. While the λ 
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Red proteins may function sufficiently in some Gram-negative bacteria, developing 
recombineering in others may require testing of additional host-specific phage-encoded systems. 
 It is likely that additional homologues of known recombination proteins will be found as 
more phages and bacteria are sequenced. Possibly more interesting, however, are the phage 
genes that are not detectably related to known recombinases, but still function similarly. The 
genes that encode the recombination system of TM4 remain anonymous, and even a recent 
analysis did not reveal any likely candidates. Clearly, a screen will be necessary to identify these 
proteins. This tactic could then be used to develop recombineering in any bacterial system for 
which phages have been isolated but recombination proteins are not recognizable (or if the phage 
is not sequenced). The simplest approach appears to be the construction of a phage genomic 
library in several different vector backbones (integrating or replicating), potentially with 
different promoters in order to test varying expression levels. Subsequently, the library of 
bacterial cells containing these plasmids would be screened for activity using ssDNA 
recombineering of an allele conferring a drug-resistant phenotype. To test this, a screen should 
be performed first using a phage genome that is known to encode recombination proteins, such 
as Che9c or Halo. If this is successful, it would lend support to the use of this approach as a 
broadly applicable method for identifying phage recombinases, potentially one that could be 
used for phages of other bacteria.  
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6.0  MATERIALS AND METHODS 
6.1 REAGENTS AND BUFFERS 
6.1.1 Growth media 
7H9 broth: 4.7 g Middlebrook 7H9 powder (Difco) was dissolved in 900 ml dH2O and 5 ml 
40% glycerol. This was autoclaved, and 100 ml ADC (see below), 2.5 ml 20% Tween 80 (if 
desired), and antibiotics were aseptically added as required. For growth of M. tuberculosis, 5 ml 
oleic acid per liter was added. 
7H9 induction medium: 4.7 g 7H9 powder (Difco) was dissolved in 900 ml dH2O and 5 ml 
40% glycerol. This was autoclaved, and 100 ml dH2O, 10 ml 20% succinate, 2.5 ml 20% Tween, 
and Kanamycin (see below) were aseptically added. 
7H10 agar: 19 g Middlebrook 7H10 powder (Difco) was dissolved in 900 ml dH2O, and 12.5 ml 
40% glycerol and 4 drops anti-bubble (Pourite) were added. This was autoclaved, and 100 ml 
ADC and antibiotics as required were aseptically added. For growth of M. tuberculosis, 5 ml 
oleic acid per liter was added. 
7H11 agar: 21 g Middlebrook 7H11 powder (Difco) was dissolved in 900 ml dH2O, and 12.5 ml 
40% glycerol and 4 drops anti-bubble (Pourite) were added. This was autoclaved, and 100 ml 
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ADC, plus 5 ml oleic acid (or 100 ml OADC, BDL), and antibiotics were aseptically added as 
required. 
Mycobacterial top agar (MBTA): 4.7 g Middlebrook 7H9 powder (Difco) and 7 g Bacto Agar 
were dissolved in 900 ml dH2O and autoclaved. 
ADC: 20 g dextrose and 8.5 g NaCl were dissolved in 950 ml dH2O. 50 g Albumin (Spectrum 
Biochem) was added and stirred with no heat until dissolved. This was filter-sterilized through a 
0.22-m-pore membrane and stored at 4C. 
20% Tween 80: Tween 80 was dissolved at 20% (v/v) by heating to 56C, filtered through a 
0.22-m-pore membrane, and stored at 4C. This was used at a final concentration of 0.05% in 
liquid media. 
20% acetamide: Acetamide (Sigma) was dissolved at 20% in dH2O, filtered through a 0.22-m-
pore membrane, and stored at 4C. This was used at a final concentration of 0.2% in media.  
20% succinate: Sodium succinate dibasic hexahydrate (succinic acid, Sigma S9637) was 
dissolved at 20% in dH2O, filtered through a 0.22-m-pore membrane, and stored at 4C. This 
was used at a final concentration of 0.2% in media.  
Oleic acid: Oleic acid (Sigma) was dissolved at 10 mg/ml in dH2O by heating the ampule in 
37C water bath and stirring into dH2O with heat until completely dissolved. 1 g NaOH was 
added and stirred until dissolved, and the solution was filtered through a 0.22-m-pore 
membrane and stored in 10 ml aliquots at -20C. Used at a final concentration of 50 g/ml in M. 
tuberculosis media. 
Luria-Bertani broth (LB broth): 20 g LB broth (Difco) was dissolved in 1 L dH2O. This was 
autoclaved and antibiotics were added aseptically when required. 
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Luria-Bertani agar (LB agar): 35 g LB agar (Difco) was dissolved in 1 L dH2O, and 4 drops 
anti-bubble (Pourite) were added. This was autoclaved, and antibiotics were added aseptically 
when required. 
Tryptic Soy Broth (TSB): 30 g TSB (Difco) was dissolved in 1 L dH2O. This was autoclaved, 
and antibiotics were added aseptically when required. 
6.1.2 Antibiotics and Supplements 
Carbenicillin: (Cb, Sigma) was dissolved at 50 mg/ml in dH2O, filtered through a 0.22-m-pore 
membrane, and stored at 4C.  
Chloramphenicol: (CM, Sigma) was dissolved at 100 mg/ml in 100% ethanol and stored at 4C.  
Cycloheximide: (Chx, Sigma) was dissolved at 10 mg/ml in dH2O, filtered through a 0.22-m-
pore membrane, and stored at 4C.  
Ethambutol: (EMB, Sigma) was dissolved at 50 mg/ml in dH2O, filtered through a 0.22-m-
pore membrane, and stored at 4C.  
Ethionamide: (ETH, Sigma) was dissolved at 50 mg/ml in 100% DMSO and stored at 4C.  
Gentamicin: (Gent, sulfate salt, Sigma) was dissolved 10 mg/ml in dH2O, filtered through a 
0.22-m-pore membrane, and stored at -20C in 1 ml aliquots.  
Hygromycin B: (Hyg, Sigma) was dissolved at 100 mg/ml in dH2O, filtered through a 0.22-m-
pore membrane, and stored at -20C in 1 ml aliquots.  
Isoniazid: (INH, isonicotinic hydrazide, Sigma) was dissolved at 50 mg/ml in dH2O, filtered 
through a 0.22-m-pore membrane, and stored at 4°C. Solutions were made fresh and used 
within one week.  
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Isopropyl -D-1-thiogalactopyranoside: (IPTG) was resuspended to either 1 M or 0.1 M in 
dH2O, filtered through a 0.22-m-pore membrane, and stored at 4°C.  
Kanamycin: (Kan, Sigma) was dissolved at 50 mg/ml in dH2O, filtered through a 0.22-m-pore 
membrane, and stored at 4C.  
Leucine: (LEU, Sigma) was dissolved at 10 mg/ml in dH2O, filtered through a 0.22-m-pore 
membrane, and stored at 4C.  
Ofloxacin: (OFX, Sigma) was dissolved at 50 mg/ml in 1 N NaOH, filtered through a 0.22-m-
pore membrane, and stored at 4C. Solutions were made fresh and used within one week.  
Pantothenate: DL-Pantothenic acid (PAN, Sigma) was dissolved at 100 mg/ml in dH2O, filtered 
through a 0.22-m-pore membrane, and stored at -20C. 
Rifampicin: (RIF, Sigma) was dissolved at 50 mg/ml in 100% DMSO and stored at 4C 
wrapped in foil. Solutions were made fresh and used within one week.  
Streptomycin: (Str, Sigma) was dissolved at 50 mg/ml in dH2O, filtered through a 0.22-m-pore 
membrane, and stored at 4C. Solutions were made fresh and used within one week.  
Tetracycline: (Tet, Sigma) was dissolved at 5 mg/ml in dH2O, filtered through a 0.22-m-pore 
membrane, and stored at -20C. Tetracycline is light sensitive – media was prepared only at the 
time needed. 
Uracil: (URA, Sigma) was dissolved at 200 mM (22.41 mg/ml; 112.1 MW) in 1 N NaOH, 
filtered through a 0.22-m-pore membrane, and stored at 4C. 
X-gal: 100 mg (entire bottle from Invitrogen) was dissolved at 50 mg/ml in 100% DMF (2 ml), 
wrapped in foil and stored at -20°C. 
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5-Fluoro-orotic acid: (5-FOA, US Biologicals) was added to agar media prior to autoclaving at 
1 mg/ml. Powder goes into solution throughout autoclave cycle.  
6.1.3 Laboratory reagents and stock solutions 
0.1 M CaCl2: 11.1 g CaCl2 was dissolved in 1 L dH2O and autoclaved. 
100X Denhardt’s solution: 2 g BSA, 2 g Ficoll, and 2 g Polyvinyl pyrrolidine were dissolved in 
100 ml dH2O, filtered through a 0.22-m-pore membrane, and stored at -20°C. 
0.1 M DTT: Dithiothreitol was dissolved in dH2O at 0.1 M (1.54 g per 10 ml; 154 MW), filtered 
through a 0.22-m-pore membrane, and stored at -20°C in 1 ml aliquots. 
0.5 M EDTA: 93.06 g disodium EDTA (Na2EDTA) was dissolved in 400 ml dH2O on low heat, 
and pH was adjusted to 7.5 with NaOH (~50 ml 0.5M NaOH). Volume was brought to 500 ml 
and autoclaved.  
0.1 M Na2EDTA pH 8.8: 37.2 g of disodium EDTA (Fisher) was dissolved in 1 L dH2O, and pH 
was adjusted to 8.8 with NaOH. 
40% Glycerol: 400 ml Glycerol was mixed in 600 ml dH2O and autoclaved. 
40% Glucose:  400 g dextrose was dissolved in 750 ml dH2O and autoclaved. Water was added 
first and dextrose was slowly added to dissolve. 
0.25 M HCl: Stock solution HCl (11 M) was diluted to 0.25 M by adding 22.7 stock HCl per one 
L of dH2O. 
0.5 N KOH: 28.1 g of KOH was dissolved in 1 L dH2O and stored at room temperature.  
1 M MgCl2: 203 g MgCl2 hexahydrate (or 95.21 g anhydrous) was dissolved in 1 L dH2O and 
autoclaved. 
1 M MgSO4: 120.37 g MgSO4 was dissolved in 1 L dH2O and autoclaved. 
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5 M NaCl: 292 g NaCl was dissolved in 1 L dH2O, heated on low to dissolve, and autoclaved. 
3 M NaOAc: 408.1 g NaOAc was dissolved in 400 ml dH2O on low heat and pH adjusted to 5.2 
with glacial acetic acid (~200 ml). Volume was brought to 1 L and autoclaved. 
5 N NaOH: 200 g of NaOH was dissolved in 1 L dH2O. 
0.4 N NaOH: 80 ml of 5 N NaOH was brought to 1 L with dH2O. 
Phage Buffer: 4 g NaCl was dissolved in 980 ml dH2O, and 10 ml of 1 M Tris pH 7.5 and 10 
mL of 1 M MgSO4 were added and autoclaved. 
Phenylmethanesulphonylfluoride: (PMSF) was dissolved in isopropanol to 100 mM. The tube 
was wrapped in foil and stored at -20°C. 
Proteinase K: proteinase K was dissolved at 10 mg/ml in dH2O, filtered through a 0.22-m-pore 
membrane, and stored at -20C in 1 ml aliquots.  
10% SDS: 100 g SDS was dissolved in 1 L dH2O, filtered through a 0.22-m-pore membrane, 
and stored at room temperature. 
20X SSC: 175.32 g NaCl and 88.23 g sodium citrate were dissolved in 1 L dH2O and pH was 
adjusted to 7.0 with HCl. 
1 M Tris pH 7.5: 121 g Trizma base was dissolved in 800 ml dH2O, and pH was adjusted to 7.5 
with HCl. Volume was brought to 1 L and autoclaved.  
1 M Tris pH 8.0: 121 g Trizma base was dissolved in 800 ml dH2O, and pH was adjusted to 8.0 
with HCl. Volume was brought to 1 L and autoclaved. 
Tris-buffered saline ± Tween: (TBS, TBS-T) 25 mM Tris pH 8.0, 125 mM NaCl, ± 0.1% 
Tween. 
Tris-EDTA (TE): 10 ml of 1 M Tris, pH 7.5 and 2.5 ml of 0.5 M EDTA were mixed in 987.5 ml 
dH2O and autoclaved. Final solution: 10 mM Tris pH 7.5, 1.25 mM EDTA. 
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6.1.4 Gel electrophoresis 
6.1.4.1 Agarose gel electrophoresis 
 
20% Ficoll dye: 2 g Ficoll was heated on low heat to dissolve in 8 ml dH2O. 1 ml 1% (w/v) 
bromophenol blue and 1 ml 1% (w/v) xylene cyanol were added.   
Tris Borate EDTA (TBE): 121.1 g Trizma base, 51.25 g Boric Acid, and 3.72 g EDTA were 
dissolved in ~890 ml to make a 10X solution. 1X = 100 mM Tris (121.1 MW), 83 mM Boric 
Acid (61.83 MW), and 1 mM EDTA (372.24 MW).  
6.1.4.2 Polyacrylamide gel electrophoresis 
 
Coomassie Blue Stain: 2.5 g Coomassie Blue was dissolved in 450 ml methanol, and 90 ml 
acetic acid was added and volume brought to 1 L dH2O. This was filtered and stored at room 
temperature. 
Glycerol loading dye: 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, and 30% 
glycerol 
Protein gel running buffer (10X): 144 g glycine, 30 g Trizma base, and 10 g SDS were 
dissolved in 1 L dH2O by mixing SDS first, and pH was adjusted to 8.3. 
4X SDS-PAGE loading dye: 125 mM Tris pH 7.5, 20% glycerol, 2% SDS, 5% -
mercaptoethanol, 0.1% bromophenol blue dye. In 8 ml, add 2.6 ml dH2O, 1 ml 0.5 M Tris pH 
7.5, 1.6 ml neat glycerol, 1.6 ml 10% SDS, 0.4 ml -mercaptoethanol, 0.8 ml 1% bromophenol 
blue. 
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SDS-PAGE Laemmli gels: For 2 small 10% separating gels: 5 ml dH2O, 2.5 ml 4X separating 
buffer, 2.5 ml 40% acrylamide:bisacrylamide (29:1), 10 l TEMED, 40 l 10% (w/v) APS. For 2 
small stacking 4.5% stacking gels: 3 ml dH2O, 1.25 ml 4X stacking buffer, 0.5 ml 40% 
acrylamide:bisacrylamide (29:1), 15 l TEMED, 25 l 10% APS. 
4X SDS-PAGE separating buffer: 18.17 g Trizma base was dissolved in ~80 ml dH2O, and 4 
ml 10% SDS was added. pH was adjusted to 8.8 with HCl (~2.5 ml), and volume was brought to 
100 ml.  
4X SDS-PAGE stacking buffer: 6.06 g Trizma base was dissolved in ~80 ml dH2O, and 4 ml 
10% SDS was added. pH was adjusted to 6.8 with HCl, and volume was brought to 100 ml. 
TBE polyacrylamide native gels: For 1 large 8% gel: 42 ml dH2O, 6 ml 10X TBE buffer, 12 ml 
40% acrylamide:bisacrylamide (29:1), 21 l TEMED, 420 l 10% APS. 
 
6.1.5 Assay buffers 
Annealing buffer: 50 mM Tris pH 7.5, 100 mM NaCl 
Binding assay reaction buffer: 33 mM Tris pH 7.5, 13 mM MgCl2, 1.8 mM DTT, 88 g/ml 
BSA 
Binding assay wash buffer: 33 mM Tris pH 7.5, 13 mM MgCl2, 1.8 mM DTT  
Exonuclease assay buffer: 20 mM Tris, pH 8.0, 10 mM MgCl2, 10 mM -mercaptoethanol 
Genomic DNA prep CTAB solution: 4.1 g NaCl was dissolved in 90 ml dH2O, and 10 g 
Cetrimide was added, stirring. This was incubated at 65°C until in solution, and stored at room 
temperature. 
 167 
Gel filtration equilibration buffer: 33 mM Tris pH 7.5, 100 mM NaCl 
Genomic DNA prep GTE solution: 25 mM Tris pH 8.0, 10 mM EDTA, 50 mM glucose 
Protein dilution buffer: 10 mM Tris pH 7.5, 1 mM DTT, 1 mg/ml BSA 
Protein purification lysis buffer: 50 mM Tris pH 8.0, 300 mM NaCl, 5% glycerol, 1 mM 
PMSF 
Protein purification wash buffer: 50 mM Tris pH 8.0, 300 mM NaCl, 5% glycerol, 0-20 mM 
imidazole 
Protein purification elution buffer: 50 mM Tris pH 8.0, 300 mM NaCl, 5% glycerol, 20-200 
mM imidazole 
Protein storage buffer: 20 mM Tris pH 8.0, 0.1 mM EDTA, 0.1 mM DTT, 50 mM NaCl, 50% 
glycerol 
Southern blot pre-hybridization buffer: 6X SSC, 2X Denhardt’s solution, 0.1% SDS 
Southern blot hybridization buffer: 6X SSC, 20 mM NaPO4, pH 7.5, 5% PEG 8000 (Sigma) 
Southern blot wash buffer 1: 2X SSC, 0.1% SDS 
Southern blot wash buffer 2: 0.2X SSC, 0.1% SDS 
Western blot transfer buffer: 48 mM Tris, 39 mM Glycine, 0.037% SDS, 20% methanol 
6.2 PLASMID CLONING 
6.2.1 Plasmid maintenance in E. coli strains 
Plasmid constructs were maintained in either E. coli DH5 or GC5 (GeneChoice; similar 
genotype to DH5) strains.  When required, BL21(DE3) pLysS cells (Invitrogen) were used for 
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protein over-expression plasmids. Plasmids were transformed into chemically competent E. coli 
strains as described below (E. coli transformations). E. coli strains containing plasmids were 
mixed with sterile glycerol at a final concentration of 20% and stored at -80°C. 
6.2.2 Plasmids 
All of the plasmids that I made are described in Table 15. The genes of interest that were cloned, 
the parental insert source (PI), and the primers or restriction sites used for the insert are listed. 
The plasmid backbone that was cloned into (parental plasmid, PP), the restriction sites used in 
the vector backbone are listed, and other pertinent information is also included. For plasmids that 
were available commercially or were obtained from other lab members or collaborators, brief 
descriptions of the pertinent aspects of the plasmid (such as antibiotic resistance cassettes, genes 
of interest, etc.) are included in Table 14.  
 
Table 14: Plasmids constructed by others. 
Plasmid name Features Reference 
p0004S Cloning vector containing HygR-sacB cassettes 
flanked by MCSs and  res sites, oriE,  cos 
packaging site, oriE 
Gift from W.R. Jacobs, Jr. 
p0004S:leuB M. smegmatis leuB KO plasmid containing upstream 
and downstream homology to the leuB locus in 
p0004S 
Gift from W.R. Jacobs, Jr. 
p0004S:leuD M. smegmatis leuD KO plasmid containing upstream 
and downstream homology to the leuD locus in 
p0004S 
Gift from W.R. Jacobs, Jr. 
pAVN30 Contains Phsp60-sacB cassette for negative selection, 
HygR 
Gift from W.R. Jacobs, Jr. 
pBluescript SK+ E. coli cloning vector, oriE Stratagene 
pBR322 E. coli cloning vector, TetR, AmpR, oriE  NEB 
pBRL301 Contains “new” modified Phsp60-sacB cassette, HygR, 
oriE 
Gift from W.R. Jacobs, Jr. 
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pET21a T7 expression vector carrying a C-terminal 6x His-
tag, AmpR, oriE 
Novagen 
pET28c T7 expression vector carrying an N-terminal 6x His-
tag, AmpR, oriE 
Novagen 
pGH542 Expresses  resolvase constitutively for unmarking 
gene knockouts, TetR, oriE, oriM 
Gift from G. Hatfull 
pGH1000A Derivative of pMOSHyg containing Giles attP-int [126] 
phAE87 Shuttle phasmid for specialized transduction; use 
with pYUB854, oriE, AmpR 
[14] 
pJL37 M. bovis BCG hsp60 promoter, KanR, oriE, oriM [18] 
pJL37-Phsp60 Derivative of pJL37 without Phsp60 [61] 
pKP134 M. smegmatis pyrF KO plasmid containing the pyrF 
gene interrupted by a GentR cassette, oriE 
[155] 
pLAM12 Derivative of pJL37 containing the Pacetamidase 
promoter in place of the Phsp60 promoter 
[227] 
pLC3 T7 expression plasmid carrying an N-terminal 6x 
His-tag, MBP-fusion, and TEV protease cleavage 
site, KanR, oriE 
Gift from J. Sacchetini 
pLT193B-B Contains tRNA amber suppressor cassette (in L5 
gene 9), HygR, KanS, oriE 
Gift from C. Peebles; [61] 
pMOSBlue Cloning vector containing T7-lacZ for blue-white 
screening, AmpR, oriE 
GE Healthcare 
pMOSHyg Derivative of pMOSBlue, HygR  [227] 
pMP6 M. smegmatis MSMEG0642 KO plasmid containing 
upstream and downstream homology to the 0642 
locus in pYUB854 
[172] 
pMPambar Pmyc1tet-tRNA amber suppressor cassette, L5 attP-Int, 
GentR, oriE 
Gift from M. Piuri 
pMsgroEL1KO M. smegmatis MSMEG4308 KO plasmid containing 
upstream and downstream homology to the 4308 
locus in pYUB854 
Gift from A. Ojha 
pMsgroEL1KO M. smegmatis groEL1 KO plasmid containing 
upstream and downstream homology to the groEL1 
locus in pYUB854 
[149] 
pMtbgroEL1KO M. tuberculosis H37Rv groEL1 KO plasmid 
containing upstream and downstream homology to 
the groEL1  locus in pYUB854 
[227] 
pMV261-lac Phsp60-lacZ , KanR, oriE, oriM [217] 
pPJM04 M. smegmatis MSMEG6008 KO plasmid containing 
upstream and downstream homology to the 6008 
locus in pYUB854 
Gift from P. Morris 
pRDK557 E. coli recT gene, KanR Gift from R. Kolodner 
pSD26 Pacetamidase, HygR, oriM [44] 
pSE100 Pmyc1tetO, HygR, oriE, oriM [67] 
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pSJ25B Bxb1 attP-int, AmpR, oriE [95] 
pSJ25Hyg Derivative of pSJ25B, HygR  [60] 
pSJ25HygSac 
(pPG01) 
Derivative of pSJ25BHyg, sacB cassette [60] 
pTEK-4SOX Psmyc-tetR1.7, KanR, oriE, oriM [67] 
pTH1-8 Pacetamidase from pSD26, L5 attP-Int, KanR, oriE T. Huang, unpublished data 
pTTP1B Tweety attP-int, KanR, oriE [170] 
pTX-2MIX Pmyc1tetO, Psmyc-tetR, AmpR, oriE Gift from S. Ehrt and D. 
Schnappinger 
pYUB854 HygR cassette flanked by MCSs and  res sites, 
oriE,  cos packaging site 
[14] 
 
SDM, site-directed mutagenesis (primers listed); KO, knockout; F, forward orientation (gene cloned); R, reverse 
orientation (gene cloned); bl., blunted restriction site by fill-in with Klenow; Pacet, acetamidase promoter; res, 
resolvase; MCS, multiple cloning site; oriE, origin of replication E. coli; oriM, origin of replication mycobacteria. 
 
 
Table 15: Plasmids constructed by JV 
Plasmid 
Name 
Gene(s) of 
Interest 
Parental 
Plasmid 
(PP) 
PP 
Cloning 
Sites 
Used 
Parental 
Insert (PI) 
Source 
PI Cloning 
Sites Or 
Primers Used 
Antibiotic 
Markers 
Mycobact. 
Repl/Int 
Other 
Features 
pJL37-
oriM 
NA pJL37 MluI, 
XbaI, bl. 
NA NA KanR oriM Phsp60 
pMV 
261-lac-
amber 
lacZ 
Q24*amber 
pMV261-
lac 
NA NA SDM: 
JCV376, 
JCV377 
KanR oriM Phsp60 
pJV02F TM4 3811-
8438 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV02R TM4 3811-
8438R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV03F TM4 8438-
13882F 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV03R TM4 8438-
13882R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV04F TM4 
13882-
17320F 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV04R TM4 
13882-
17320R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV05R TM4 
17320-
21543R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV06F TM4 
21543-
22750F 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV06R TM4 pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
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21543-
22750R 
pJV07F TM4 
22750-
29001F 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV07R TM4 
22750-
29001R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV09F TM4 
34461-
39007F 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV09R TM4 
34461-
39007R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV11F TM4 
42691-
45427F 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV11R TM4 
42691-
45427R 
pJL37 HpaI TM4 NaeI KanR oriM Phsp60 
pJV15 TetR  
cassette 
pSJ25B DraI, 
HindIII, 
bl. 
pBR322 AvaI, HindIII, 
bl. 
TetR Bxb1 
attP/Int 
 
pJV16 lacZ 5' piece pJV15 BsaAI pMV261-lac PCR: JCV07, 
JCV08 
TetR Bxb1 
attP/Int 
 
pJV17 sacB 
cassette 
pJV16 BsaAI pAVN30 PCR: sacBF/R TetR Bxb1 
attP/Int 
sacB 
pJV18 PmlI site pJV17 NA NA SDM: JCV23, 
JCV24 
TetR Bxb1 
attP/Int 
 
pJV19 EcoRV site pTH1-8 NA NA SDM: JCV21, 
JCV22 
CbR, KanR L5 attP/Int Pacet 
pJV20 lacZ 3' piece pJV18 PmlI pMV261-lac PCR: JCV09, 
JCV10 
TetR Bxb1 
attP/Int 
sacB 
pJV21 TM4 "7-20 
region" 
pBR322 BsaAI TM4 PCR: JCV01, 
JCV03 
TetR   
pJV23 Che9c 
genes 59-62 
pJL37 HpaI Che9c PCR: JCV19, 
JCV20 
KanR oriM Phsp60 
pJV24 Che9c 
genes 59-62 
pLAM12 HpaI Che9c PCR: JCV19, 
JCV20 
KanR oriM Pacet 
pJV25 Che9c 
genes 59-62 
pJV19 EcoRV Che9c PCR: JCV19, 
JCV20 
KanR L5 attP/Int Pacet 
pJV26 Che9c 
genes 59-62 
pJL37-
Phsp60 
HpaI Che9c PCR: JCV19, 
JCV20 
KanR oriM  
pJV27 Msmeg recA 
upstream 
homol.  
pYUB854 XbaI, StuI M. 
smegmatis 
PCR: JCV15, 
JCV16 
HygR   res 
sites 
pJV28 Msmeg recA 
downstream 
homol.; 
final recA 
KO plasmid  
pJV27 HindIII, 
bl. 
M. 
smegmatis 
PCR: JCV17, 
JCV18 
HygR   res 
sites 
pJV29 pJV28+ 
shuttle 
phasmid 
phAE87 
phAE87 PacI pJV28 PacI HygR shuttle 
phasmid 
 
pJV30F TM4 "5-
16kb 
region"  
pJL37 HpaI TM4 KpnI, bl. KanR oriM Phsp60 
pJV30R TM4 "5-
16kb 
region"  
pJL37 HpaI TM4 KpnI, bl. KanR oriM Phsp60 
pJV30F- NA pJV30F HindIII, NA NA KanR oriM  
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Hsp60 XbaI, bl. 
pJV30R-
Hsp60 
NA pJV30R HindIII, 
XbaI, bl. 
NA NA KanR oriM  
pJV31 TM4 gene 
70 
pJL37 HpaI TM4 PCR: JCV13, 
JCV14 
KanR oriM Phsp60 
pJV32 TM4 gene 
70 
pJL37-
oriM 
HpaI TM4 PCR: JCV13, 
JCV14 
KanR  Phsp60 
pJV33 Che9c gene 
60 
pET21a NdeI, 
XhoI 
Che9c PCR: JCV47, 
JCV48 
CbR  C-term 
His tag;  
T7 
expression 
pJV34 Che9c gene 
61 
pET21a NdeI, 
HindIII 
Che9c PCR: JCV49, 
JCV50 
CbR  C-term 
His tag;  
T7 
expression 
pJV35 Halo gene 
42 
pET21a NdeI, 
XhoI 
Halo PCR: JCV51, 
JCV52 
CbR  C-term 
His tag;  
T7 
expression 
pJV36 Halo gene 
43 
pET21a NdeI, 
HindIII 
Halo PCR: JCV53, 
JCV59 
CbR  C-term 
His tag;  
T7 
expression 
HygR lacZ 5' piece pSJ25Hyg
Sac 
XmnI pJV37 pMV261-lac PCR: 
JCV07,JCV08 
Bxb1 
attP/Int 
sacB 
pJV38 lacZ 3' piece HygR Bxb1 
attP/Int 
SapI, bl. pMV261-lac pJV37 PCR: JCV09, 
JCV10 
sacB 
pJV39 L5 attP/Int 
cassette, R 
pMOSHyg DraI pMH94 SalI, bl. HygR L5 attP/Int Interr. 
lacZ 
pJV40 TM4 "5-
16kb 
region"  
pSJ25Hyg KpnI TM4 KpnI HygR Bxb1 
attP/Int 
 
pJV41 Halo gene 
42 
pET28c NdeI, 
XhoI 
pJV35 NdeI, XhoI CbR  N and C-
term His 
tag;  T7 
expression 
NdeI, XhoI CmR pJV42 Halo gene 
42 
pLC3 NdeI, 
XhoI 
pJV35  MBP-
fusion 
pJV43 GentR 
cassette, R 
pJL37 BamHI pKP134 BamHI KanR, GentR oriM Phsp60 
pJV44 GentR 
cassette, R 
SpeI, 
NheI, bl. 
pKP134 BamHI, bl. pJL37 GentR oriM Phsp60 
pJV45 GentR 
cassette, R 
pJV39 AatII, 
ClaI, bl. 
pKP134 BamHI, bl. GentR L5 attP/Int Interr. 
HygR 
pJV46 Che9c 
genes 59-
62, R 
pMOS 
Blue 
EcoRV pJV23 PCR: JCV19, 
JCV20 
CbR  Interr. 
lacZ 
pJV47 Halo genes 
41-44, R 
pMOS 
Blue 
EcoRV Halo PCR: JCV61, 
JCV62 
CbR  Interr. 
lacZ 
pJV48 sacB 
cassette, R 
pJV24 SpeI pAVN30 PCR: sacBF/R KanR oriM Pacet, 
sacB 
pJV49 Che9c 
genes 59-62 
pJL37-
oriM 
HpaI pJV23 PCR: JCV19, 
JCV20 
KanR  Pacet 
pJV50 sacB 
cassette, R 
pJL37 SpeI, bl. pAVN30 PCR: sacBF/R KanR oriM Phsp60, 
sacB 
pJV51 sacB 
cassette, R 
pLAM12 SpeI, bl. pAVN30 PCR: sacBF/R KanR oriM Pacet, 
sacB 
pJV52 Che9c gene 
61 
pLAM12 HpaI pJV23 PCR: JCV49, 
JCV78 
KanR oriM Pacet 
pJV53 Che9c 
genes 60-61 
pLAM12 HpaI pJV23 PCR: JCV47, 
JCV78 
KanR oriM Pacet 
pJV54 Che9c gene pJV50 NheI, bl. pJV23 PCR: JCV49, KanR oriM Phsp60, 
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61 JCV78 sacB 
pJV55 Che9c gene 
60 
pLAM12 NdeI, 
EcoRI 
pJV23 PCR: JCV47, 
JCV77 
KanR oriM Pacet 
pJV56 Che9c gene 
60/acet 
pJV54 NotI, 
XbaI, bl. 
pJV61 DraI, NheI, bl. KanR oriM Pacet-60; 
Phsp60-
61; sacB 
pJV57 Halo genes 
41-44 
pJL37 HpaI Halo PCR: JCV61, 
JCV62 
KanR oriM Phsp60 
pJV58 Halo genes 
41-44 
pLAM12 HpaI Halo PCR: JCV61, 
JCV62 
KanR oriM Pacet 
pJV59 Halo genes 
41-44 
pJV19 EcoRV Halo PCR: JCV61, 
JCV62 
KanR L5 attP/Int Pacet 
pJV60 Halo genes 
41-44 
pJL37-
Phsp60 
HpaI Halo PCR: JCV61, 
JCV62 
KanR oriM  
pJV61 Che9c gene 
60 
pLAM12 HpaI pJV23 PCR: JCV47, 
JCV77 
KanR oriM Pacet 
pJV62 Che9c gene 
61 
pLAM12 NdeI, 
NheI 
pJV52 NdeI, NheI KanR oriM Pacet 
pJV63 Che9c 
genes 60-61 
pLAM12 NdeI, 
NheI 
pJV53 NdeI, NheI KanR oriM Pacet 
pJV64 Msmeg 
leuD , R 
pSJ25Hyg HindIII, 
bl. 
M. 
smegmatis 
PCR: 
JCV113, 
JCV118 
HygR Bxb1 
attP/Int 
 
pJV64op
al 
leuD R15* 
R16* opal 
pJV64 NA NA SDM: 
JCV132, 
JCV133 
HygR Bxb1 
attP/Int 
 
pJV64a
mber 
leuD K31* 
R32*  
amber 
pJV64 NA NA SDM: 
JCV134, 
JCV135 
HygR Bxb1 
attP/Int 
 
pJV67 Msmeg recB 
upstream 
homol. 
pYUB854 BglII, 
XhoI 
M. 
smegmatis 
PCR: 
JCV136, 
JCV137 
HygR   res 
sites 
pJV68 Msmeg recB 
downstream 
homol; final 
recB KO 
plasmid 
pYUB854 AflII, XbaI M. 
smegmatis 
PCR: 
JCV138, 
JCV139 
HygR   res 
sites 
pJV69 pYUB854: 
Hyg - res 
sites 
pYUB854 NheI, 
XbaI 
pMsgroEL1
KO 
PCR: 
JCV181, 
JCV182 
HygR   
pJV70 groEL KO: 
Hyg - res 
sites 
pMsgroEL
1KO 
NheI, 
XbaI 
pMsgroEL1
KO 
PCR: 
JCV181, 
JCV182 
HygR   
pJV71 MtbgroEL 
KO: Hyg - 
res sites 
pMtbgroE
L1KO 
NheI, 
XbaI 
pMsgroEL1
KO 
PCR: 
JCV181, 
JCV182 
HygR   
pJV72 Che9c gene 
61 
pJL37 HpaI pJV23 PCR: JCV49, 
JCV78 
KanR oriM Phsp60 
pJV73 HygR 
cassette, F 
pJL37 SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
KanR, HygR oriM Phsp60 
pJV74 HygR 
cassette, F 
pLAM12 SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
KanR, HygR oriM Pacet 
pJV75 HygR 
cassette, F 
pJV52 SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
KanR, HygR oriM Pacet 
pJV76 HygR 
cassette, F 
pJV53 SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
KanR, HygR oriM Pacet 
pJV77 HygR 
cassette, F 
pJV61 SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
KanR, HygR oriM Pacet 
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JCV183 
pJV78 HygR 
cassette, F 
pJV72 SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
KanR, HygR oriM Phsp60 
pJV73 
amber 
Hyg D15* 
D16* amber 
pJV73 NA NA SDM: 
JCV184, 
JCV185 
KanR oriM Phsp60; 
HygS 
pJV74 
amber 
Hyg D15* 
D16* amber 
pJV74 NA NA SDM: 
JCV184, 
JCV185 
KanR oriM Pacet; 
HygS 
pJV75 
amber 
Hyg D15* 
D16* amber 
pJV75 NA NA SDM: 
JCV184, 
JCV185 
KanR oriM Pacet; 
HygS 
pJV76 
amber 
Hyg D15* 
D16* amber 
pJV76 NA NA SDM: 
JCV184, 
JCV185 
KanR oriM Pacet; 
HygS 
pJV77 
amber 
Hyg D15* 
D16* amber 
pJV77 NA NA SDM: 
JCV184, 
JCV185 
KanR oriM Pacet; 
HygS 
pJV78 
amber 
Hyg D15* 
D16* amber 
pJV78 NA NA SDM: 
JCV184, 
JCV185 
KanR oriM Phsp60; 
HygS 
pJV73 
opal 
Hyg D15* 
D16* opal 
pJV73 NA NA SDM: 
JCV186, 
JCV187 
KanR oriM Phsp60; 
HygS 
pJV74 
opal 
Hyg D15* 
D16* opal 
pJV74 NA NA SDM: 
JCV186, 
JCV187 
KanR oriM Pacet; 
HygS 
pJV75 
opal 
Hyg D15* 
D16* opal 
pJV75 NA NA SDM: 
JCV186, 
JCV187 
KanR oriM Pacet; 
HygS 
pJV76 
opal 
Hyg D15* 
D16* opal 
pJV76 NA NA SDM: 
JCV186, 
JCV187 
KanR oriM Pacet; 
HygS 
pJV77 
opal 
Hyg D15* 
D16* opal 
pJV77 NA NA SDM: 
JCV186, 
JCV187 
KanR oriM Pacet; 
HygS 
pJV78 
opal 
Hyg D15* 
D16* opal 
pJV78 NA NA SDM: 
JCV186, 
JCV187 
KanR oriM Phsp60; 
HygS 
pJV79 Bxb1 
attL(CT)-
50, F 
pMOSBlu
eHyg 
NdeI, bl.  attL(CT)-
50mer, 
attL(CT)-
50mer AP 
NA HygR, CbR   
pJV80 Bxb1 
attL(CT)-
50, R 
pJV69 XbaI, bl. attL(CT)-
50mer, 
attL(CT)-
50mer AP 
NA HygR   
pJV81 Bxb1 
attR(CT)-
50, F 
pJV79 SmaI attR(CT)-
50mer, 
attR(CT)-
50mer AP 
NA HygR, CbR  Bxb1 
attL/attR(
CT) 
flanking  
HygR 
pJV82 Bxb1 
attR(CT)-
50, R 
pJV80 NheI, bl. attR(CT)-
50mer, 
attR(CT)-
50mer AP 
NA HygR   
pJV83 marinum 
ATCC927 
recA, F 
pMOS 
Blue 
EcoRV M. marinum 
ATCC 
PCR: 
JCV194, 
JCV197 
CbR   
pJV84 marinum  
ATCC927 
pYUB854 XbaI, bl. M. marinum 
ATCC 
PCR: 
JCV194, 
HygR   res 
sites 
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recAupstrea
m homol., R 
JCV195 
pJV85 marinum 
recA 
downstream 
homol; final 
KO 
plasmid, R 
pJV84 NdeI M. marinum  
ATCC 
PCR: 
JCV196, 
JCV197 
HygR   res 
sites 
pJV86 HygR 
cassette, R 
pSJ25B DraI pMOSBlue 
Hyg 
PCR: AB01, 
AB02 
HygR Bxb1 
attP/Int 
 
pJV87 HygR 
cassette, F 
pSJ25B DraI pMOSBlue 
Hyg 
PCR: AB01, 
AB02 
HygR Bxb1 
attP/Int 
 
pJV88 L5 attP/Int 
cassette, R 
pMOSBlu
eHyg 
DraI pMH94 SalI, bl. HygR L5 attP/Int Interr. 
lacZ 
pJV89A GentR 
cassette, F 
pJV86 XmnI pJV43 BamHI, bl. HygR, GentR Bxb1 
attP/Int 
 
pJV89B GentR 
cassette, R 
pJV86 XmnI pJV43 BamHI, bl. HygR, GentR Bxb1 
attP/Int 
 
pJV89 
amber 
Hyg D15* 
D16* amber 
pJV89A NA NA SDM: 
JCV184, 
JCV185 
GentR Bxb1 
attP/Int 
HygS 
pJV90A SacB 
cassette, F 
pJV86 XmnI pAVN30 PCR: sacBF/R HygR Bxb1 
attP/Int 
sacB 
pJV91A GentR 
cassette, F 
pJV87 XmnI pJV43 BamHI, bl. HygR, GentR Bxb1 
attP/Int 
 
pJV91B GentR 
cassette, R 
pJV87 XmnI pJV43 BamHI, bl. HygR, GentR Bxb1 
attP/Int 
 
pJV91 
amber 
Hyg D15* 
D16* amber 
pJV91A NA NA SDM: 
JCV184, 
JCV185 
GentR Bxb1 
attP/Int 
HygS 
pJV92A GentR 
cassette, F 
pJV39 SmaI pJV43 BamHI, bl. HygR, GentR L5 attP/Int  
pJV92B GentR 
cassette, R 
pJV39 SmaI pJV43 BamHI, bl. HygR, GentR L5 attP/Int  
pJV92 
amber 
Hyg D15* 
D16* amber 
pJV92A NA NA SDM: 
JCV184, 
JCV185 
GentR L5 attP/Int HygS 
pJV93A SacB 
cassette, F 
pJV39 SmaI pAVN30 PCR: sacBF/R HygR L5 attP/Int sacB 
pJV93B SacB 
cassette, R 
pJV39 SmaI pAVN30 PCR: sacBF/R HygR L5 attP/Int sacB 
pJV94A GentR 
cassette, F 
pJV88 SmaI pJV43 BamHI, bl. HygR, GentR L5 attP/Int  
pJV94 
amber 
Hyg D15* 
D16* amber 
pJV94A NA NA SDM: 
JCV184, 
JCV185 
GentR L5 attP/Int HygS 
pJV95B SacB 
cassette, R 
pJV88 SmaI pAVN30 PCR: sacBF/R HygR L5 attP/Int sacB 
pJV96 Pacet pJV44 NdeI, 
XbaI 
pLAM12 NdeI, XbaI GentR oriM Pacet 
pJV97 Lambda 
gam  
pJV44 HpaI Lambda PCR: 
JCV145, 
JCV146 
GentR oriM Phsp60 
pJV98 Lambda 
gam 
pJV53 NheI, bl. Lambda PCR: 
JCV145, 
JCV146 
GentR oriM Pacet 
pJV99 Lambda 
gam 
pJV96 HpaI Lambda PCR: 
JCV145, 
JCV146 
GentR oriM Pacet 
pJV100 M. marinum 
M strain 
recA KO 
pYUB854 BglII, 
NcoI, 
AflII, XbaI 
M. marinum 
M strain 
PCR: 
JCV208-211 
HygR   res 
sites 
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pJV101 M. 
smegmatis 
recD KO 
pYUB854 BlgII, 
HindIII, 
AflII, XbaI 
M. 
smegmatis 
PCR: 
JCV212-215 
HygR   res 
sites 
pJV102 attL-hygR-
attR 
pJV39 XbaI, 
KpnI 
pJV81 XbaI, KpnI HygR L5 attP/Int Bxb1 
attL-INT/ 
attR(CT) 
flanking  
HygR 
pJV103 Halo gene 
43 
pLAM12  HpaI pJV57 PCR: JCV53, 
JCV226 
KanR oriM Pacet 
pJV104 E. coli recT pLAM12  HpaI pRDK557 PCR: 
JCV230, 
JCV237 
KanR oriM Pacet 
pJV105 Lambda bet  pLAM12  HpaI Lambda 
DNA 
PCR: 
JCV227, 
JCV228 
KanR oriM Pacet 
pJV106 Halo gene 
43 
pLAM12  NdeI, 
EcoRI 
pJV57 PCR: JCV53, 
JCV226 
KanR oriM Pacet 
pJV107 E. coli recT pLAM12  NdeI, 
EcoRI, bl. 
pRDK557 PCR: 
JCV229, 
JCV237 
KanR oriM Pacet 
pJV108 Lambda bet  pLAM12  NdeI, 
EcoRI 
Lambda 
DNA 
PCR: 
JCV227, 
JCV228 
KanR oriM Pacet 
pJV109 Bxb1 attL 
(CT)-INT 
pJV81 SpeI, 
HpaI, bl. 
Bxb1 
lysogen 
PCR: 
attL(CT)-50, 
JCV243 
HygR, CbR  Bxb1 
attL-INT/ 
attR(CT) 
flanking  
HygR 
pJV110 Bxb1 attL 
(CT)-INT 
pJV102 SpeI, 
HpaI, bl. 
Bxb1 
lysogen 
PCR: 
attL(CT)-50, 
JCV243 
HygR L5 attP/Int Bxb1 
attL-INT/ 
attR(CT) 
flanking  
HygR 
pJV111 Msmeg 
katG (6384) 
KO 
pYUB854 AflII, 
XbaI, 
BglI, 
HindIII 
M. 
smegmatis 
PCR: 
JCV249-252 
HygR   res 
sites 
pJV112 Phsp60-lacZ pJV45F HindIII, 
XbaI 
pMV261-lac HindIII, XbaI GentR L5 attP/Int lacZ, 
Interr. 
HygR 
pJV113
R 
sacB-new 
(no 
Phsp60), R 
pJV53 NheI pBRL301 PCR: 
JCV288, 
JCV289 
KanR oriM Pacet, 
Che9c 60-
61 
pJV114
F 
sacB-new 
(no 
Phsp60), F 
pJV62 NheI pBRL301 PCR: 
JCV288, 
JCV289 
KanR oriM Pacet, 
Che9c 61 
pJV114
R 
sacB-new 
(no 
Phsp60), R 
pJV62 NheI pBRL301 PCR: 
JCV288, 
JCV289 
KanR oriM Pacet, 
Che9c 61 
pJV115
F 
sacB-new 
(no 
Phsp60), F 
pJV75 
amber 
NheI pBRL301 PCR: 
JCV288, 
JCV289 
KanR oriM Pacet, 
Che9c 61, 
HygS 
pJV115
R 
sacB-new 
(no 
Phsp60), R 
pJV75 
amber 
NheI pBRL301 PCR: 
JCV288, 
JCV289 
KanR oriM Pacet, 
Che9c 61, 
HygS 
pJV116 Giles gene 
53  
pLAM12 NdeI, 
EcoRI 
Giles PCR: 
JCV338, 
JCV339 
KanR oriM Pacet 
pJV117 Halo gene 
43, 
alternative 
pLAM12 NdeI, 
EcoRI 
Halo PCR: 
JCV379, 
JCV226 
KanR oriM Pacet 
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upstream 
start codon 
pJV118 tRN A 
amber 
suppressor 
pSE100 BamHI, 
HindIII 
pLT193B-B PCR: 
JCV290, 
JCV291 
HygR oriM Tet 
operator 
pJV119 GentR 
cassette  
pJV39 XmaI, 
SpeI 
pJV44 PCR: 
JCV292, 
JCV293 
GentR L5 attP/Int Interr. 
lacZ 
pJV120 Pmyc1TetO
p-tRNA 
amber 
suppressor, 
whole 
cassette 1, R 
pJV119 SmaI pLT193B-B PCR: 
JCV333, 
JCV334, 
JCV346, 
JCV45 
GentR L5 attP/Int Interr. 
lacZ 
pJV121 Pmyc1TetO
p-tRNA 
amber 
suppressor, 
gene 9 
pJV119 SmaI pLT193B-B PCR: 
JCV334, 
JCV335, 
JCV346, 
JCV345 
GentR L5 attP/Int Interr. 
lacZ 
pJV122 sacB-new 
(no 
Phsp60), F 
pJV69 NheI pBRL301 PCR: 
JCV288, 
JCV289 
HygR   
pJV123 Che9c 
genes 60-61 
pTX-
2MIX 
PmlI pJV23 PCR: JCV47, 
JCV78 
CbR  TetR; Tet 
operator 
pJV124 Che9c gene 
61 
pTX-
2MIX 
PmlI pJV23 PCR: JCV49, 
JCV78 
CbR  TetR; Tet 
operator 
pJV125 Msmeg 
leuD KO 
plasmid 
pJV122F AflII, 
XbaI, 
HindIII, 
XhoI 
M. 
smegmatis 
PCR: 
Becky1+6, 
Becky3+8 
HygR   
pJV126 Phsp60-
sacB (new), 
R 
pJV53 NheI pBRL301 XbaI KanR oriM Pacet, 
Che9c 60-
61 
pJV127 Phsp60-
sacB (new), 
R 
pJV62 NheI pBRL301 XbaI KanR oriM Pacet, 
Che9c 61 
pJV128 Phsp60-
sacB (new), 
R 
pJV75 
amber 
NheI pBRL301 XbaI KanR oriM Pacet, 
Che9c 61, 
HygS 
pJV129 Phsp60-
sacB (new), 
R 
pJV76 
amber 
NheI pBRL301 XbaI KanR oriM Pacet, 
Che9c 60-
61, HygS 
pJV130 HygR 
cassette, F 
pMV261-
lac 
NheI, 
SpeI,  
pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
HygR oriM Phsp60-
lacZ 
pJV131
R 
TetR 1.7 
(mutant), R 
pJV75 
opal 
NheI pTEK-4SOX SpeI KanR oriM Pacet, 
Che9c 61, 
HygS 
pJV132
R 
TetR 1.7 
(mutant), R 
pJV127 SpeI pTEK-4SOX SpeI KanR oriM Pacet, 
Che9c 61, 
SacB, 
HygS 
pJV133
R 
TetR, R pJV75 
opal 
NheI pTX-2MIX PCR: 
JCV363, 
JCV364 
KanR oriM Pacet, 
Che9c 61, 
HygS 
pJV134 TetR, R pJV127 SpeI pTX-2MIX PCR: 
JCV363, 
JCV364 
KanR oriM Pacet, 
Che9c 61, 
SacB, 
HygS 
pJV135
F 
Phsp60-
sacB (new), 
F 
pJV119 XbaI pBRL301 XbaI GentR L5 attP/Int Interr. 
lacZ 
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pJV135
R 
Phsp60-
sacB (new), 
R 
pJV119 XbaI pBRL301 XbaI GentR L5 attP/Int Interr. 
lacZ 
pJV136
F 
GentR 
cassette, F 
pJV39 SmaI, 
HpaI 
pJV44 PCR: 
JCV292, 
JCV293 
GentR L5 attP/Int Interr. 
lacZ 
pJV136
R 
GentR 
cassette, R 
pJV39 SmaI, 
HpaI 
pJV44 PCR: 
JCV292, 
JCV293 
GentR L5 attP/Int Interr. 
lacZ 
pJV137 Pmyc1TetO
p-tRNA 
amber 
suppressor 
pJV119 HindIII, 
SpeI 
pJV118 HindIII, SpeI GentR L5 attP/Int Interr. 
lacZ 
pJV138 HygR 
cassette, R 
pJV53 NheI, SpeI pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
HygR oriM Pacet, 
Che9c 60-
61 
pJV139 tRNA 
amber 
suppressor 
(whole 
cassette 2) 
pSE100 EcoRV pLT193B-B PCR: 
JCV380, 
JCV381 
HygR oriM Tet 
operator 
pJV140 Phsp60RBS
-lacZ 
pSE100 EcoRV pMV261-lac PCR: 
JCV384, 
JCV10 
HygR oriM Tet 
operator 
pJV141
F 
Pmyc1TetO
p-tRNA 
amber 
suppressor, 
whole 
cassette 2, F 
pJV136F XbaI, bl. pJV129 SpeI, ClaI, bl. GentR L5 attP/Int Interr. 
lacZ 
pJV141
R 
Pmyc1TetO
p-tRNA 
amber 
suppressor, 
whole 
cassette 2, R 
pJV136F XbaI, bl. pJV129 SpeI, ClaI, bl. GentR L5 attP/Int Interr. 
lacZ 
pJV142 tRNA 
amber 
suppressor 
cassette 
pMPambar DraI, 
XhoI, bl. 
pLT193B-B PCR: 
JCV380, 
JCV381 
GentR L5 attP/Int TetR 
repressor, 
Tet 
operator-
tRNA 
pJV143 Lambda 
gam 
pJV44 NdeI NA NA GentR oriM Phsp60 
pJV144 Lambda 
gam 
pJV44 NdeI NA NA GentR oriM Pacet 
pJV145 Giles gene 
53 
pLAM12 HpaI Giles PCR: 
JCV338, 
JCV339 
KanR oriM Pacet 
pJV146 Phsp60RBS
-lacZ 
pMPambar DraI, 
XhoI, bl. 
pMV261-lac PCR: JCV10, 
JCV384 
GentR L5 attP/Int TetR 
repressor, 
Tet 
operator-
lacZ 
pJV148 HygR 
cassette  
pTTP1B HindIII, 
bl. 
pMsgroEL1
KO 
PCR: 
JCV181, 
JCV183 
HygR, CbR Tweety 
attP/Int 
 
pJV149 Phsp60-
sacB (new), 
R 
pMsgroEL
1KO 
NheI pBRL301 XbaI HygR  groEL1 
KO 
plasmid, 
sacB 
pJV150
F 
Phsp60-
sacB (new), 
pJV69 NheI pBRL301 XbaI HygR  HygR, 
sacB KO 
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F plasmid 
pJV150
R 
Phsp60-
sacB (new), 
R 
pJV69 NheI pBRL301 XbaI HygR  HygR, 
sacB KO 
plasmid 
 
6.2.3 Cloning procedures 
6.2.3.1 Preparation of the insert and vector for plasmid constructions 
Plasmid cloning was performed using DNA inserts generated either by PCR-
amplification or restriction digest of the parental insert source as described in Table 15. PCR 
reactions were set up as described below (PCR), and the products were cleaned up using the 
QIAquick PCR cleanup protocol (QIAGEN), eluting in 50 l EB buffer. Restriction digests of 
either plasmid DNA or PCR DNA were used to obtain the vector backbone or desired insert. 
Restriction enzymes were from NEB exclusively, and digests were performed according to 
manufacturer’s instructions for preferred buffers and reaction conditions, typically in 50 l 
reaction volumes.  Restriction digests were incubated at the required temperature for 2 hr for 
plasmid DNAs and 4 hr for PCR products. Following digestion, the vector backbone digest was 
heat-killed (if possible) and treated with 1 l calf intestinal phosphatase (CIP; NEB) to remove 
the 5 phosphate and prevent ligation of the vector to itself.  The digest reactions were then run 
on 0.8% agarose gels, the bands containing the desired DNA fragments were extracted, and these 
were cleaned up using the QIAquick gel extraction protocol (QIAGEN). The DNA was 
quantified by analyzing 2 l on an agarose gel and comparing to the GC #1 quantitative DNA 
ladder (GeneChoice) using Quantity One 4.6 software. 
In cases in which a PCR product was cloned into a blunt site in the parental plasmid, the 
PCR product was treated with T4 polynucleotide kinase (Roche) and the accompanying buffer 
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directly in the PCR reaction (without cleanup) for 1 hr at 37C. Plasmids and inserts that 
required blunt ends were treated with the Klenow enzyme (NEB). The DNA digest was first 
heat-killed (if possible), and subsequently 0.5 M dNTPs, 1X buffer were added, and 0.5 l of 
Klenow in a total reaction volume of 60 l. The reactions were incubated at room temperature 
for 15 mins, and these were immediately cleaned up using the QIAquick gel extraction protocol 
for enzymatic cleanup (QIAGEN) or run on an agarose gel to be gel extracted.  
6.2.3.2 Ligations and transformations 
Ligations were performed with the Fast-link DNA ligase enzyme (Epicentre) in 15 l 
volumes using 1.5 l ATP for sticky-end ligations and 0.75 l ATP for blunt-end ligations. 
These were incubated at room temperature for 2 hr or longer and heat-killed at 75°C for 15 mins. 
The heat-killed ligations were transformed into E. coli GC5 cells as described below (E. coli 
transformations). All plasmids that were constructed were checked by restriction digest with two 
different enzymes, and the insert was sequenced.  
6.3 PCR  
Primers were designed typically with melting temperatures at or above 60°C (if possible) to 
simplify amplification from the high-G+C% mycobacterial or mycobacteriophage templates. If 
restriction sites were used, these were engineered in the center of the oligonucleotide by 
changing nucleotides when required, with perfect homology to the template flanking the site. 
Oligonucleotides were synthesized as described above (DNA substrates) and resuspended in TE 
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buffer to 100 M stock solutions upon receipt of the lyophilized pellet of DNA. Working 
solutions were 10 M, and all stock solutions were stored at -20°C.  
PCR reactions were performed as described [7], typically using Pfu polymerase 
(Stratagene) and when necessary, Pfu Turbo (for extended length targets longer than 4 kbp). 
Reactions (50 l) contained template DNA (5-10 ng), 0.5 M primers, 0.2 mM dNTPs, 1X 
buffer, 0-5% DMSO (typically 5%), and 1-5 U polymerase. Cycling conditions were set with an 
initial 95°C denaturation for 5 min, and 25 cycles of denaturation (95°C for 30 sec), annealing 
(varying temperature, 30 sec), and extension (72°C, varying length). Annealing temperatures 
used were 2°C lower than the lowest primer melting temperature, and the extension was equal to 
approximately 1 min per 1 kbp of desired product. A final extension at 72°C for 7 mins was 
used, followed by cooling to 4°C. The 72°C extension temperature was used only for Pfu 
polymerase; it was adjusted to 68°C for all Taq polymerases. 
6.3.1 Colony PCR 
PCRs used as a screening method (see section 7.10.4) typically were performed with Taq DNA 
polymerase (NEB). Colonies were resuspended using sterile toothpicks in 200 l dH2O, vortexed 
vigorously, boiled for 5 min, and vortexed again, and a volume equal to 1/10 the total PCR 
reaction volume was used. Reaction volumes often were decreased to 25 l for screening PCRs. 
6.3.2 MAMA-PCR 
Mismatch amplification mutation assay PCR (MAMA-PCR) [30,219] was used to identify 
mutant alleles – either point mutations or deletions – in a population consisting primarily of wild 
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type alleles. Primers (~20 nt) were designed in which the 3 ultimate base of the primer matched 
the mutant sequence. For point mutations, this was the most 3 of the mutated bases; for 
deletions, this was at the junction of the new deletion allele locus. Typically, the penultimate 
base was also changed such that neither base would anneal at a wild type locus, and only the 
ultimate base would anneal at a mutant locus (Figure X). Reactions were performed using 
Platinum Taq High Fidelity DNA Polymerase (Invitrogen), in which 100 l of culture or 
resuspended colonies were used for colony PCR as described above. Reaction conditions were as 
described above for basic PCR with 2 mM MgSO4 added to increase the fidelity of the 
polymerase.   
6.3.3 Reverse transcription-PCR 
Reverse transcription-PCR (RT-PCR) was performed essentially as described [228]. RNA was 
extracted and purified from M. smegmatis cultures using the RiboPure-Bacteria kit (Ambion). 
Each sample was disrupted with the mini bead-beater (30 sec) following an 8 min vortexing on 
the vortex adapter. RNA samples were treated with DNaseI, as well as RNaseOUT to kill any 
contaminating RNase enzymes; DNase Inactivation reagent was used following DNase 
treatment. RNA aliquots were analyzed on agarose gels, quantified and stored at -80°C. RT-PCR 
reactions were performed with the Qiagen OneStep RT-PCR kit (Qiagen) with equal amounts of 
RNA and analyzed on agarose gels. Control PCR reactions using Pfu polymerase (Stratagene) 
were used as controls to assess the presence of contaminating DNA in the RNA samples. 
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6.3.4 Sequencing 
Sequencing of plasmids or PCRs was done either through the DNA synthesis facility of the 
University of Pittsburgh or GeneWiz company. Typically 5-8 l of plasmid miniprep DNA was 
used (~800 ng), and either 3.2 pmols (DNA synthesis facility) or 8 pmols (Genewiz) of primer 
were used. Sequencing primers were designed 100 bp upstream of the region to be sequenced.  
6.3.5 Site-directed mutagenesis (SDM) 
The QuikChange site-directed mutagenesis (and sometimes the XL kit; Stratagene) was used for 
all experiments. Primers were typically PAGE-purified, and PCR conditions were used as 
recommended by the manufacturer. 
6.4 DNA SUBSTRATES 
All oligonucleotides (Table 16) were purchased from Integrated DNA Technologies, and when 
required (lengths exceeding 30 nt), the oligonucleotides were PAGE-purified. When necessary, 
oligonucleotides were radiolabeled with [-32P]-ATP (Perkin-Elmer) and T4 polynucleotide 
kinase (Roche) for 30 min at 37°C and purified on ProbeQuant G-50 Micro Columns 
(Amersham) to remove unincorporated label. When short (50 – 100 bp) dsDNA substrates were 
required, complementary oligonucleotides were annealed at 0.4 M in annealing buffer (50 mM 
Tris, pH 7.5 and 100 mM NaCl) by incubating for 5 min at 95C in a water bath and slow 
cooling overnight to room temperature.  
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Table 16: Oligonucleotides. 
Primer Name Sequence 
TM413069-13089  
1089F 
CAAGGCTATCGAGGACAAGCA 
TM4414137-14157 
1089R 
GGGTGGCAGTAATACCACTTG 
TM41444-1464 880F ATGCGTAAAGCGTTGGGCGAT 
TM42323-2303 880R TCGCCAGTTCCTTGACTTCGT 
TM430497-30517 699F CCTGCTGTGCACCAAGTGCTT 
TM431195-31175 699R TCCTGCACGACTCGATGTTCT 
TM446441-46461 
1328F 
GCGTGTTGACAGCTCAACAGT 
TM447748-47769 
1328R 
GTCATGTGGTTGGTCATCTCG 
1512-1536F ACGCTCAGTCGAACGAAAACTCACG 
1624-1648R   AGCTTCGTGGATCCAGATATCCTGC 
pYUB854 1442-1466F TGCAAGCAGCAGATTACGCGCAGAA  
pYUB854 1775-1751R TCAGATATCGGACAAGCAGTGTCTG 
pYUB854 509-533F ATGATCGTGCTCCTGTCGTTGAGGA 
pYUB854 1069-1093R TGAGCTATGAGAAAGCGCCACGCTT 
pJL37F ACTGCGCCCGGCCAGCGTAAGTAGC 
pJL37R ATCAGAGATTTTGAGACACAACGTGG 
LJM20 CCGCAGTTGTTCTCGCATACCCCATC 
LJM23 CGGACGGTTGCTAGCACGCGCACCAT 
SACB-F GGACATCCTGAGCTTGCTAGAGGA 
SACB-R CTCGACGACCTGCAGGATCG 
M13-50MER AAACAGCTATGACCATGATTACGAATTCGAGCTCGGTACCCGGGGATCCT 
M13-50MER-AP AGGATCCCCGGGTACCGAGCTCGAATTCGTAATCATGGTCATAGCTGTTT 
DJ20 CGTAGGAATCATCCGAATCA 
DJ76 CAGAATTCCTGGTCGTTCCGCAGGCTCGCGTAGGAATCATCCGAATCAATACGGTCGAG
AAGTAACAGGGATTCTT 
AB01 GTCGACTCTAGAGGATCTACTAGTC 
AB02 GTAAAACGCTAGCCAGTGAATTCGAG 
Bxb1 attB-50 TCGGCCGGCTTGTCGACGACGGCGGTCTCCGTCGTCAGGATCATCCGGGC 
Bxb1 attB-50-AP GCCCGGATGATCCTGACGACGGAGACCGCCGTCGTCGACAAGCCGGCCGA 
Bxb1 attB-100 TGGCCGTGGCCGTGCTCGTCCTCGTCGGCCGGCTTGTCGACGACGGCGGTCTCCGTCGT
CAGGATCATCCGGGCCACCGAGGCGGCGTTGAGAACAGC 
Bxb1 attB-100-AP GCTGTTCTCAACGCCGCCTCGGTGGCCCGGATGATCCTGACGACGGAGACCGCCGTCGT
CGACAAGCCGGCCGACGAGGACGAGCACGGCCACGGCCA 
JCV01 GCAAGGTCGTCACCGAGCGGTTCAA  
JCV02 TTCTCGACGGCCTTCACGATCACCT  
JCV03 CTCGAAATGCGTCACCTCGTACAC  
JCV04 GGAGACAGGTGCATATGACAACCGA 
JCV05 CAGCAGGTCGACGCGGTAGTGCCTC 
JCV06 GACTTGATCAGAAGCTTGATGCGGT 
JCV07 GAACTCCGTTGTAGTGCTTGTGGTG 
JCV08 TCGGTTGCACTACGTGTACTGTGAG 
JCV09 TGCCAATGAATGCTCTGACCGATGA 
JCV10 AACTACGTCGGCATTCATAAGCTTC 
JCV11 CATTCGCCATTCAGGCTGCGCAACT 
JCV12 CATTAGGCACCCCAGGCTTTACACT 
JCV13 AGCACGAGTCGCTGTTCGAGCTACC 
JCV14 ACTACCTGCGAAAACACGTCGATAC 
JCV15 GCGCGGTAGGCCTTTCGCGGTTCTG 
JCV16 ACAGCGATGCTCTAGATGGCGAT 
JCV17 GCCGAGCTCGAGACCCAGCTGACCA 
JCV18 GAACGCAGGCTGCGCAGATCTACCCGC 
JCV19 CTGACGATCGAATCGAGACGGAGAA 
JCV20 CGCTGGCTGGCATCTCCAGGTCGA 
JCV21 GGGCGAAAAACCGGATATCAGGGCGATGGCCCAC 
 185 
JCV22 GTGGGCCATCGCCCTGATATCCGGTTTTTCGCCC 
JCV23 GACCAAAATCCCTTCACGTGAGTTTTCGTTCCAC 
JCV24 GTGGAACGAAAACTCACGTGAAGGGATTTTGGTC 
JCV25 TACGCGCCGTGTAAGGGCACGCAGA 
JCV26 GGCAGCGAGGACAACTTGAGCCGTC 
JCV27 GGTTACGATGCGCCCATCTACACCA 
JCV28 CACTCGCTTTAATGATGATTTCAGC 
JCV29 CTGCATGGTCAGGTCATGGATGAGC 
JCV30 TGCGCCAAGCTTCCTGCTGAACATC 
JCV31 CATACACGGTGCCTGACTGCGTTAG 
JCV32 GTCAGATGCGGGATGGCGTGGGACG 
JCV33 CAAAACAGGCGGCAGTAAGGCGGTCG 
JCV34 GAGTTGGTAGCTCTTGATCCGGCAAAC 
JCV35 GACCCCGAGGTGCACGGGCTGAAGGC 
JCV36 CGGCTCTACGCCGACTGCATGGAATC 
JCV37 CTACCAGGGCATCGTCAAACTGTTC 
JCV38 CAACGACGCCGATTGGTTCAAGTTCC 
JCV39 CTTCAGCAGAGCGCAGATATCAAATACTGTCCTTC 
JCV40 GAAGGACAGTATTTGATATCTGCGCTCTGCTGAAG 
JCV41 CGTAGTTAGGCCACCACGTGAAGAACTCTGTAGCACC 
JCV42 GGTGCTACAGAGTTCTTCACGTGGTGGCCTAACTACG 
JCV43 GTGGTTTGTTTGCCGGATCACGTGCTACCAACTCTTTTTCC 
JCV44 GGAAAAAGAGTTGGTAGCACGTGATCCGGCAAACAAACCAC 
JCV45 CTGGCTTCAGCAGAGCGCATATGCCAAATACTGTCCTTC 
JCV46 GAAGGACAGTATTTGGCATATGCGCTCTGCTGAAGCCAG 
JCV47 ACGAGATCGGCGGCCGCATATGAGT 
JCV48 TGCTTGGTGACAGCACTCGAGGCCATA 
JCV49 AAGGGGATTACACATATGGCTGAAA 
JCV50 TGGTTCGCCGGGGAAGCTTTGCGTT 
JCV51 TGATGAACGGGCCCCGCATATGAC 
JCV52 TGTTTGGTGCCTCTCGAGTGCGGT 
JCV53 TGAGGAAGGCACCAAACCATATGACC 
JCV54 TGAATCAGTCCCAAAGCTTCTCGT 
JCV55 GACGGCTCAAGTTGTCCTCGCTGCC 
JCV56 TTTCGCTAAATACTGGCAGGCGTTT 
JCV57 CACATGTTCTTTCCTGCGTTATCCC 
JCV58 GCTAACTCACATTAATTGCGTTGCG 
JCV59 GAATCAGTCCCAAAGCTTCTCGTTCCCTTCAC 
JCV60 GAATCAGTCCCAGAATTCCTCGTTCCCTTCAC 
JCV61 GTCGACGAACTGCTCGAACGACTCAT 
JCV62 GTGAGTCGCGGAACATCGCGAAGCAC 
JCV63 CTGCGCCGTTACCACCGCTGCGTTC 
JCV64 GATATCGACCCAAGTACCGCCACCT 
JCV65 CTCTCATGTATAGAGTGCTAGGTGGC 
JCV66 GGTCGTGGTTTCGCCGCCAGGAGCGGA 
JCV67 GTGACACCGTCATCTACAGCAAGTACGGC 
JCV68 CGGTCTCGCAGGCCTCGAAAAACCGCTCAG 
JCV69 GTCCGGGGCGGTACGCGTAGGCGTCTGAAAG 
JCV70 CTCCGTCGTCAGGATCATCCGGGCCAC 
JCV71 AGCGGCTCCCAGAATTCCTGGTCGTTC 
JCV72 GCGAACTGCTCGCCTTCACCTTCCTGCAC 
JCV73 GTCCGGGGCGGTACGCGTAGGCGTCTGAAAGAGACTTATGAGCAATCTAGGGGGATCC
GATAAATCAATCTAAAG 
JCV74 CTCCGTCGTCAGGATCATCCGGGCCACCGAGGCGGCGTTGAGAACAGGCAGGTCGACT
CTAGAGGATCTACT 
JCV75 TCGCGCCCACCACGACACCGAACGG 
JCV76 GACGTCACCGTCGCGCAGTCGATCGT 
JCV77 GTGCCTTGGGCGAATTCTGCTTGGT 
JCV78 GCAGATCAACCACCGCGTCGGAATTCGC 
JCV79 GAAATTCCGCTGGGAGATGGACAACA 
JCV80 CGACCAGTAGATCGATGTACCAGG 
JCV81 GTGTCAACGGCGAGTGCTACCTC 
 186 
JCV82 CGAGCGCCTGCGACTGTGACAGG 
JCV83 GTCCCGAAGAACGATGGCATTTACG 
JCV84 CACCAGCAGCAGGCGTTCTACGAAG 
JCV85 GATTCCGCGGGAAGCCGGAAGAGGCT 
JCV86 GTGAAGAAGTCGGTCGTCGGAAACA 
JCV87 GAAAACCCGGATGCGGCAAGCACTC 
JCV88 CGAACGCGCCGAAATCTATCTGTCC 
JCV89 CACGGCCTCGACGGGTCCGTCGACCA 
JCV90 GCGTCCACCTGCTGTTTTGCCTTCA 
JCV91 GTGCGGCGCAGCACCATGACGTTGT 
JCV92 CTCGTGCTCGGCCGGGCACGCAGGCG 
JCV93 GTTCCCACTCGGAGGCAGGCAGA 
JCV94 CGGCGACGTATCGGCGCACCTCAT 
JCV95 GGGGATCCGATAAATCAATCTAAAG 
JCV96 GCAGGTCGACTCTAGAGGATCTACT 
JCV97 CTTATGAGCAATCTAGGGGGATCCGATAAATCAATCTAAAG 
JCV98 CGGCGTTGAGAACAGGCAGGTCGACTCTAGAGGATCTACT 
JCV99 GGATCGATGTCGACTGCCAGGCATCA 
JCV100 CCAGTGAATTCGAGCTCGGTACCC 
JCV101 CGCCAAGCTCTAATACGACTCACTA 
JCV102 CGACGTTGTAAAACGACGGCCAGTGA 
JCV103 GTCCGGGGCGGTACGCGTAGGCGTCTGAAAGAGACTTATGAGCAATCTAGGGATCGAT
GTCGACTGCCAGGCATCA 
JCV104 CTCCGTCGTCAGGATCATCCGGGCCACCGAGGCGGCGTTGAGAACAGGCCCAGTGAAT
TCGAGCTCGGTACCC 
JCV105 GGTCGCGACGAATCGAAAACGGTGCGA 
JCV106 CAGCGTCGCCGCCGCGATGTTCTAT 
JCV107 GCTTCCACCGGTTGCCTGCGCGTTCT 
JCV108 GACGCGTTCGCCACACACCAGTGCGT 
JCV109 GATCACCTCGTCGTCCACGCCCTT 
JCV110 CACGGGCACAGCAGGATGAGGTC 
JCV111 CAAGCGCGACGGAGACGGCCAGGGTA 
JCV112 CACCTGGTGGATATCGAGTCCGGT 
JCV113 CTGCCGCCCGGCGTGAGCGCCAAGGA 
JCV114 GGACTGGTGGGCGCCGACTATCTGA 
JCV115 GTGCACCAACGGCCGGATCGAGGAT 
JCV116 GAGGTCGGCTTGACCTTCACGGTCT 
JCV117 GAAAGCTCGCGTCCCCTGCAGATCTA 
JCV118 CGCAGTTTCAGGCGAAGCTAGCGAA 
JCV119 CATCGGTGTCCCGCTGCGGCGGTCCAA 
JCV120 CGAGCCGCCTCGTAGGCCTCGATCTGA 
JCV121 GTGTCCCGCTGCGGCGGTCCAACGTCGACACCGACCAGATCATCCCGGCGGGGCCTTA
CGCTGCGGAAACTCGATCAGATCGAGGCCTACGAGGCGGCTC 
JCV122 GAGCCGCCTCGTAGGCCTCGATCTGATCGAGTTTCCGCAGCGTAAGGCCCCGCCGGGAT
GATCTGGTCGGTGTCGACGTTGGACCGCCGCAGCGGGACAC 
JCV123 GACTCTAGAGGATCTACTAGTCATA 
JCV124 GAATTCGAGCTCGGTACCCGGGGAT 
JCV125 TACGACTCACTATAGGGAAAGCTTG 
JCV126 CTGGATCCACGAAGCTTCCCATGGT 
JCV127 AGAGCTCACCTAGGTATCTAGAAC 
JCV128 GTGTCACCGGTGTTCGGTGACCGACT 
JCV129 ACCATGGGAAGCTTCGTGGATCCAGCTCCAGCACCGTGGTGGTGTTCGGT 
JCV130 GTTCTAGATACCTAGGTGAGCTCTGTATCTGTTCGTACGTGGCATGTGC 
JCV131 CGTCAGCCCTTGCGAGAGCGCAA 
JCV132 CATCCCGGCGGTCTACCTGTAGTAGGTGACCCGAACGGGTTTCG 
JCV133 CGAAACCCGTTCGGGTCACCTACTACAGGTAGACCGCCGGGATG 
JCV134 CCGGCATCGGTGTCCCGCTGTGATGATCCAACGTCGACACCGACC 
JCV135 GGTCGGTGTCGACGTTGGATCATCACAGCGGGACACCGATGCCGG 
JCV136 GTGTCACAGATCTTCGGTGACCGACT 
JCV137 CGCTGGCCTCGAGCACCGTGGTGGTGTT 
JCV138 GCGACGCATCTAGATGGTGTGCTGTAT 
JCV139 CGTCAGCCCTTAAGAGAGCGCAA 
 187 
JCV140 ACCATGGGAAGCTTCGTGGATCCAGCGCTGGCCTCCAGCACCGTGGTGGTGTT 
JCV141 CTTCAGCAGATCCACCGCCTCGGT 
JCV142 TGCCGAAATCCGGTCCGGCGACAA 
JCV143 GATGCGCGACATCGCCGTGGACA 
JCV144 ACGCCAGCTGGCGAAAGGGGGATGT 
JCV145 CGTCGACGCTTATAAACATATGGATATT 
JCV146 CGACACGTTCAGCAAGCTTCCCAG 
JCV147 CACCAGTGAAGGGAACATATGACCA 
JCV148 GAACATCGCGAAGCTTGCCGCGCAC 
JCV149 GTCCGGGGCGGTACGCGTAGGCGTCTGAA 
JCV150 GGTCTCCGTCGTCAGGATCATCCGGGC 
JCV151 GTAATCACTCGTGTTCACCGCCCC 
JCV152 TGGTGGCCGTGGCCGTGCTCGTCCT 
JCV153 GAGGAGTACCTGATCCTGTCGGCCC 
JCV154 CAAGCGGACCGGGGGTGTCGCGTGA 
JCV155 ACACCGTCATCTACAGCAAGTACG 
JCV156 TCGAAAAACCGCTCAGCGGCGCCCGCA 
JCV157 CCCACGAAGGAGAAGCGTGATGGAGGCTTTCACCACTCACACCGGCATCGGTGTCCCG
CTGCGGCGGTCCAA 
JCV158 CGCCGAAGGCCCGGATCAGGCCGGGAGAGTGCGCGGTTTCCAGGCCGGACGAGCCGCC
TCGTAGGCCTCGATCTG 
JCV159 CGAACTGCTCGCCTTCACCTTCCT 
JCV160 CTGTCCGCACCGCGGTCAGGCGTTG 
JCV161 CAGCAACGCCAACAGCCGTGCCACGGT 
JCV162 CCGTACGTCTCGAGGAATTCCTGCAGGATATCTGGATCCACGAAGCTTCCGGTCTCCGT
CGTCAGGATCATCCGGGC 
JCV163 TCGTTCATCCATAGTTGCCTGACTCCCAGTCCGTAATACGACTCACTTAAGTCCGGGGC
GGTACGCGTAGGCGTCTGAA 
JCV164 GGTCTCCGTCGTCAGGATCATCCGGGCCACCGAGGCGGCGTTGAGAACAGGACACGAC
TTATCGCCACTGGCAGC 
JCV165 GTCCGGGGCGGTACGCGTAGGCGTCTGAAAGAGACTTATGAGCAATCTAGGGAAACGA
CAGGTGCTGAAAGCGAGCT 
JCV166 CATGCGTTAGAGGTCGGTGAGCCCT 
JCV167 CACCGTCATCTACAGCAAGTACG 
JCV168 CTCATCTATCCGCCCGGGATAGCAT 
JCV169 AAGTGGTAATTCGGACGGTTCCG 
JCV170 GTGAGGAGTTTCATTCACCGTGATA 
JCV171 GCTGGACGTTGCGGAGGGTGACA 
JCV172 CTCACCGGTGAACGGGTGTTCGAT 
JCV173 GTGCGGCGTGATCGCCGTCGGTAGC 
JCV174 GATGCCAACGGGCCCGCCGGCACCA 
JCV175 GCTGACCGGAGTTCAGTGCGCGTG 
JCV176 CTGCGTAGAGGAGCCTGATGAGCAA 
JCV177 CTTGCTGATGCCCGAACCCAGCGCGAT 
JCV178 GAGACCGACCTGAAGAAGCGCAAGGA 
JCV179 GAAAGGCCGGTGCGGTGAAGGTTTT 
JCV180 CATGCACATCGGCGGGTTCGAGGATCT 
JCV181 GATTTAGGATACATGCTAGCCACCT 
JCV182 ACCGCAGCACCATCTAGAACGTCCC 
JCV183 ACCGCAGCGCTAGCGAGAACGTCCC 
JCV184 CGACCGTATTGATTCGTAGTAGTCCTACGCGAGCCTG 
JCV185 CAGGCTCGCGTAGGACTACTACGAATCAATACGGTCG 
JCV186 CGACCGTATTGATTCGTGATGATCCTACGCGAGCCTGC 
JCV187 GCAGGCTCGCGTAGGATCATCACGAATCAATACGGTCG 
JCV188 CTTCTCGACCGTATTGATTCGTAGTAGTCCTACGCGAGCCTGCGG 
JCV189 CCGCAGGCTCGCGTAGGACTACTACGAATCAATACGGTCGAGAAG 
JCV190 CCGTATTGATTCGGATGATTGATGAGCGAGCCTGCGGAACGACC 
JCV191 GGTCGTTCCGCAGGCTCGCTCATCAATCATCCGAATCAATACGG 
JCV192 GAGTTGGTAGCTCTTGATCCGGCA 
JCV193 CTCCACGAGCTGCCCGTGGAGGACT 
JCV194 GAACTACGCCCTGGCTCAAGACGCA 
JCV195 CGGGATGATCGAAATCGGTTGCCGT 
 188 
JCV196 GGCTTCATCCGGAAATCCGGTGCGT 
JCV197 GCTTTTCGCGCCTGAGCTTGGTCCT 
JCV198 CCGCTGTGACACAAGAATCCCTGTTACTTCTCGACCGTATTGATTCGGATGATTCCTAC
GCGAGCCTGCGGAACGACCAGGAATTCTGGGAGCCGCTGGC 
JCV199 GCCAGCGGCTCCCAGAATTCCTGGTCGTTCCGCAGGCTCGCGTAGGAATCATCCGAATC
AATACGGTCGAGAAGTAACAGGGATTCTTGTGTCACAGCGG 
JCV200 GACGAAAGGGCCTCGTGATACGCCTA 
JCV201 CGAGCTCGGTACCCGGACATCCTGA 
JCV202 CGATGTCGACTGCCAGGCATCAAAT 
JCV203 GTTGGTGGGTGGCCGTGCATGTGAT 
JCV204 TCAGGATGTCCGGGTACCGAGCTCGGGAAGCGGAAGTGCGCGCTGCGATA 
JCV205 ATTTGATGCCTGGCAGTCGACATCGGTCAGCCGTTGCGCCACATGCACAT 
JCV206 CTGCGTGGTGGACGGTTCGCACGGTTGT 
JCV207 CATTCGCCATTCAGGCTGCGCAACT 
JCV208 GAACTAAGATCTGGCTCAAGACGCA 
JCV209 CGGGATGATCGACCATGGTTGCCGT 
JCV210 GGCTTCATCTAGAAATCCGGTGCGT 
JCV211 GCTTTTCGCGCTTAAGCTTGGTCCT 
JCV212 GTTGGTGGGAGATCTTGCATGTGAT 
JCV213 GGAAGCGGAAGCTTGCGCTGCGATA 
JCV214 GTCAGCCGTCTAGACACATGCACAT 
JCV215 CTGCGTGGTGGACGCTTAAGACGGTTGT 
JCV216 GGATCACCGCCGAGATCGGTGAGGGCAACAAGATCGACGGTGTGGTGCACGCGATCGG
GTTCATGCCGCAGAGCGGTATGGGCATCAACCCGTTCTTCGAC 
JCV217 GTCGAAGAACGGGTTGATGCCCATACCGCTCTGCGGCATGAACCCGATCGCGTGCACC
ACACCGTCGATCTTGTTGCCCTCACCGATCTCGGCGGTGATCC 
JCV218 CAGCCCGCAGCGTCGCGGCGTGTGCACGCGCGTTTACACCACCACTCCGAGGAAGCCG
AACTCGGCGCTCCGGAAGGTCGCGCGCGTGAAGCTGACCAGCC 
JCV219 GGCTGGTCAGCTTCACGCGCGCGACCTTCCGGAGCGCCGAGTTCGGCTTCCTCGGAGTG
GTGGTGTAAACGCGCGTGCACACGCCGCGACGCTGCGGGCTG 
JCV220 TGTGGTCACCGACCAGATCGACTACCTGACCGCCGACGAGGAGGACCGCCATGTCGTG
GCGCAGGCCAACTCGCCGACCGACGAGAACGGCCGCTTCACCG 
JCV221 CGGTGAAGCGGCCGTTCTCGTCGGTCGGCGAGTTGGCCTGCGCCACGACATGGCGGTC
CTCCTCGTCGGCGGTCAGGTAGTCGATCTGGTCGGTGACCACA 
JCV222 TGTGGTCACCGACCAGATCGACTACCTGACCGCCGACGAGGAGGACCGCCGCGTCGTG
GCGCAGGCCAACTCGCCGACCGACGAGAACGGCCGCTTCACCG 
JCV223 CGGTGAAGCGGCCGTTCTCGTCGGTCGGCGAGTTGGCCTGCGCCACGACGCGGCGGTC
CTCCTCGTCGGCGGTCAGGTAGTCGATCTGGTCGGTGACCACA 
JCV224 GCTGGTGTAGTCGTGGCCGTTTCGAT 
JCV225 CATTGTCGAAGCTGTTGGATGCGGA 
JCV226 GCTGGTCCTGAATTCAGTCCCATGGT 
JCV227 CAGAGGTATAAAACATATGAGTACTGCACT 
JCV228 GCAGGAGAATTCCCGGTGTCATGCT 
JCV229 TGACTAAGCAACCACCAATCGCAA 
JCV230 GAATATGCAAATGACTAAGCAACCACC 
JCV231 GACAGGCCTACTCGAAGGCAAGCGCA 
JCV232 GCGCTCTTGGCGACGGTCATCCAGT 
JCV233 GCCAACCATTCAGCAGCTGGTCCGCA 
JCV234 GCTCTTCTCCTTCTTCGCGCCATAGC 
JCV235 CCGGCCTCGAGGTCCGCGACGTGCA 
JCV236 CACCAGCGGTGCCTCGCTGCGCACCA 
JCV237 ACACCGCCAGGCTGAATTATTCCTCTG 
JCV238 GATCACACCCGTGATCACAGCCCAATTCACCACTCCCGAAAGGAAATGCACACACAAC
CACCTGGACGCCCAGGCCGGCCTCACAGCCGGCCTGGGCGTT 
JCV239 AACGCCCAGGCCGGCTGTGAGGCCGGCCTGGGCGTCCAGGTGGTTGTGTGTGCATTTCC
TTTCGGGAGTGGTGAATTGGGCTGTGATCACGGGTGTGATC 
JCV240 CACAGCCCAATTCACCACTCCCGAAAGGAAATGCACACACAACCACCTGGACGCCCAG
GCCGGCCTCACA 
JCV241 GATGCCCATACCGCTCTGCGGCATGAACCCGATCGCGTGCACCACACCGTCGATCTTGT
TGCCCTCACCGA 
JCV242 GATGCCCATACCGCTCTGCGGCATGAACCCGATGGAGTGCACCACACCGTCGATCTTGT
TGCCCTCACCGA 
 189 
JCV243 GCTTTTCTGCGTTCTCGGGTAGCCGCT 
JCV244 CAACAGCGCTAGCATCCTTGAGAGTT 
JCV245 CAGGTTCGGTGGCGCGCTACGAATCT 
JCV246 CGGCCAGCACGATGCGCGCGGATGCGT 
JCV247 CCGCTCTGCGGCATGAACCCGATCGCGTGCACCACACCGTCGATCTTGTTG 
JCV248 GCATGAACCCGATCGCGTGCACCACACCGTC 
JCV249 CGCACGCTTAAGCCGACACGGTCAT 
JCV250 CACGGTTTCTAGAACCGGCCACCGGA 
JCV251 CGCGTCGAAGCTTCAGCTGCGGGCCCT 
JCV252 GTGCGCGCAAGATCTCGCCCAGCAGCA 
JCV253 CATGGACCAGAACAACCCGCTGTCGGGTCTGACCCGCAAGCGTCGTCTTTCGGCGCTGG
GCCCCGGCGGTC 
JCV254 GACCGCCGGGGCCCAGCGCCGAAAGACGACGCTTGCGGGTCAGACCCGACAGCGGGTT
GTTCTGGTCCATG 
JCV255 CACTACGGACCGCTGTTCATCCGCATGGCCTGGCAGGCCGCGGGCACCTACCGCGTCA
GTGACGGCCGCGG 
JCV256 CCGCGGCCGTCACTGACGCGGTAGGTGCCCGCGGCCTGCCAGGCCATGCGGATGAACA
GCGGTCCGTAGTG 
JCV257 CACTACGGACCGCTGTTCATCCGCATGGCCTGGTAGGCCGCGGGCACCTACCGCGTCAG
TGACGGCCGCGG 
JCV258 CCGCGGCCGTCACTGACGCGGTAGGTGCCCGCGGCCTACCAGGCCATGCGGATGAACA
GCGGTCCGTAGTG 
JCV259 CGAGACGATGGGTAACTACCATCCGCACGGCGACGTCTCGATCTACGACACCCTGGTC
CGCATGGCCCAGC 
JCV260 GCTGGGCCATGCGGACCAGGGTGTCGTAGATCGAGACGTCGCCGTGCGGATGGTAGTT
ACCCATCGTCTCG 
JCV261 GTGATCGGCGCCAACTCGTCCGACGACGGCTACATGCTGCAGATGGCGCGCACGGCCG
AGCACGCGGGCTA 
JCV262 TAGCCCGCGTGCTCGGCCGTGCGCGCCATCTGCAGCATGTAGCCGTCGTCGGACGAGTT
GGCGCCGATCAC 
JCV241 GATGCCCATACCGCTCTGCGGCATGAACCCGATCGCGTGCACCACACCGTCGATCTTGT
TGCCCTCACCGA 
JCV263 CGAACAAACCGTCCTCGAAACCCGTTCGGGTCACCTACTACAGGTAGACCGCCGGGAT
GATCTGGTCGGTGTCGA 
JCV264 TCGGGGCGGGCAACAAGCTCGACGGGGTGGTGCATGCGATTGGGTTCATGCCGCAGAC
CGGGATGGGCATC 
JCV265 GATGCCCATCCCGGTCTGCGGCATGAACCCAATCGCATGCACCACCCCGTCGAGCTTGT
TGCCCGCCCCGA 
JCV266 GTCGAAGAACGGGTTGATGCCCATCCCGGTCTGCGGCATGAACCCAATCGCATGCACC
ACCCCGTCGAGCTTGTTGCCCGCCCCGATCGCCTCGGTCACCC 
JCV267 CACTACGGGCCGCTGTTTATCCGGATGGCGTGGCAGGCTGCCGGCACCTACCGCATCCA
CGACGGCCGCGG 
JCV268 GTATGGCACCGGAACCGGTAAGGACGCGATCACCACCGGCATCGAGGTCGTATGGACG
AACACCCCGACGA 
JCV269 GCCACTACGGGCCGCTGTTTATCCGGATGGCGTGGTAGTAGGCCGGCACCTACCGCATC
CACGACGGCCGCGGCGG 
JCV270 GTGCCCGAGCAACACCCACCCATTACAGAAACCACCACCGGAGCCGCTAGCAACGGCT
GTCCCGTCGTGGGAAGTTCGTGCAGGACTTCGTCGCTGCCTGGGACAAGGTGATGAAC
CTCGACAGGTTCGACGTGCGCTGA 
JCV271 GACCACCTCGCAGCCGTGGTGGCCCGCCGACTACGGCCACTACGGGCCGCTGTTTATCC
GGATGGCGTGGGCACCTACCGCATCCACGACGGCCGCGGCGGCGCCGGGGGCGGCATG
CAGCGGTTCGCGCCGCTTAACAG 
JCV272 CGAACAAGCCGTCCTCGAAACCGGTTCGGGTGACCTACTACAGAAAGACCGCGGGAAT
GATCTGATCGGTGTCGA 
JCV273 ATCACGTCGAGCGGCGGCGGCGCCGCAGCGGCGGCCTACTAGATCTCCGACAGGCTCA
CCGAGGCTTCACGCGCGG 
JCV274 TTATTTTTGACACCAGACCAACTGGTAATGGTAGCGACCGGCGCTCAGCTGGAATTCCG
CCGATACTGACGTTTGAGGGGACGACGACAGTATCGGCCTCAGGAAGATCGCACTCCA
GCCAGCTTTCCGGCACCGCTTCT 
JCV275 GCATCTGCCAGTTTGAGGGGACGACGACAGTATCGGATCGCACTCCAGCCAGCTTTCCG
GCACCGCTTCT 
JCV276 GGATAGGTCACGTTGGTGTAGATGGGCGCATCGTAGATCGCACTCCAGCCAGCTTTCCG
 190 
GCACCGCTTCT 
JCV277 TGCATCTGCCAGTTTGAGGGGACGACGACAGTATCCTACTAAGGAAGATCGCACTCCA
GCCAGCTTTCCGGCACCG 
JCV278 GATCCGCACCGTCGAGCAGTCCGACA 
JCV279 GGCTCGACTACCGTTTCGGATTGCT 
JCV280 GCCATCAATGAAAGAGCAACTGGCA 
JCV281 CCAGCTTTACTCAGGCTGCGCACCA 
JCV282 GGTGATGCCAGCGATGCGCAGTTCA 
JCV283 CAGGAATCCAAGAGCTTTTACTGCTT 
JCV284 GAAAGCTTCGAATTCTGCAGCTGGATC 
JCV285 CCAAGACAATTGCGGATCCCGTCGT 
JCV286 CGGCGATCCGGTCGTCGACGGGAGCGGCGGAAGCCTACTACATACGCACACCGGCGGC
CGCCATCACTGCCAGGG 
JCV287 TGTCGCGGTGCAGCAGCACCAGCGCGTCTTCGAGATCTGCTTCCTGCGAGTCGAAGTCG
GTGACGAAGTAG 
JCV288 GACAATTGCGGAGCTAGCCATGGACAT 
JCV289 GTCATACGCGGCTAGCGGATCCCGTTA 
JCV290 GCCTTCGGATCCTCCCCTGACGTGTA 
JCV291 CGTTGTAAGCTTCGGGTGGATGTCA 
JCV292 GCCATCATGGCCGCGGTGATCAGCTA 
JCV293 GGTACCGAGCACTAGTTGACATAAGC 
JCV294 TGTGCGTATGCCGAC 
JCV295 TGTGCGTATGTAGTA 
JCV296 CAGTGCACGCCGAGTTCGGGCAGCA 
JCV297 GGTCTACCTGAAGCG 
JCV298 GGTCTACCTGTAGTA 
JCV299 GTGCGCCAGAGATAACCGCCTTGAACT 
JCV300 CGACGGTGTGGTGCACT 
JCV301 CGACGGTGTGGTGCAGG 
JCV302 CGTAGATCACGGTGCCGGTGGT 
JCV303 GATGCCCATACCGCTCTGCGGCATGAACCCGATCGCATGGACCACACCGTCGATCTTGT
TGCCCTCACCGA 
JCV304 CGACGGTGTGGTCCATG 
JCV305 GACTCGCAGGAAGCAGT 
JCV306 GACTCGCAGGAAGCACA 
JCV307 CACGATGCCCTCCTCGACCGCT 
JCV308 GACTCGCAGGAAGCAGATCTCGAAGAC 
JCV309 GCCGGTGTGCGTATGTAGTAGGCTTCCGCCG 
JCV310 CCGGCGGTCTACCTGTAGTAGGTGACCCGAA 
JCV311 CCGGCGGTCTACCTGAAGCG 
JCV312 CCGGCGGTCTACCTGTAGTA 
JCV313 GCCGGTGTGCGTATGCCGAC 
JCV314 GCCGGTGTGCGTATGTAGTA 
JCV315 GTCCTCCCTATCAGTGATAGATA 
JCV316 CTACTTCGTCACCGACTTCGACTCGCAGGAAGCAGATCTCGAAGACGCGCTGGTGCTGC
TGCACCGCGACA 
JCV317 TACCTCGAGGTCACCGAGGGCGTCGGGTTCGACAAGGGCTTCCTGTCGGCCTACTTCGT
CACCGACTTCGACTCG 
JCV318 CTCGGCGACCTTCTCCAGCAGCGGCAGCAGATCCGGCAGCGAGCTGATCTTGTCGCGGT
GCAGCAGCACCAGCGC 
JCV319 GCTGGAACTCGACGTGCAGAACGAGGAGCACCTGTCGACTCTGGCCGACCGGATCACC
GCCGAGATCGGTGAGGG 
JCV320 TACGAGTACGCCGAGATGTGGATGCCCTTGGACACATCCTCGTACGGCGCGTCGAAGA
ACGGGTTGATGCCCATA 
JCV321 GACGAATCTCTCACGACGCAGTGT 
JCV322 TCAGCGCACGTCGAACCTGTCGAGGTTCATCACCTTGTCCCAGGCAGCGACGAAGTCCT
GCACGAACTTCCCACGACGGGACAGCCGTTGCTAGCGGCTCCGGTGGTGGTTTCTGTAA
TGGGTGGGTGTTGCTCGGGCAC 
JCV323 CTGTTAAGCGGCGCGAACCGCTGCATGCCGCCCCCGGCGCCGCCGCGGCCGTCGTGGA
TGCGGTAGGTGCCCACGCCATCCGGATAAACAGCGGCCCGTAGTGGCCGTAGTCGGCG
GGCCACCACGGCTGCGAGGTGGTC 
JCV324 CCGCCGCGGCCGTCGTGGATGCGGTAGGTGCCGGCCTACTACCACGCCATCCGGATAA
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ACAGCGGCCCGTAGTGGC 
JCV325 CATGGACCAGAACAACCCGCTGTCGGGGTTGACCCGCAAGCGCCGACTGTCGGCGCTG
GGGCCCGGCGGTC 
JCV326 GACCGCCGGGCCCCAGCGCCGACAGTCGGCGCTTGCGGGTCAACCCCGACAGCGGGTT
GTTCTGGTCCATG 
JCV327 CCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTTGGCGCTGGGGCCCGGCGGTCTGT
CACGTGAGCGTG 
JCV328 CACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAACAGTCGGCGCTTGTGGGTCAA
CCCCGACAGCGGG 
JCV329 TGGTGTATGCACCCGCGTGTACACCACCACTCCGAGGAAGCCGAACTCGGCGCTTCGG
AAGGTTGCCCGCG 
JCV330 CGCGGGCAACCTTCCGAAGCGCCGAGTTCGGCTTCCTCGGAGTGGTGGTGTACACGCG
GGTGCATACACCA 
JCV331 GCCATCCTGACGGATGGCCT 
JCV332 GCATGCGGATCGTGCTCATT 
JCV333 CGCCGCCCGAAATGAGCACGATCCGCATGCCACCGCACCCATCAGAGATGGT 
JCV334 TAAAAAAGGGGACCTCTAGGGTCCCCAATTAATTAGTTGTTCCTTTCGGGTGGATGTCA 
JCV335 CGCCGCCCGAAATGAGCACGATCCGCATGCGCACACACCCCTGACTCCTGCTA 
JCV336 CGAGCCTGCGGAACGACTAGGAATTCTGGGAGCCG 
JCV337 CGGCTCCCAGAATTCCTAGTCGTTCCGCAGGCTCG 
JCV338 GAAGGTGACCAAACCATATGACCACCA 
JCV339 CATGCTGGAATTCGGGGCGATCATT 
JCV340 TGCTGACATGCGGGCGTAGCTCAATGGTAGAGCCCTAGTCTTCCAAACTAGCTACGCGG
GTTCGATTCCCGTCGCCCGCTCGGTAGGGACCGCCACGTGCGATTTAGGATACATGCTA
GCCACCT 
JCV341 GTGCGCCGATTTCTGCACCACGGTCGTGATCTGCGACGAACCACGACCTTGGTGCAGAA
ATCGCGGGGGCAGTTGAGCACTCGGCAACGAAAAAGGGACCACCGCAGCGCTAGCGA
GAACGTCCC 
JCV342 ACCAGATCATCCCGGCGGTC 
JCV343 ACCAGATCATCCCGGCGGGG 
JCV344 CAGAAGGCCATCCTGACGGATGGCCT 
JCV345 GCATGCGGATCGTGCTCATTTCGG 
JCV346 GATTAGCTAAGCAGAAGGCCATCCT 
JCV347 CTACGCGAGCCTGCGGAACGACTAGGAATTCTGGGAGCCGCTGGC 
JCV348 GCCAGCGGCTCCCAGAATTCCTAGTCGTTCCGCAGGCTCGCGTAG 
JCV349 GCTCGACGGGGTGGTGCAAT 
JCV350 GCTCGACGGGGTGGTGCAAG 
JCV351 CAGACAGCAGCGCGCACACCGTCTT 
JCV352 GCTCGACGGGGTGGTGCATGCGATTGGGT 
JCV353 CCCGCGGTCTTTCTGAAGCG 
JCV354 CCCGCGGTCTTTCTGTAGTA 
JCV355 GAGTTTCCGCAGCGTAAGGGCTAT 
JCV356 CCCGCGGTCTTTCTGTAGTAGGTCAC 
JCV357 GATCCAATATTACTAGTAGATCTCGT 
JCV358 GACGTCTTAATTAATATGCATCAAT 
JCV359 GACGTCTTAATTAATATGCATCAATTGATTTA 
JCV360 GATCCAATATTACTAGTAGATCTCGTAATATTG 
JCV361 GAATAGAGGTCCGCTGTGACATAGGAATCCCTGTTACTTCTC 
JCV362 GAGAAGTAACAGGGATTCCTATGTCACAGCGGACCTCTATTC 
JCV363 GACCTCTAGGGTCCCCAGCTGGCTAG 
JCV364 CACGGCCGTGACGCTAGCGACGATCCA 
JCV365 AAAACGATTGTCATTATCGTACGACGGTACCGCACGACGAAGGAGAGTCAATGGCTCG
CAACGAGATCCGGCCCATCGTGAAGCTGCGGTCCACTGCGGG 
JCV366 CCCGCAGTGGACCGCAGCTTCACGATGGGCCGGATCTCGTTGCGAGCCATTGACTCTCC
TTCGTCGTGCGGTACCGTCGTACGATAATGACAATCGTTTT 
JCV367 AGAAGGTCTGATGGCTCGCAACGAGATCCGGCCCATCGTGAAGCTGCGGTATGGCGAA
GAAGTCGAAGATTGTCAAGAACGAGCAGCGGCGAGAACTGGT 
JCV368 ACCAGTTCTCGCCGCTGCTCGTTCTTGACAATCTTCGACTTCTTCGCCATACCGCAGCTT
CACGATGGGCCGGATCTCGTTGCGAGCCATCAGACCTTCT 
JCV369 AAATACGATCCGGTCCTGCGCCGCCACGTCGAGTTCCGCGAGGAACGCTGATGGCAGT
CAAGAAGTCCAGAAAGCGCACGGCCGCAACTGAACTCAAGAA 
JCV370 TTCTTGAGTTCAGTTGCGGCCGTGCGCTTTCTGGACTTCTTGACTGCCATCAGCGTTCCT
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CGCGGAACTCGACGTGGCGGCGCAGGACCGGATCGTATTT 
JCV371 GAGATGGCGCATCGCGGCGAGTTGCCCGGTGTGCGGAAGGCGAGTTGGTGGGCGTGCG
GTATGACACCATCGGTGCCGAAGGCGACTGCGGATCGAGGAA 
JCV372 TTCCTCGATCCGCAGTCGCCTTCGGCACCGATGGTGTCATACCGCACGCCCACCAACTC
GCCTTCCGCACACCGGGCAACTCGCCGCGATGCGCCATCTC 
JCV373 GTGGCTGACGAGCAGGGTGCCAGGT 
JCV374 CACCGATGGTGTCATACCGCACGCCT 
JCV375 ATCATCCCGGCGGGGCCTTACGCT 
JCV376 GGAAAACCCTGGCGTTACCTAGCTTAATCGCCTTGCAG 
JCV377 CTGCAAGGCGATTAAGCTAGGTAACGCCAGGGTTTTCC 
JCV378 GTCTCTGACGAGCGGGAGAACCCA 
JCV379 GAGCTTCAACCCACCATATGAGGAAGGCA 
JCV380 GTCACGACCGGTTGTGTGAGCCAGA 
JCV381 CTGTCCTCGTTGGGTACCGAGCTCGA 
JCV382 CGACGAAGGAGAGTCAATCT 
JCV383 CGACGAAGGAGAGTCAATCG 
JCV384 GATCCGGAGGAATCACTTCGCAATG 
JCV385 TGATGTCGCTGCAGGAACTGCACAGCGAACTGGGGTCGCGCCGGTCATGACGGGCCCA
CCACGCGACAGCGCCATTGCGCCGACAATCGTCGGTCCAACG 
JCV386 CGTTGGACCGACGATTGTCGGCGCAATGGCGCTGTCGCGTGGTGGGCCCGTCATGACC
GGCGCGACCCCAGTTCGCTGTGCAGTTCCTGCAGCGACATCA 
JCV387 CTCGGCCGCGGTGCAGGGCATCGAGGCCGGCATCCGCGGCGACATCGGCGTGATGTCG
CTGCAGGAACTGCACAG 
JCV388 GCACAGGGCTGCCGGCTCGGACACATCTGAAATCCGGCTCCTACCTGAGCCGTTGGAC
CGACGATTGTCGGCGCA 
JCV389 CATCCCGTGCGTCACCACGGTGCA 
JCV390 GTGATGGACTGCGCCGCAGGCGAACT 
JCV391 GGCGACCAGCACTACCGGCGTACGCATGGGACCTCCCGGTTTGCTTATTGAAAACGATT
GTCATTATCGTACGAC 
JCV392 GGTCCGGGTCGTTGCGGCGATTCTTGCGGGTGACGTACGTGTATCCGGTTCCCGCAGTG
GACCGCAGCTTCACGA 
JCV393 CCGTAGGCCTCGAAGAACGCGACCTACGGTTTGACGATGGCGAAGCCCGCG 
JCV394 CCGTATGACTCAAAAAACGCCACCTACGGTTTGACCACCGCGAAATCAGCG 
JCV395 CCCCGCCGAACCGTAGGCCTCGAAGAACGCGACCTACGGTTTGACGATGGCGAAGCCC
GCGAACGCCGCGA 
JCV396 GGCGTCGACCGTCAGGCCCCAGGCGTTCAAGAGCTACTAATGCGGGTCGATGCCGGGG
CACAGCGGCCCGCGCG 
JCV397 TCCTCCCACTCCCTCGGTCTCACCT 
JCV398 TCGGCCGCGGTGCAGGGCATCGAGG 
JCV399 CGAAGAGGCCGACCCGATTGAAGGGGATTACATCTATGGCTGAAAATGCTGGGCCCAA
CGCATGAGCGCCCCGGCGAACCACGACGCGGTGGTTGATCTG 
JCV400 ACCGTCGGCGACGTCGTCACCGACAGCTATATCTACGACACCGACCCGCTCGAAGAGG
CCGACCCGATTGAAGGG 
JCV401 GGCCTCGGCGTAGTGGTACGTCGGCGGGCGCGTCATGACTGCACCACCTGCAGATCAA
CCACCGCGTCGTGGTTC 
JCV402 GACGTGGTCACGATCAGCCTGCCCT 
JCV403 CAACTTGAACGCGATCGCGGGCACG 
JCV404 GCTCCGGGCTCGCAGCAGCGGGCTT 
JCV405 CAACGCAATTAATGTGAGTTAGCTCA 
JCV406 GGGTGATGTCCGGGGCGGTACGCGTAGGCGTCTGAAAGAGACTTATGAGCGTTCTCAA
CGCCGCCTCGGTGGCCCGGATGATCCTGACGACGGAGACCGC 
JCV407 GCGGTCTCCGTCGTCAGGATCATCCGGGCCACCGAGGCGGCGTTGAGAACGCTCATAA
GTCTCTTTCAGACGCCTACGCGTACCGCCCCGGACATCACCC 
JCV408 GCGCAGTCGATCGTCGACGCGGTCGCGCAGGCGAACCGGGAGGCGGATCCGGCGGCGC
GCGACGGCGATCCGGTGGGCCCGTTCGGTGTCGTGGTGGGCG 
JCV409 CGCCCACCACGACACCGAACGGGCCCACCGGATCGCCGTCGCGCGCCGCCGGATCCGC
CTCCCGGTTCGCCTGCGCGACCGCGTCGACGATCGACTGCGC 
JCV410 GAGGAGTCAACCCCATATGATGTCGAT 
JCV411 GGTCGGCGAATTCCGTTGTCATGTC 
JCV412 AGCTGCACATATGCGCTGCGCCCGT 
JCV413 GGATAGGTCAGGAATTCGCCGGTCA 
JCV414 GTCGCGCCATATGGTGCAGATTCT 
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 JCV415 GGTGGCGCTGAATTCGTCGTACGTCA 
JCV416 GAGGTGGCGTCCATATGCACATGCA 
JCV417 CGTCTGCTGCTTGAATTCGGTCACAG 
JCV418 CGGATGCTCACGGATCCGATCTGCCA 
JCV419 GATCTTGGCGATGAATTCGCTGCGCT 
JCV420 GAGGGCGGCATATGAGCGCCGA 
JCV421 CTGTCCCTATCGAATTCGGCCTGGT 
JCV422 GGCGCATATGAGCCGCGAGCTGCT 
JCV423 CTTCGCCTCGTCGAATTCCGGGTCGT 
JCV424 GTGCAATGACATATGAGTGACGGAC 
JCV425 CATCGTTTGTGAATTCTCGCTTGAA 
JCV426 GGATCGACATATGAAGCGCACCAGGA 
JCV427 CTCGCCGGAATTCTGCTACGGGTCGA 
JCV428 GCGGTCGACATATGCTGAGCGTGCAGCC 
JCV429 CTGCATAACCGGAATTCAGGGCGTGT 
6.5 PROTEIN PURIFICATION 
C-terminally 6x-his-tagged Che9c gp60, Che9c gp61, and Halo gp43 proteins were purified by 
over-expression from T7-inducible vectors in E. coli BL21(DE3) pLysS (Invitrogen) 
transformed with pJV33 and pJV34, respectively, using nickel-affinity chromatography. In 
addition, empty vector pET21a was also transformed into BL21(DE3) pLysS cells and prepared 
in parallel as a negative control.  
Che9c gp60 was purified as follows: cells containing pJV33 were grown at 37C to an 
OD600 of 0.4. Che9c gp60 expression was induced by addition of 1 mM IPTG, and cells were 
harvested by centrifugation after 4 hr growth at 30C. Cell pellets were resuspended in lysis 
buffer at 5 ml per gram wet weight and sonicated 6-8x at bursts of 10 s with 1 min cooling in 
between bursts. Cell lysate was centrifuged at 13,000 rpm for 30 min at 4C, and the supernatant 
was incubated with 750 l Ni-NTA agarose resin (Qiagen; washed 2x with dH2O) rocking at 4C 
for 1.5 h. This was applied to a column and washed 2x with 20x column volumes of wash buffer 
containing 10 mM imidazole (first wash) or 20 mM imidazole (second wash). Protein was eluted 
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4x with 1 column volume elution buffer. Eluted fractions were analyzed by SDS-PAGE, and the 
fractions containing the least contaminating proteins were dialyzed against storage buffer.  
Che9c gp61 purification was performed similarly except 2.5 ml Ni-NTA agarose resin 
was used, washes did not contain imidazole, and elutions were performed with a gradient of 
imidazole concentrations (20, 40, 60, 80, 100, 150, 200, and 250 mM imidazole). Elution 
fractions with 150 and 200 mM imidazole were dialyzed against storage buffer. Proteins were 
analyzed by SDS-PAGE and quantified by Bradford protein assay (Bio-rad). 
Halo gp43 protein purification was performed similarly to that for gp61 except 5 ml of 
resin was used. Two combinations of elution fractions (80 and 100; 150 and 200 mM imidazole)  
were dialyzed against storage buffer and analyzed and quantified as above. 
6.5.1.1 Antibody synthesis 
Anti-gp61 and anti-gp43 antibodies were synthesized by Pocono Rabbit Farms. 
Screening bleeds were initially tested from rabbits and found to have very high background on 
wild type M. smegmatis cell extracts. Therefore, multiple mouse screening bleeds were tested, 
and three mice were chosen for each protein (Che9c gp61 and Halo gp43). Approximately 1 – 
1.5 mg of nickel-affinity purified protein was sent to Pocono Rabbit Farms, and mouse bleeds 
were obtained. Mice S12 and S14 were inoculated with Che9c gp61 protein (mouse S13 died), 
and mice S19, S20, and S21 were inoculated with Halo gp43 protein. Titermax adjuvant was 
used in place of Freund’s, which is not suitable for mycobacteria. Approximately four bleeds 
were collected for each mouse, and subsequently the final bleeds were extracted. All antibodies 
were stored in 5 l aliquots at -80°C. 
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6.6 IN VITRO ASSAYS 
6.6.1 Exonuclease assays 
Exonuclease activity of Che9c gp60 was determined as described [227] by three assays - A, B, 
and C - in which  Exo (5 U/l; NEB) was used as a positive control for DNA degradation, 
while mock purified pET21a vector control protein preparations were used as a negative control.  
Assays A and B were used to determine the exonuclease activity of Che9c gp60 on linear 
dsDNA, while assay C was used to determine its activity on supercoiled or nicked open-circle 
dsDNA. 
In assay A, reaction mixtures (50 l) contained 8 nM 32P-labeled 100 bp Bxb1 attB, 40 
nM unlabeled 100 bp Bxb1 attB (see Table 16), and gp60 or control proteins in exonuclease 
assay buffer. Che9c gp60 (10.6 pmol/l),  Exo, and mock purified control protein were added at 
1 l per reaction of serially diluted concentrations (neat, 2x, 4x, 8x, 16x, and 32x in protein 
dilution buffer) with respect to the stock concentration of each protein.  Reactions were 
incubated for 5 min at room temperature and stopped with final concentrations of 10 mM EDTA 
and 0.5% SDS and addition of glycerol loading dye (0.25% bromophenol blue, 0.25% xylene 
cyanol, and 30% glycerol). Samples were analyzed by gel electrophoresis on 8% native TBE 
polyacrylamide gels, dried on Whatman paper for 1.5 hr at 85C, and exposed to BioMax 
Maximum Resolution film (Kodak) overnight.  
In assay B, reaction mixtures (50 l) contained 0.8 nM pBluescript SK+ (Stratagene) 
linear dsDNA (linearized by digesting with EcoRV) and protein in exonuclease assay buffer.  
Che9c gp60 and mock-purified protein were added at equal volumes (1 l) from parallel 
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purifications, with gp60 at a final concentration of 212 nM;  Exo was added at 5 U per reaction. 
Negative control reactions were routinely performed using 1 l storage buffer instead of enzyme. 
Reactions were incubated for 0 – 10 min at room temperature, stopped with EDTA and SDS as 
above, and loading dye was added. 25 l of each reaction was analyzed by gel electrophoresis in 
0.8% agarose gels, visualized with ethidium bromide (0.4 g/ml) and photographed using a Bio-
Rad Gel Doc 2000 and Quantity One 4.6 software.  
In assay C, reaction mixtures (20 l) contained either 2 nM linearized or 2 nM 
circularized pBluescript SK+ and protein in exonuclease assay buffer. Che9c gp60 was added to 
a final concentration of 530 nM by addition of 1 l protein and 1 l mock-purified control 
protein was used;  Exo was added at 5 U per reaction. Reactions were incubated for 0 – 10 min 
at room temperature, stopped by addition of EDTA and SDS as above, and loading dye added. 
Reactions were analyzed on agarose gels as with assay B. 
6.6.2 DNA binding assays  
6.6.2.1 Double-filter binding assay 
 Filter-binding assays were used to determine the DNA binding activity of Che9c gp61 
and Halo gp43 [227]. A double-filter binding assay was utilized [20,239] in which nitrocellulose 
filter membranes were stacked on top of DEAE-cellulose filters and filtered by means of a FH 
225 V filter manifold system (GE Healthcare). Protein and protein/DNA complexes are bound by 
the nitrocellulose filter on the top, and the unbound DNA is captured by the DEAE filter below, 
so that the total DNA counts per sample are accounted for. DEAE-cellulose filters, grade DE81 
(Whatman), were prepared as described [20] in which the membranes were treated with 0.1 M 
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Na2EDTA pH 8.8 for 10 min rocking at room temperature, followed by 3-10 min washes in 500 
mM NaCl. The filters are then briefly treated with 500 mM NaOH (less than 30 sec), washed 15 
times with dH2O, washed with TBS buffer, and stored at 4°C in that same buffer. Protran BA85 
nitrocellulose filters (Whatman/Schleicher & Schuell) were prepared by removing the blue 
packaging papers, and incubating the filters in 500 mM KOH on a rocking platform for 25 min 
(time critical) at room temperature. The filters were washed 15 times with dH2O, washed twice 
with TBS buffer, and stored at 4C in TBS buffer.   
 DNA binding reactions (30 l) contained 32P-labeled Bxb1 ss-attB (50 nt or 100 nt; Table 
16), enzyme, and binding assay buffer similar to the conditions described for assaying DNA 
binding of RecT [68]. Reactions containing dsDNA (~66.7 nM) used an annealed 32P-labeled 50 
bp attB substrate (Table 16) which was gel-extracted from a native 8% TBE polyacrylamide gel 
(exposed to film for 30 sec to locate probe), electroeluted in dialysis membrane (SpectraPor, 
MWCO 1000) in TBE at 100 v for 45 min, phenol:chloroform extracted and ethanol precipitated. 
In most reactions, 90% of the DNA added was cold, and 10% was used ‘hot’ to reduce the 
amount of radioactivity use. The concentrations of gp61 used were in the range of 0.2 – 3.7 M 
(diluted in protein dilution buffer), and storage buffer was used as a ‘no protein’ control. 
Reactions were incubated at 37C for 20 mins and filtered. Each reaction (25 l) was filtered and 
washed once with wash buffer. Filters were individually placed in 5 ml ScintSafe 30% 
scintillation fluid (Fisher) and the radioactive counts per minute (CPM) were determined by 
counting in a scintillation counter, with 1 min counting per sample. Percent DNA bound was 
determined by the following equation: 
 
%DNAbound 
CPMNC
CPMNC CPMDEAE   
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 CNC is the CPM retained on the nitrocellulose filters (protein and protein/DNA complexes), and 
CPMDEAE is the CPM on DEAE filters (unbound DNA), and this is further normalized to 
negative controls in which no protein was added. Binding constants were determined by non-
linear regression using SigmaPlot 8.0. Error bars represent the standard deviation from three 
independent experiments.  
6.6.2.2 Gel shift assay 
Gel shift assays were performed with the DNA binding reaction conditions similar to 
those described for the filter-binding assays using either ss-attB (50 nt) or ds-attB substrates 
(Table 16). DNA binding reactions were loaded on native 8% TBE polyacrylamide gels with 
glycerol loading dye, dried on Whatman paper for 1.5 hr at 85C, and exposed to BioMax 
Maximum Resolution film (Kodak) overnight or on a Fujifilm phosphoimager plate. 
Phosphoimager plates were scanned with a Fujifilm FLA-5100, and quantitation of shifted bands 
was performed using MultiGauge software. 
6.6.3 Electron Microscopy 
Samples were prepared and analyzed by transmission electron microscopy as described [20] with 
reactions (50 l) containing purified Che9c gp61 [227] at a concentration of 50 g/ml (1.2 M) 
and 1.95 M ss-attB DNA (100 nt; Table 16) or oligonucleotides of various lengths. Briefly, the 
reactions were absorbed to glow-discharged, formvar carbon-coated 400 mesh copper grids, and 
these were negatively stained with 2% uranyl acetate. Images were collected at a magnification 
of 140,000x. 
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6.6.4 Gel filtration 
Analytical gel filtration of purified Che9c gp61 protein was performed using a Superdex 200 
10/300 GL high performance gel filtration column (Tricorn, Amersham) controlled by the 
System Gold high-pressure liquid chromatography system (Beckman Coulter, Inc.) as previously 
described [101]. The column was standardized using a gel filtration calibration kit (Amersham) 
in which both low molecular and high molecular weight protein standards were run in duplicate 
to determine their respective elution volumes. Standards included: ribonuclease A (13.7 kDa), 
chymotrypsinogen (25 kDa), ovalbumin (43 kDa), albumin (67 kDa), aldolase (158 kDa), 
catalase (232 kDa), and apoferritin (443 kDa). Tryptophan and Barnyard Phage particles were 
used to determine the bed and void volumes, respectively. Approximately 330 g of each 
standard was used for calibration at 100 l volumes. The column was first equilibrated in one 
column volume (approximately 25 ml) of equilibration buffer (33 mM Tris, pH 7.5, 100 mM 
NaCl) at a flow-rate of 0.2 ml/min. Protein standards or gp61 protein were loaded through a 100 
l loop and eluted at a flow-rate of 0.5 ml/min. Elution volumes of proteins (recorded as the time 
of peak absorbance) were monitored at a wavelength of 280 nm using protein fluorescence and, 
as an additional reading, on a Jasco fluorescence detector. The Kav values (fractional retentions 
of the samples [68]) for each protein standard were calculated based on the following equation: 
 
Kav =  
Ve - Vo
Vt - Vo
 
 
Ve is the elution volume of the protein, Vo is the column void volume, and Vt is the total bed 
volume of the column. The Kav value for each protein standard was plotted against the molecular 
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weight (Daltons) on a logarithmic scale, and a trendline was determined based on the standards. 
To assay the size of gp61 protein complexes, gp61 protein was tested at concentrations of 5 M, 
10 M, and 25 M. The elution volumes were collected for each, and the Kav values were 
determined. Using the equation from the slope of the line, and solving for y, the molecular 
weight for each gp61 reaction was determined. The column error was determined for the 
molecular weight of the protein standards compared to the value obtained using the slope 
equation in order to determine the range of accuracy for the gp61 reactions.  
 
6.7 WESTERN BLOT ANALYSIS 
Che9c gp61 and Halo gp43 protein expression were monitored using western blot analysis [227]. 
M. smegmatis cells were collected, resuspended in SDS-PAGE buffer and normalized to OD600. 
To do this, the OD600 was measured (OD per ml), the cells pelleted, and resuspended to a 
concentration of 0.05 ODs per l. Strain samples (0.5 ODs of cells) and purified protein (0.5 g) 
as positive controls were loaded on 10% SDS-polyacrylamide gels following boiling for 3 – 5 
min at 95°C in 4x SDS-PAGE loading dye diluted down to 1-2x. Proteins were transferred to 
Sequi-blot PVDF membranes (Bio-rad) using a Bio-rad semi-dry transfer cell in transfer buffer 
(48 mM Tris, 39 mM glycine, 0.037% SDS, 20% methanol) at 0.8 mAmps per cm2 of gel. The 
blots were allowed to dry, rewetted with methanol, and blocked in 5% milk in TBS-T for 1 hr 
rocking at room temperature. These were probed with either mouse anti-gp61 polyclonal 
antibodies or mouse anti-gp43 polyclonal antibodies in 1% milk in TBS-T (1:5,000) and rocked 
for 1 hr at room temperature. The blots were then washed 3 times for 5 min in TBS-T, and 
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subsequently probed with sheep anti-mouse horseradish peroxidase-linked secondary antibody in 
0.5% milk in TBS-T (1:15,000) for 45 min rocking at room temperature. The blots were washed 
again and submerged in 14 ml Western Lightening Reagent (Perkin-Elmer) for 2 mins to detect 
the secondary antibody. Blots were visualized using a Fujifilm LAS-3000. 
6.8 SOUTHERN BLOT ANALYSIS 
6.8.1 Genomic DNA preparation from Mycobacterial cultures 
DNA was isolated from saturated M. smegmatis and M. tuberculosis cultures as described [229]. 
Briefly, 10 ml of culture was centrifuged at 2,000 x g for 20 min, and the cell pellet was 
resuspended in 1 ml GTE Solution (25 mM Tris-HCl pH 8.0, 10 mM EDTA, 50 mM glucose). 
This was transferred to a microcentrifuge tube and pelleted for 10 min, and resuspended in 450 
µl GTE Solution. To this, 50 l of lysozyme solution (10 mg/ml in Tris pH 8.5) was added, 
gently mixed, and incubated at 37°C overnight. 100 µl 10% SDS was then added and gently 
mixed, and 50 µl 10 mg/ml Proteinase K (Sigma) was added and mixed gently; this was 
incubated at 55°C for 20 to 40 min. 200 µl 5M NaCl was then added and gently mixed, and 160 
µl of CTAB (preheated at 65C) was added and mixed gently. This was incubated at 65°C for 10 
min. Finally, an equal volume (~1 ml) chloroform:isoamyl alcohol (24:1) was added to the tube, 
the aqueous phase containing the DNA was extracted and precipitated similar to the procedure 
for preparing mycobacteriophage genomic DNA (see below), and this was stored at -20C. When 
applicable, the BSL3 M. tuberculosis strains were only removed from the BSL3 lab following 
extraction with chloroform:isoamyl alcohol. 
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 6.8.2 Southern blotting procedures 
Southern blots were performed as described [7] to determine the genotype of a putative mutant 
strain, such as an allelic replacement mutant. The predicted sequence of the mutant strain was 
used to choose restriction sites that would result in different sized fragments (1 – 10 kbp) when 
the DNA was digested, making it possible to distinguish between wild type and mutant strains. 
Chromosomal DNA was isolated as described above and DNA digests (20 l) were incubated 8 
hr – O/N and run on an agarose gel to separate fragments.  
 The DNA was transferred to a nylon membrane using alkaline transfer conditions 
followed by downward capillary transfer. To prepare the gel, it was rinsed in dH2O and placed in 
0.25 M HCl on a rocking platform at room temperature for 30 min. The gel was rinsed with 
dH2O and placed in 0.4 M NaOH on a rocking platform at room temperature for 20 min to 
denature the DNA. To setup for the downward capillary transfer, a stack of paper towels (~2 
inches) topped with four pieces of Whatman paper (all cut to the size of the gel) were stacked 
next to a dish containing transfer buffer (0.4 M NaOH). The nylon membrane was placed on top 
of the Whatman paper (one piece wetted with transfer buffer), and the gel was gently placed on 
top of the nylon membrane, removing bubbles. Three wet pieces of Whatman were placed on top 
of the gel, and a long piece of Whatman was placed on top of this that extended down into the 
dish of transfer buffer. Two glass gel plates were placed on top of the stack to prevent 
evaporation and to provide some weight, and this was left to transfer for 2 hr or longer. After 
transfer, the wells were marked with a pencil, and the membrane air-dried. DNA was cross-
linked to the nylon by using a Stratalinker UV Crosslinker (Stratagene) on auto-crosslink mode.  
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Membranes were treated with 20 ml of a pre-hybridization solution in a roller bottle at 
50°C for 2 hr, and at this time the radioactive probe was prepared. A dsDNA substrate (typically 
500 bp of PCR product) was used for hybridization to detect genotypic differences between 
strains tested by Southern blot. The DNA was denatured by boiling for 5 min at 95°C and cooled 
on ice, and a random primers labeling reaction (50 l) was used to radiolabel the substrate. The 
reaction (ssDNA substrate, random primers mix, dTTP, dCTP, dGTP, [-32P]dATP, and Klenow 
enzyme) was incubated for 1 hr at 30°C, denatured at 95°C, and cooled on ice. Denatured probe 
and 1 mg denatured sheared salmon sperm DNA were added to 10 ml hybridization solution. The 
membrane was transferred to this solution and incubated in a roller bottle overnight at 65°C.  The 
membrane was washed one time in wash solution 1 for 20 min at room temperature rolling, and 
two times in wash solution 2 for 20 min., first at room temperature and then at 65°C rolling. The 
membrane was exposed to film overnight and developed.  
 
6.9 BACTERIAL STRAINS, GROWTH CONDITIONS, AND MANIPULATIONS 
6.9.1 Escherichia coli 
6.9.1.1 Strains/Media 
 E. coli DH5, E. coli GC5, and E. coli 5 strains were grown in LB broth or on LB agar 
plates supplemented with kanamycin (Kan, 20 g/ml), hygromycin (Hyg, 150 g/ml), 
carbenicillin (Cb, 50 g/ml), tetracycline (Tet, 6.5 g/ml), chloramphenicol (15 g/ml), 
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gentamicin (Gent, 15 g/ml), and/or x-gal (40 g/ml) as required. Strains were stored in 20% 
glycerol at -80°C. 
6.9.1.2 Transformations 
 Transformations of all chemically competent E. coli cells were performed according to 
manufacturers’ instructions for GC5 or DH5 cells. Briefly, DNA was added to 50 l cell 
aliquots on ice for 30 min, heat-shocked at 42C for 45 sec, recovered in 450 l TSB for 1 hr, 
and plated on selective media. Electrocompetent cells (typically XL1-Blue) were transformed by 
thawing cell aliquots on ice, adding DNA to cells, and incubating on ice for 10 min. Cells were 
transferred to chilled 0.2 M cuvettes (Bio-rad) and transformed with a Bio-Rad Gene Pulser II 
set at 2.5 kV, 200 , and 25 F. Cells were recovered in 1 ml TSB broth for 1 hr at 37°C, and 
plated on selective media. 
6.9.2 Mycobacterium smegmatis mc2155 
6.9.2.1 Strains/Media 
 The high-efficiency transformation strain M. smegmatis mc2155 was used for all 
manipulations [211].  M. smegmatis was grown in 7H9 broth (Difco) supplemented with 10% 
ADC, 0.2% glycerol, and 0.05% tween, and on 7H10 agar (Difco) plates supplemented with 10% 
ADC and 0.5% glycerol as described [18] unless otherwise mentioned. When required, media 
was supplemented with the following: Kan (20 g/ml), Hyg (150 g/ml), Cb (50 g/ml), Chx 
(10 g/ml), Tet (2.5 g/ml), Gent (10 g/ml plates; 2.5 g/ml liquid), isoniazid (INH; 25 g/ml), 
ethionamide (ETH; 25 g/ml), rifampicin (Rif; 200 g/ml), streptomycin (Str; 20 g/ml), 
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ofloxacin (Ofx; 0.5 g/ml), ethambutol (10 g/ml), x-gal (40 g/ml), 5-fluoroorotic acid (5-
FOA; 1 mg/ml), uracil (0.2 mM), and/or leucine (100 g/ml). Single colonies were picked and 
routinely inoculated from streak plates into 3 ml 7H9 broth with ADC, tween, and the 
appropriate antibiotic, and these were incubated with shaking at 37°C until saturated. Strains 
were stored at -80°C in 20% glycerol, and were streaked on 7H10 plates directly from these 
frozen glycerol stocks when required. M. smegmatis strains constructed are listed in Table 17. 
 
Table 17. M. smegmatis strains. 
Strain 
background 
Relevant 
mutation(s) 
Replicating 
plasmid 
Antibiotic 
resistance 
Recombineering substrate 
used to construct strain 
M. smegmatis 
mc2155 
0642:res-hygR-res pJV24 KanR, HygR AES; pMP6 
M. smegmatis 
mc2155 
4308:res-hygR-res pJV24 KanR, HygR AES; pMs4308 
M. smegmatis 
mc2155 
6008:res-hygR-res pJV24 KanR, HygR AES; pPJM04 
M. smegmatis 
mc2155 
groEL1:res-hygR-
res 
pJV24 KanR, HygR AES; pMsgroEL1 
M. smegmatis 
mc2155 
groEL1:res-sacB-
hygR-res 
pJV53 KanR, HygR AES; pJV149 
M. smegmatis 
mc2155 
leuB:res-sacB-
hygR-res 
pJV53 
 
KanR, HygR AES; p0004SleuB 
M. smegmatis 
mc2155 
leuD pJV76amber KanR, HygR 100bp dsDNA 
M. smegmatis 
mc2155 
leuD:res-sacB-
hygR-res 
pJV24 KanR, HygR AES; p0004SleuD 
M. smegmatis 
mc2155 
pyrF:gentR pJV98 KanR, GentR AES; pKP134 
M. smegmatis 
mc2155 
recA pJV53 KanR Unmarked with  res; 
removed pGH542 
M. smegmatis 
mc2155 
recA:res-hygR-res pJV53 KanR, HygR AES; pJV28 
M. smegmatis 
mc2155 
recB pJV53 KanR Unmarked with  res; 
removed pGH542 
M. smegmatis 
mc2155 
recB:res-hygR-res pJV53 KanR, HygR AES; pJV68 
M. smegmatis 
mc2155 
recD pJV53 KanR Unmarked with  res; 
removed pGH542 
M. smegmatis 
mc2155 
recD:res-hygR-res pJV53 KanR, HygR AES; pJV101 
M. smegmatis blaS 25* 26* pJV62 KanR ssDNA (JCV286) 
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mc2155 
M. smegmatis 
mc2155 
gyrA A91V pJV62 KanR, OFXR ssDNA (JCV260) 
M. smegmatis 
mc2155 
inhA S94A pJV62 KanR, INHR ssDNA (JCV217) 
M. smegmatis 
mc2155 
rpoB H442R pJV62 KanR, RIFR ssDNA (JCV254) 
M. smegmatis 
mc2155 
rpsL K43R pJV62 KanR, StrR ssDNA (JCV219) 
 
These are strains with specifically engineered mutations that were constructed by recombineering; the type of 
recombineering substrate used for each mutation is described. This list does not include strains constructed merely 
by introducing a replicating or integrating plasmid. Abbreviations: AES, allelic exchange substrate; res, resolvase 
site. 
 
6.9.2.2 Competent cell preparations 
Electrocompetent cells of M. smegmatis were made as described [18,227]. Briefly, 
cultures were grown to an OD600 = 0.8 – 1.0 and placed on ice for 30 min to 2 hr. These were 
centrifuged at 5,000 rpm for 10 min at 4°C, the supernatant was discarded, and the pellets were 
washed with ½ the original volume of ice-cold 10% glycerol. Centrifugation and washing of the 
cell pellets was repeated 2-3 times using 1/4, 1/8, and 1/10 volumes for washes. The final cell 
suspension was in 10% glycerol at approximately 1/15 – 1/25 the original volume, or between an 
OD600 = 5.5 – 7.0. After variation of experimental conditions, it seems that there is a window of 
cell concentration in which the highest level of competency can be achieved. Additionally, using 
larger wash volumes (i.e., ½, ½, and ¼ in succession) and larger culture volumes (>50 ml) results 
in better cell competency. Cell aliquots were placed on dry ice and frozen at -80°C until use.  
6.9.2.3 Transformations 
Transformations of electrocompetent cells were performed by thawing competent cell 
aliquots on ice, using approximately 100 l per transformation. DNA was added to cells, mixed 
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gently, allowed to incubate on ice for 10 min, and the cell mixture was transferred to chilled 0.2 
M cuvettes (Bio-rad). Cells were transformed with a Bio-Rad Gene Pulser II set at 2.5 kV, 1000 
, and 25 F, typically with time constants above 20. Transformed cells were recovered for 2 hr 
or longer in 7H9 broth with ADC and tween shaking at 37°C. These were plated on 7H10 
selective media, and incubated at 37°C for 3 – 5 days. 
6.9.2.4 Assay for UV sensitivity 
M. smegmatis strains to be tested for their phenotype following UV exposure were grown 
in the desired medium to an OD600 = 0.8. The assay was performed in two ways. In one 
approach, 1 ml of the culture was placed in a sterile Petri dish and exposed to UV at levels 
between 50 – 300 J/m2 using the Stratalinker UV Crosslinker. The cells were subsequently 
serially diluted and plated on solid media. Alternatively, serial dilutions of the cultures were 
plated first and then subjected to UV treatment. Following either experiment, the plates were 
incubated at 37°C and colony numbers recorded wild type and recA strains were always used as 
positive and negative controls, respectively. 
 
6.9.3 Mycobacterium tuberculosis 
6.9.3.1 Strains/Media 
 M. tuberculosis H37Rv and M. tuberculosis mc27000 were used for all manipulations.  
M. tuberculosis mc27000 is a derivative of H37Rv in which the RD1 region and panCD were 
both deleted, resulting in a pan- phenotype [150]. M. tuberculosis was grown in 7H9 broth 
(Difco) supplemented with 10% OADC (ADC plus oleic acid, BDL), 0.5% glycerol, and 0.05% 
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tween, and on 7H11 agar (Difco) plates supplemented with 10% OADC and 0.5% glycerol as 
described [18] unless otherwise mentioned. All experiments with M. tuberculosis mc27000 were 
performed with pantothenate added to media at 100 g/ml. When required, media was 
supplemented with the following: Kan (20 g/ml), Hyg (50 g/ml), Cb (50 g/ml), Chx 
(10g/ml), INH (0.2 g/ml), Eth (10 g/ml), Rif (10 g/ml), and/or Str (6 g/ml).  Strains were 
stored at -80°C in 20% glycerol and were streaked on 7H11 plates directly from these frozen 
stocks when required. Single colonies were picked and inoculated routinely from streak plates 
into 5 ml 7H9 broth with OADC, tween, and the appropriate antibiotic, and incubated standing at 
37°C until saturated. M. tuberculosis strains constructed are listed in Table 18. 
 
Table 18. M. tuberculosis strains. 
Strain 
background 
Relevant 
mutation(s) 
Replicating 
plasmid 
Antibiotic 
resistance 
Recombineering substrate 
used to construct strain 
M. tuberculosis 
H37Rv 
groEL1:res-sacB-
hygR-res 
pJV53 KanR, HygR AES; pMtbgroEL1 
M. tuberculosis 
mc27000 
rpoB H451R pJV62 KanR, RIFR ssDNA (JCV326) 
M. tuberculosis 
mc27000 
rpsL K43R pJV62 KanR, StrR ssDNA (JCV330) 
 
These are strains with specifically engineered mutations that were constructed by recombineering; the type of 
recombineering substrate used for each mutation is described. This list does not include strains constructed merely 
by introducing a replicating or integrating plasmid. Abbreviations: AES, allelic exchange substrate; res, resolvase 
site. 
 
6.9.3.2 Competent cell preparations 
Competent cells were prepared as described [229] and similarly to those as described for 
M. smegmatis (section 6.9.2.2) with slight differences. Culture volumes used were no larger than 
50 ml per 250 ml bottle, and these were grown standing at 37°C for up to 2 weeks, or until they 
reached an OD600 = 0.8. The cells were not incubated on ice, but prepared at room temperature 
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by pelleting and washing with 10% glycerol and finally resuspending in 10% glycerol in the 
same manner as for M. smegmatis. The cells were typically not frozen but used immediately for 
transformation. Extra cell aliquots were frozen and stored at -80°C until use. 
6.9.3.3 Transformations 
M. tuberculosis cells were transformed using the conditions described for M. smegmatis 
above (section 6.9.2.3 and [229]), except for the following: the cells were never incubated on ice, 
and the cells were recovered – following transformation – in 7H9 broth supplemented with 
OADC and tween for 1 – 3 days standing at 37°C. Transformations were plated on selective 
media and incubated at 37°C for 20 – 30 days.   
6.10 RECOMBINEERING PROTOCOLS 
6.10.1 Strain growth and media 
6.10.1.1 M. smegmatis 
M. smegmatis mc2155 recombineering strains were made as described [227-229] by 
transforming the pJV plasmids into wild type electrocompetent cells and plating on 7H10/Kan 
media. The transformants were streaked for single isolates, inoculated into 3 ml cultures of 
7H9/ADC/tween/Kan, grown shaking at 37°C until saturated, and frozen at -80°C. These were 
then sub-cultured for growing competent cell batches.  
To grow competent cells, recombineering strains were inoculated in 7H9 induction 
medium (7H9, 0.2% succinate, Kan, and tween) to an OD600 = 0.010 – 0.025 approximately 15 
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hr prior to the desired preparation time and incubated shaking at 37°C. The media was prepared 
by bringing the 90 ml of 7H9 up to 100 ml with dH2O, and adding 1 ml of 20% succinate 
(succinic acid dibasic sodium salt) to a final concentration of 0.2%, and these were grown to an 
OD600 = 0.4 – 0.5, acetamide added to a final concentration of 0.2% (to induce gene expression), 
and grown for 3 hr shaking at 37°C. The competent cells were then prepared as described above 
(section 6.9.2.2).   
Electrocompetent cells of recombineering strains were transformed with the 
recombineering substrate as described above (section 6.9.2.3). Cells were recovered in 7H9 with 
ADC and tween for 4 hr (unless otherwise described) and plated on selective media, always with 
Kan present in addition to the specific antibiotic required for each recombineering protocol. 
6.10.1.2 M. tuberculosis 
M. tuberculosis H37Rv and M. tuberculosis  mc27000 recombineering strains were made 
as described [227-229]. Plasmids for recombineering were transformed into wild type 
electrocompetent cells prepared as described above (sections 6.9.2.2 and 6.9.2.3) and plated on 
7H11/Kan media (plus pantothenate for mc27000). The colonies were inoculated into 5 ml 
cultures of 7H9/ADC/tween/Kan (plus pantothenate for mc27000), grown standing at 37°C until 
saturated, and frozen at -80°C. These cultures were then sub-cultured for growing competent cell 
batches.  
Recombineering strains were subcultured into 50 ml of 7H9 induction medium (7H9, 
0.2% succinate, Kan, tween, and pantothenate for mc27000) to an OD600 = 0.01 – 0.025 and 
incubated standing at 37°C for approximately 10 days. Once the cultures reached OD600 = 0.45 – 
0.50, acetamide was added to a final concentration of 0.2%, and the cells were grown at 37C 
overnight (>16 hrs). Electrocompetent cells were prepared as described above (section 6.9.3.2).  
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The cells were transformed as described above (section 6.9.3.3) with the recombineering 
substrate. Transformed cells were recovered in 7H9 plus OADC and tween (plus pantothenate 
for mc27000) for >16 hr (unless otherwise described) and plated on 7H11/Kan selective media 
containing antibiotics specific to each protocol below. 
 
6.10.2 Recombineering substrates: synthesis and preparation 
6.10.2.1 Gene replacements 
To construct substrates for making allelic replacement mutants or “gene knockouts 
(KOs),” allelic exchange substrates (AESs) or “KO substrates” were constructed for each target 
gene (see Figure 29). These contain homologous sequences upstream and downstream of the 
gene and were cloned flanking an antibiotic resistance cassette. Primers were designed to 
amplify ~500 bp regions of homology at the 5 and 3 ends of the gene, typically designed such 
that ~100 bp at each end of the target gene is intact following gene replacement.  Primers also 
were engineered to contain specific restriction enzyme sites to facilitate directional cloning. The 
PCR products were cloned into a vector flanking a hyg-resistance cassette, typically either 
pYUB854 (containing  res sites for unmarking), pJV69 (pYUB854 without res sites), or 
pJV150 (pJV69 plus a sacB cassette).  The cloning was often performed as a 4-way ligation in 
which the cloning vector was digested with all four restriction enzymes, corresponding to the 
sites in the PCR primers, and these two pieces were ligated simultaneously to the two digested 
PCR products to yield one final plasmid (confirmed by analytical restriction digest). 
The vector (containing the homologous sequences) was linearized by restriction digest 
with two enzymes, preferably the two enzymes used to clone at the most distal regions of the 
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targeting substrate. This yielded two fragments; one containing the hygR cassette flanked by the 
two homologous regions, and the other fragment containing the oriE backbone. Alternatively, 
the section with the homologous regions was amplified by PCR (such as for the pMsgroEL1KO 
substrate). The digest reaction or PCR reaction was cleaned up to remove enzyme using the 
QIAquick gel extraction protocol for enzymatic cleanup (QIAGEN), and DNA was eluted in 
dH2O (in order to minimize salt for transformations). The linear DNA containing the homology 
was quantified by agarose gel electrophoresis or UV spectrometry. 
 
6.10.2.2 Point mutations 
Substrates for making point mutations are ssDNA oligonucleotides. The shortest 
recommended length is 48 nucleotides (Figure 25; [228]), although longer substrates (70 nt – 100 
nt) were used for some experiments. The mutation(s) to be introduced was centered in the 
oligonucleotide. From experimental evidence it was determined that oligonucleotides that are 
complementary to the lagging strand for DNA synthesis work better than those that anneal to the 
leading strand. The oligonucleotides were synthesized as described above (DNA substrates) and 
resuspended in TE buffer upon receipt of the lyophilized DNA pellet, typically to 1 M. The 
sequences of oligonucleotides used in this study are summarized in Table 16. 
6.10.2.3 Unmarked deletions 
 Recommended substrates for deletions are 200 bp, with 100 bp of homology on each side 
of the deletion locus based on a method previously described [172]. First, a 100 nt 
oligonucleotide was designed with 50 nt of homology on each end. Primers, called “extenders,” 
were designed that contained 50 nucleotides at the 5 end that had homology to the target gene 
 213 
followed by 25 nt that annealed to the template (100 nt oligonucleotide). The final PCR product 
was 200 bp and contained 100 bp of homology upstream and downstream of the target 
gene/region (Figure 28).  
6.10.3 Construction of mutants 
6.10.3.1 Gene replacements 
 Electrocompetent cells of strains containing plasmid pJV53 (or a similar plasmid 
containing Che9c 60-61) were transformed with 100 ng targeting substrate DNA as described 
above (6.9.2.3 and 6.9.3.3). The transformations were recovered by incubating at 37C in 7H9 
broth containing ADC and tween, and OADC if for M. tuberculosis. For M. smegmatis, the cells 
were recovered for 4 hrs, and for M. tuberculosis, the cells were recovered 1-3 days.  
 Following recovery, the entire reaction (~1 ml) was plated on 7H10 or 7H11 agar plates 
(containing Kan and Hyg, and oleic acid for M. tuberculosis), and incubated at 37C until 
colonies were of sufficient size for sub-culturing (~5 days for M. smegmatis, 3-4 weeks for M. 
tuberculosis). Typically, between 50-200 recombinant colonies were recovered.  All batches of 
competent cells were tested for cell competency by transforming (in a separate aliquot of cells) 
50 ng of a HygR integration-proficient vector (either pJV39 or pSJ25Hyg), plating on 7H10/Hyg 
plates, and determining the number of cfu per g of plasmid DNA. The number of viable cells in 
each transformation reaction was determined by plating serial dilutions of the cell competency 
control reaction on 7H10/Kan media.  
 214 
6.10.3.2 Point mutations 
Selectable point mutations in either the mycobacterial chromosome or on 
extrachromosomal plasmids were generated by transforming the ssDNA substrate (containing the 
point mutation) into electrocompetent recombineering cells. The strain background was typically 
pJV62 or a derivative, since only the recombinase (gp61) is required for recombination with 
ssDNA. 100 ng of ssDNA substrate was transformed as described above (6.9.2.3 and 6.9.3.3), 
and the cells were recovered in 7H9 broth with ADC, tween, and OADC for M. tuberculosis, at 
37°C. For M. smegmatis, cultures were recovered shaking for 4 hrs, and for M. tuberculosis they 
were recovered for 3 days standing. The recovered cells were diluted, plated on selective media, 
and incubated for 4-5 days (M. smegmatis) or 3 weeks (M. tuberculosis) at 37°C. Cell 
competency and viability counts were determined as described above for gene replacements.  
 For non-selectable mutations, transformations with ssDNAs were performed as above 
using excess ssDNA compared with a HygR, integration-proficient plasmid (pJV39 or 
pSJ25Hyg) or a ssDNA that could also be recombined to confer HygR (JCV198 ssDNA in 
backgrounds with hygS). Optimal results were obtained with 500 ng of the mutating ssDNA and 
100 ng of the HygR selectable element, respectively. Following recovery (4 hr for M. smegmatis, 
3 days for M. tuberculosis), the cells were diluted in 7H9 broth (plus ADC/OADC and tween) 
containing Hyg and Kan to approximately 10–100 HygR cells per well (1 ml media) in a sterile 
96-well culture block. These dilutions were simultaneously plated on 7H10/Hyg/Kan agar plates 
to determine HygR cell counts. The cultures were incubated (shaking at 250 rpm for M. 
smegmatis; standing for M. tuberculosis) at 37°C to an OD600 = 1.0 and screened by colony PCR 
(MAMA-PCR). Each culture well containing a mutant allele was plated for single colonies and 
re-screened by colony PCR to identify the isolated mutant.  
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6.10.3.3 Unmarked deletions 
To make unmarked deletions, 100 – 200 ng of the dsDNA substrate was co-transformed 
with 50 – 100 ng of a HygR-selectable substrate, either a HygR plasmid or another ssDNA that 
could confer HygR (JCV198 in a hygS background strain). The cells were recovered as described 
for non-selectable point mutations; the transformation was either plated on Hyg media or were 
serially diluted in 7H9 broth with Hyg. Transformants or liquid culture dilutions were screened 
by PCR or identifying phenotype (e.g. leucine auxotrophy for leuD mutants) for the presence of 
the desired mutation. Each culture containing the mutation was plated for single colonies and re-
screened by PCR to identify the mutant strain. 
6.10.4 Analysis of recombinant colonies 
6.10.4.1  Gene replacements 
 Colonies recovered from transformations with the targeting substrate were analyzed by 
either colony PCR or Southern blot to confirm the genotype of the strain.  For colony PCR, the 
colonies were either allowed to grow to a large size or were patched onto a fresh plate to get 
enough cells for the PCR. Primers were designed within the homologous regions of the targeting 
substrate to determine if the gene locus contained the HygR resistance cassette or if it was wild 
type, which would result in differently sized PCR products. Colony PCR was performed as 
described above (6.3.1). 
 For Southern blot analysis, colonies were inoculated into ~10 ml 7H9 broth containing 
ADC, tween, Kan, and Hyg (and OADC for M. tuberculosis). The cultures were incubated at 
37C for 3 days (M. smegmatis) or 10 days (M. tuberculosis) until the culture had a substantial 
amount of visible growth. The cells were collected and genomic DNA was prepared as described 
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above (6.8.1). Southern blot analysis was performed as described above (6.8) on each 
recombinant strain to be tested, using the pJV53 strain as a control. Probes were synthesized 
using primers either to the upstream or downstream homologous region in order to determine if 
the gene locus contained the HygR resistance cassette or if it was wild type. Alternatively, a 
probe to the HygR cassette was also used. 
6.10.4.2  Point mutations 
Point mutations that were selectable (such as the rpsL K43R mutation) were confirmed 
by sequencing. PCR was performed with primers that amplified the gene locus, and this DNA 
was cleaned up using QIAquick PCR purification (QIAGEN) and sequenced as described above 
using the same primers. 
 For large-scale identification of non-selectable point mutations, culture wells or single 
colonies were screened by MAMA-PCR with primers designed to distinguish between wild type 
and mutant alleles as described above (6.3.2) [30,219]. Primers were synthesized for both the 
mutant allele and the wild type allele as a control. Positive control templates for mutant alleles 
were synthesized by PCR-amplification by one of four methods: 1) using the recombineering 
substrate that was used to make the point mutation as a forward primer, 2) synthesizing a new 
primer that contained the mutation as a forward primer, 3) using the mutant MAMA-PCR 
screening primer to amplify from a wild type template but with the Pfu polymerase that could 
read through the non-matching 3 end of the wild type template, or 4) PCR amplifying a known 
mutant with sequencing primers.    
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6.10.4.3  Unmarked deletions 
Deletion mutants were identified by PCR from a colony or culture using primers that 
flanked the deleted region, which were designed to amplify either wild type or mutant loci. The 
deletion mutants would therefore yield a smaller-sized PCR product. Colony PCR was 
performed as described above (6.3.1), and cultures that contained mutant alleles were plated for 
single colonies and re-screened to identify the isolated mutant strain. 
6.10.5 Strain unmarking 
Gene replacement strains that were constructed by recombineering often contained -res sites 
for removing the interrupting HygR cassette (if the targeting substrate was constructed in a 
pYUB854 vector backbone). Alternatively, dsDNA recombineering was used to remove the 
HygR cassette, but only in conjunction with a sacB cassette for negative selection (if the targeting 
substrate was constructed in a pJV150 vector backbone). Ultimately, the pJV53 plasmid (or 
similar recombineering plasmid) was occasionally removed from the strain by serial dilution, or 
by using sacB as a negative selection in strains that contain a pJV recombineering plasmid with a 
sacB cassette (e.g. pJV48, pJV126).  
6.10.5.1 Removing HygR by -resolvase 
Unmarking of M. smegmatis recombinant replacement strains using  resolvase was 
accomplished by transforming the strain with pGH542, a TetR plasmid that constitutively 
expresses the resolvase. Electrocompetent cells of the recombinant strain were prepared, 
transformed with 50 ng of plasmid pGH542, and plated on 7H10 agar plates containing Tet. The 
plates are incubated at 37C for 3-4 days until colonies are of sufficient size for sub-culturing. 
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The recovered colonies were patched onto multiple selective 7H10 agar plates containing 
antibiotics in the order as follows: 1) Hyg, 2) Tet, 3) Cb/Chx, and were incubated at 37C for 3-4 
days. Colonies that are HygS and TetR are therefore “unmarked” and the removal of the HygR 
cassette can be verified by colony PCR at that locus.  
 The pGH542 plasmid was removed from this strain at the same time as the 
recombineering plasmid following the protocol described below (6.10.5.2). However, 
occasionally it was desired to retain the recombineering plasmid but remove the pGH542 
plasmid, and in these cases, the recombineering plasmid was selected during the serial dilutions, 
whereas the pGH542 was not (media containing Kan and not Tet). Ultimately, strains that were 
determined (by patching on multiple selective plates) to be TetS, KanS, and HygS were retained 
and stored. 
6.10.5.2 Removing the recombineering plasmid 
In cases in which it was desired to remove the recombineering plasmid from a 
recombinant M. smegmatis strain, this was subcultured into a 10 ml culture of 7H9 media 
(containing only ADC, tween, and Cb and Chx) and incubated with shaking at 37C until it 
reached saturation (~2 days). This culture was subcultured into another 10 ml culture exactly as 
above, using 1 l of the culture (1:10,000) and incubated with shaking at 37C until saturation 
(~2 days). Dilutions (10-4 – 10-7) of this culture were plated on 7H10 agar plates (containing Cb 
and Chx only). The recovered colonies were patched onto multiple selective 7H10 agar plates 
containing antibiotics in the order as follows: 1) Hyg, 2) Tet, 3) Kan, 4) Cb/Chx only. The plates 
were incubated at 37C for 3-4 days. KanS colonies were saved and stored.  
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6.11 MYCOBACTERIOPHAGE MANIPULATIONS 
6.11.1 Mycobacteriophage lysate preparation 
Mycobacteriophages TM4 and Che9c were propagated on M. smegmatis mc2155 as described 
[198]. M. smegmatis cultures were grown in ADC (no tween) until saturated in baffled flasks. 
For typical small-plate lawns, 1.5 ml MBTA was mixed with 1.5 ml 7H9/ADC/CaCl2 and 300 l 
M. smegmatis cultures, and this was solidified and used for spot-tests with serially-diluted phage. 
For plate infections, serially-diluted phage were added to the 300 l of cells, incubated standing 
at 37°C for 20 mins and subsequently plated with MBTA and 7H9 as above. Lysates were 
prepared by flooding plates (5-8 ml) with phage buffer plus CaCl2 at room temperature for 2 hrs, 
or overnight at 4°C. These were collected, the debris removed by centrifugation at 3500 x g, and 
the supernatant was filtered (0.22 M filters) and stored at 4°C. For large-plates, 5 ml MBTA, 5 
ml 7H9/ADC/CaCl2 and 1 ml M. smegmatis cells were used. 
6.11.1.1 Large-scale preparation of mycobacteriophage CsCl stock 
TM4 was prepared in which 30 large plates were made of TM4 infections that yielded 
“webbed” lawns (approximately 6000 pfu total per large plate). Lysates were prepared, and these 
were treated either by the conventional PEG precipitation protocol and continuous CsCl gradient 
purification [198], or using the following protocol.  
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For the modified TM4 “large prep protocol,” the lysates collected from 30 large plates 
were centrifuged in four Ti75 rotor tubes (~60 ml per tube) at 20,000 x g in the ultracentrifuge 
for 1.5 hr (phage buffer was used to balance tubes). The supernatant was removed, and the phage 
pellet was resuspended in 2 ml phage buffer (plus 1 mM CaCl2) overnight standing at 4°C. The 
phages were collected by gently swirling the pellet, and this was titered. At this stage, either a 
continuous CsCl or step CsCl gradient was used to purify the phage from any cell debris. The 
step gradient yielded better results, and this was performed by layering the following solutions in 
this order: 1) 8 ml phage into one tube, 8 ml phage buffer in another tube (as a balance), 2) 
Pasteur pipeting 1 ml 10% glycerol under phage/phage buffer, 3) 1.5 ml of 1.4 mg/ml CsCl 
under glycerol, and 4) 1.5 ml of 1.6 mg/ml CsCl under that. These tubes were centrifuged at 
30,000 x g in a swinging bucket SW41 rotor for 1.5 hrs. The phage band was extracted with a 
syringe, and the phage were dialyzed twice against 500 ml phage buffer with 1 mM CaCl2 at 4°C 
for 4 hr each time.   
6.11.1.2 Genomic DNA isolation from mycobacteriophage stock 
Genomic DNA was isolated as described [198]. Briefly, ~500 l of dialyzed phage were 
extracted with buffer-equilibrated phenol repeatedly (with TE back-extraction) until protein was 
removed. This was followed by an extraction with phenol:chloroform:isoamyl alcohol (25:24:1) 
and another extraction with chloroform. The DNA was ethanol precipitated, washed, and 
resuspended in TE. 
6.11.1.3 Small-scale genomic DNA isolation from lysates 
To make small amounts of phage DNA, 2-3 small plate lysates were prepared, and the 
phage was pelleted by incubating on ice with equal volumes of saturated ammonium sulfate for 
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1-3 hr [198]. The phage were pelleted at 3500 x g and resuspended in phage lysis buffer. This 
was treated with proteinase K at 10 g/ml for 2 hr at 37°C and subsequently phenol extracted as 
described above. It is important to note that the aqueous layer in the first extraction is underneath 
the organic layer due to the presence of the lysis buffer. To fix this, an equal volume of TE was 
added to the phage lysis buffer following treatment with proteinase K; this resulted in a shift of 
the aqueous layer to the top for all extractions. 
6.11.2 TM4 Cosmid library construction 
Approximately 4 g TM4 genomic DNA was ligated to itself to form concatemers using T4 
DNA ligase overnight at room temperature; this facilitated connection of the otherwise linear 
ends. This was partially digested with a frequently-cutting enzyme to yield approximately 40-45 
kbp fragments; this was accomplished best with a 15 min digest with Sau3AI at 37°C.  This was 
immediately placed on ice, phenol extracted, ethanol precipitated, and resuspended in 10 l TE. 
The DNA was then ligated to digested pYUB854 DNA cut with Bgl II (ends compatible with 
Sau3AI) using the FastLink ligase (Epicentre) for 15 mins at room temperature, and packaged 
into  heads using Gigapack III Gold Packaging Extract (Stratagene) according to 
manufacturer’s instructions. HB101 cells were grown and infected with the -packaged 
molecules, and colonies were selected on Hyg (resistance conferred by pYUB854). Colonies 
were miniprepped, and these were analyzed by restriction digest and sequencing to identify the 
segment of TM4 that was cloned into the cosmid. Alternatively, pools of E. coli HB101 colonies 
were prepared together by scraping colonies into 25 ml LB broth plus Hyg, growing to 
saturation, and midi-prepping the DNA (QIAGEN).  
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6.11.3 TM4 cosmid recombination assays 
TM4 cosmids that were defined by analytical restriction digest and sequencing were used to 
assay for recombination in vivo in M. smegmatis. Individual cosmids or pooled cosmid preps 
were transformed into electrocompetent M. smegmatis as described above (6.9.2.2 and 6.9.2.3), 
except tween was not used in the cultures. Concentrated stocks of cosmid DNAs were critical for 
good transformation frequencies; 1 g total DNA was transformed (500 ng each cosmid if in 
pairs), and 50-200 ng TM4 DNA was used as a control. Transformations were recovered in 1 ml 
LB broth for 30 min and plated in 300 l M. smegmatis cells with 0.5 ml 7H9 and 1.5 ml MBTA 
on 7H10 agar plates. These were incubated at 37°C overnight, and plaque numbers recorded for 
single cosmid transformations versus pair-wise combinations.  PCR assays to detect TM4 phage 
DNA (band = 880 bp) and pYUB854 DNA (band = 584 bp) simultaneously contained primers to 
both (TM41444-1464 880F, TM42323-2303 880R; pYUB854 509-533F, pYUB854 1069-
1093R) and were conducted as described above (6.3). 
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APPENDIX A 
 
THE ROLE OF HOST NUCLEASES IN MYCOBACTERIAL RECOMBINEERING 
A.1 INTRODUCTION 
A.1.1 The E. coli RecBCD complex and λ Gam 
The RecBCD complex in E. coli functions for recombinational repair of double-strand DNA 
breaks and broken replication forks (reviewed by A. Kuzminov [106] and by Amundsen and 
Smith [5]). It is a highly processive multienzyme complex that possesses strong helicase activity 
and ATP-dependent dsDNA and ssDNA exonuclease activities. During repair, the enzyme 
degrades dsDNA in a 5 to 3 direction, and following recognition of a Chi site (by RecD), 
RecBCD stimulates RecA polymerization on the 3 ssDNA tail (along with SSB), which 
promotes strand invasion at homologous targets for recombination. However, the RecBCD 
complex also degrades foreign dsDNA molecules – such as the ends of the λ genome – after 
digestion by restriction enzymes upon entry into the cell. More than 40 years of research have 
been dedicated to examining RecBCD, providing a detailed understanding of the genetic and 
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biochemical properties of this very complex enzyme [106]. However, this appendix will focus on 
a small portion of this work and discuss only the most pertinent aspects of its biology.  
 Mutant E. coli strains of recB, recC, and recD display different phenotypes in response to 
DNA damage induced by UV, as well as in regard to their recombination activity [106]. Null 
recB or recC mutations render cells sensitive to UV and have decreased overall viability (~30%), 
whereas recD mutants survive like wild type after UV treatment [133]. The UV phenotype of 
recBCD mutant strains can be suppressed by expression of λ Exo/Beta, and the viability of this 
strain is even increased ~10-fold compared to wild type [135]. Further, the nuclease activities of 
RecBCD are eliminated in a either a recB or recD mutant strain [5]. However, in a recD mutant 
strain, some of the helicase activity is retained, although it is decreased because RecD provides 
the faster helicase subunit [5]. These recD strains are described as ‘hyper-recombination’ 
mutants [106] because they constitutively load RecA for homologous recombination. This 
phenotype essentially mimics the activity of RecBCD following recognition of Chi, which is 
attributed to the removal of the RecD subunit after Chi; the presence of RecD can actually inhibit 
RecA polymerization [5]. Interestingly, there is a specific recB mutation (recB1080) that 
abolishes nuclease activity but can still unwind DNA; however, this is incapable of 
recombination due to the presence of RecD [5]. 
The λ Gam protein inhibits all known activities of RecBCD by binding to the RecB 
subunit and preventing the complex from binding to dsDNA ends [39,93,122,133,138,176]. 
However, Gam expression does not cause all the examined phenotypes of a recBCD strain. 
This is due to the presence of a portion of RecBCD that is not bound by Gam and is therefore 
able to degrade dsDNA [138]. There is also some evidence that Gam interacts with SbcC, though 
this is not well studied [102]. Because of these activities, dsDNA is protected from nuclease 
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attack in the presence of Gam, which makes λ Red recombination more efficient 
[38,142,240,241]. Therefore, although Gam is not essential for phage λ propagation [53] or 
recombineering [43,241], expression of Gam in recombineering assays with dsDNA increases 
frequencies ~10-fold [43]. Gam expression in wild type cells yields a UV-sensitive phenotype 
that mimics a recBC strain (~10-fold decrease in viability compared to wild type) [135]. 
However, Gam does not increase the sensitivity of either recBC or recD strains, which suggests 
that the UV phenotype is a result of Gam interaction only with RecBCD and not any other 
complex [135]. 
Other phages encode proteins that function analogously to λ Gam, such that they protect 
linear dsDNA ends from degradation, although the means by which they accomplish this differs. 
For example, both phage Mu (Gam) [2] and phage T4 (gp2) [6,115,208] have proteins that bind 
dsDNA ends, whereas λ Gam specifically inactivates RecBCD. Conversely, the Abc proteins of 
P22 actually modify the activity of RecBCD in order to exploit its 5-3 ssDNA exonuclease 
activity for P22 Erf-mediated recombination [136,176]. A decrease in host nuclease activity has 
been observed following infection with several additional dsDNA phages [195], which is most 
likely being facilitated by similar types of proteins. 
A.1.2 Mycobacteria encode both RecBCD and AddA homologues. 
Recent bioinformatic analysis of several mycobacterial genomes has revealed a number of genes 
that encode homologues of the B. subtilis AddA protein (Figure 34, D. Ennis and G. Cromie, 
personal communication). B. subtilis AddA is a part of the AddAB enzyme complex. These 
proteins are functionally analogous to E. coli RecBCD in vivo [98], although the complexes have 
slightly different biochemical properties. These genes were originally believed to be restricted to 
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Gram-positive bacteria [32], but recently they have also been identified in the Gram-negative 
bacteria, Rhizobium etli [245] and Coxiella burnetii (D. Ennis, personal communication). The 
AddA subunit has homology to RecB and contains a similar nuclease domain, as well as helicase 
and ATPase domains. The AddB subunit does not have homology to RecC or RecD, but it does 
have ATPase and nuclease domains that are slightly divergent in sequence compared to AddA 
[32]. 
It is apparent that the list of genomes that encode these proteins is not likely complete, 
and also that some bacteria may encode both types of enzymes. For example, M. tuberculosis 
was listed in the review by Chedin et al. as having only a ‘RecBCD-type enzyme’ [32], but 
bioinformatic data suggests that AddA homologues are also present. Further, there is an E. coli 
RecD homologue present in both B. subtilis and Lactococcus lactis, as well as in other bacteria 
that contain neither RecBC nor AddAB. Collectively, these findings suggest that there is still 
much to learn about the roles of these proteins in bacteria that encode homologues of both types 
of enzymes.  
The putative mycobacterial AddA proteins are highly conserved between species (>60% 
amino acid identity) and are similar to the B. subtilis AddA protein at specific regions, including 
the ATPase domains (Walker A and B motifs) and RecB nuclease domains (Figure 34). For 
example, M. smegmatis MSMEG_1943 has 24% and 27% identity to B. subtilis AddA at its N- 
and C-terminus, respectively. However, BLAST analysis with B. subtilis AddB does not identify 
any obvious homologues in the mycobacteria. Instead, these analyses identify multiple genes in 
each mycobacterial genome with similarity to AddA, and some of these are found in pairs (e.g. 
MSMEG_1943 and MSMEG_1941). Typically, the gene with the highest degree of identity was 
aligned in Figure 34A, and the adjacent gene was aligned in Figure 34B.  
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The high degree of sequence similarity between the mycobacterial AddA-like ORFs and 
B. subtilis AddA suggests that these bacteria encode not only RecBCD, but also an AddA 
nuclease. However, it is unclear if the mycobacterial AddA proteins are active or if they function 
in a complex with another protein, such as the more distantly related AddA-like proteins encoded 
by the adjacent genes. It has yet to be determined, to my knowledge, if these genes are expressed 
in vivo or active in any mycobacterial species. It will be interesting to observe if the AddA and 
RecBCD proteins are functionally redundant, or if one affords a separate function in vivo. 
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Figure 34. Multiple sequence alignments of putative mycobacterial and B. subtilis AddA proteins. 
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Figure 34. These al ignments wer e performed a nd p rovided c ourtesy o f Gar eth C romie. The  B. subtilis subsp. 
subtilis ( bottom line) A ddA pr otein was  aligned wi th predicted proteins f rom vari ous m ycobacterial ge nomes. 
Mycobacterial ORFs with similarity to B. subtilis AddA were identified and aligned; those with the most similarity 
were placed in alignment (A) and the adjacent gene with less similarity was alig ned in (B). Th e putative Walker A 
and B motifs are indicated, as well as the regions with similarity to the RecB nuclease domain. Aligned from top to 
bottom: M. avium 104, M. avium subsp. paratuberculosis K- 10, M. bovis AF2122, M. bovis BCG str. Pasteur,  
Mycobacterium gilvum, M. smegmatis mc2155, Mycobacterium sp. JLS, Mycobacterium sp. KMS, Mycobacterium 
sp. MCS, M. tuberculosis CDC1551, M. tuberculosis C, M. tuberculosis F11, M. tuberculosis H37Ra, M. 
tuberculosis H37Rv, Mycobacterium ulcerans Agy99, Mycobacterium vabbaalenii PY R-1, an d B. subtilis subsp. 
subtilis str. 168. 
A.1.3 Recombineering in E. coli: the effect of host RecBCD 
The degree to which λ Gam is required to inactivate host nuclease activity for λ Red 
recombineering with dsDNA substrates differs in varying reports. In studies by K. Murphy and 
Yu et al., the data indicated that Gam expression (or inactivation of recBCD by mutation) was 
absolutely required for recovery of gene replacement mutants [135,240]. This was observed 
using long (~1 kbp) dsDNA substrates, with either 50 bp or 1 kbp homology lengths. However, 
later studies using similar length or shorter substrates showed only an ~10-fold decrease in 
efficiency in the absence of Gam [43,241]. There does not appear to be a difference in 
recombineering frequencies between a recBCD strain or Gam-expressing strain [135], but there 
are clearly advantages to using Gam to facilitate recombineering in any background. Finally, 
there is only a modest decrease (~5-fold) in ssDNA recombineering frequencies in the absence of 
Gam [52]. 
This appendix will discuss the results of the preliminary experiments that have been 
performed in M. smegmatis recB and recD strains, as well as assays in which the expression 
of the λ gam gene is controlled by the acetamidase promoter in M. smegmatis. These strains were 
assayed for both UV sensitivity and dsDNA recombineering activity. While these experiments 
have provided some data regarding the activity of M. smegmatis RecBCD, additional 
experiments will be required to fully understand the role of the mycobacterial nucleases. 
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A.2 RECOMBINEERING ACTIVITY IN REC- M. SMEGMATIS STRAINS 
A.2.1 Recombineering in recB and recD strains 
The mycobacteria encode both RecBCD and AddA proteins, as discussed above. The RecBCD 
genes are grouped together, likely in one operon, in the chromosome of M. smegmatis (Figure 
35A), the organism in which all these experiments were performed. Conceivably, one approach 
to increase recombineering frequencies is to inhibit the potentially negative effects of host 
nucleases. With regard to RecBCD, a recD mutant would be ideal because, at least in E. coli, it 
has wild type viability, does not lose viability after treatment with DNA damaging agents, and 
retains the helicase and recombination-stimulating activities of the complex [5,106]. In order to 
study the role of RecBCD more thoroughly, M. smegmatis mutant strains were constructed that 
contained gene replacements of either the recB and recD genes, and were subsequently 
unmarked by  resolvase (Figure 35B,C). These strains were then tested for dsDNA 
recombineering by targeting the M. smegmatis groEL1 gene (section 3.3.3), and the data were 
compared to recombineering frequencies obtained in a wild type genetic background. 
The recB strain demonstrated a slight increase in recombineering activity, typically 
between 3- and 5-fold compared to wild type (Figure 35D, Table 19). Since reports in E. coli 
vary regarding the effect of RecBCD, it is difficult to directly compare these data. However, it 
was surprising that the increase was only 5-fold, particularly because the smallest effect observed 
in E. coli is a 10-fold increase in efficiency [43]. The recD strain was also slightly increased for 
recombineering activity, although to a lesser extent than recB (~2-fold increase). These results 
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indicate that while recB and recD may have a small effect on recombineering efficiency, their 
activities do not drastically inhibit recombination with dsDNA substrates. 
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Figure 35. Recombineering frequencies in recB and recD M. smegmatis strains. 
 
 
Figure 35. (A) Schematic of the M. smegmatis chromosome at the region encoding the recBCD genes. (B) Southern 
blot analysis of DNA prepared from four individual recB gene replacement mutants made by recombineering; wild 
type DNA is used as a control (4,077 bp and 5,175 bp, respectively). Also shown, colony PCR analysis of 10 recB 
mutants that were unmarked with  resolvase; the hygR marked mutant strain is used as a control (1,396 bp and 
3,130 bp, respectively). (C) Colony PCR analysis of both unmarked and marked recD gene replacement mutants 
made by recombineering, using wild type DNA as a control (401 bp, 2,138 bp, and 1,787 bp, respectively). (D) 
Recombineering frequencies from experiments targeting the M. smegmatis groEL1 gene in wild type, recB, and 
recD M. smegmatis mc2155 strains containing plasmid pJV53. Frequencies are represented on a log scale and 
multiplied by 105 for presentation purposes. The data shown are the averages of three experiments for wild type and 
recB, and two experiments for recD; error bars represent standard deviation. 
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A.2.2 Expression of λ gam in M. smegmatis 
In order to determine the activity of λ Gam in mycobacteria, this gene was cloned either singly 
under Pacetamidase (pJV99) or Phsp60 (pJV97) or together with the Che9c genes 60 and 61 under 
Pacetamidase (pJV98). In the latter case, the gam gene plus 19 bp of sequence upstream of the start 
codon were cloned downstream (158 bp) of Che9c 61 in plasmid pJV53. Competent cells of an 
M. smegmatis strain containing the pJV98 plasmid (Che9c 60 and 61, λ gam) were prepared 
similarly to Che9c recombineering strains and tested for dsDNA recombineering activity using 
groEL1 as a target gene (sections 6.10.1.1 and 3.3.3). The results did not show a difference in 
recombineering frequency as compared to the typical pJV53 strain that expresses only Che9c 
genes (Table 19). This may be due to expression problems, protein instability, or potentially the 
Gam protein is inactive in M. smegmatis. 
 
Table 19. Recombineering frequencies in recB, recD, and Gam-expressing M. smegmatis strains 
Strain (proteins encoded)a Recombinant coloniesb 
Cell 
competencyc 
Recombineering 
frequencyc Ratio
e 
mc2155:pJV53  
(Che9c gp60/61) 226 6.0 x 10
6 3.8 x 10-4 N/A 
mc2155:pJV53 recB  
(Che9c gp60/61) 254 1.7 x 10
6 1.5 x 10-3 3.9 
mc2155: pJV53 recD 
(Che9c gp60/61) 30 5.3 x 10
5 5.6 x 10-4 1.5 
mc2155:pJV98  
(Che9c gp60/61, λ Gam) 123 3.7 x 10
6 3.3 x 10-4 0.9 
 
a. The M. smegmatis recA strain was constructed by allelic gene replacement with recombineering and unmarked 
using resolvase, as described in the Materials and Methods.  
b. Electrocompetent cells of the strains were transformed with 100 ng of the groEL1 AES (see Figure 18), and HygR 
colonies were recovered; the data represent the average of two experiments. 
c. Cell competency is determined as the cfu/g plasmid pJV39, an integration-proficient vector providing 
hygromycin resistance, when 50 ng was transformed. 
d. Recombineering frequency is calculated as the number of recombinant cfu per g DNA divided by the cell 
competency. 
e. The ratio is calculated by dividing the recombineering frequency of the test strain (recB, recD, or pJV98) by 
the recombineering frequency of the wild type mc2155:pJV53 strain. 
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A.3 EXAMINATION OF THE UV PHENOTYPE OF M. SMEGMATIS STRAINS 
The experiments performed with the various M. smegmatis strains (recB, recD, or Gam-
expressing) suggested, somewhat inconclusively, that RecBCD has a minor effect (if at all) on 
recombineering frequencies. To further assess the activity of RecBCD, and specifically to 
determine the effect of expressing Gam, these strains were subjected to UV treatment to assay 
for sensitivity to DNA damage. As expected, the recA strain consistently showed a decrease in 
viability that ranged from 100- to 1,000-fold (depending on the assay; Figure 36 and data not 
shown). However, the recA percent survival is higher (100-fold) in this experiment and others 
compared to previous studies with this strain (~0.1% after treatment with 39 J/m2; [155]).  
 Surprisingly, even with a high level of UV treatment (300 J/m2), the recB strain showed 
viability similar to wild type (Figure 36). Two different recB strains have been constructed 
(mc2155:pJV53 recB, Figure 36, and mc2155 recB, a gift from K. Derbyshire), and both 
demonstrate wild type viability following UV treatment (data not shown).  Further, the recD 
strain also showed wild type viability, but this is similar to what is observed in E. coli for a recD 
null mutant [133].  
 With regard to λ Gam, the mc2155:pJV99 strain (Pacetamidase:gam) appeared to have a 
slight viability decrease (3.5-fold) compared to the control (mc2155:pJV96) in this particular 
experiment. However, repetition of this assay did not show the same defect. Further, a similar 
strain in which gam is expressed from the constitutive hsp60 promoter did not show a decrease in 
viability. These assays suggest that although recB strains are increased in recombination, they 
are not UV-sensitive. In addition, the strains expressing λ Gam do not appear to have either a UV 
or recombination phenotype. 
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Figure 36. UV phenotypes of recA, recB, recD, and Gam-expressing M. smegmatis strains 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. M. smegmatis strains were assayed for UV sensitivity by exposure to 100, 200, and 300 J/m2 UV light 
and plated on solid media to determine the number of viable cells as described in the Materials and Methods (section 
6.9.2.4). The number of surviving cfu were normalized to cells that had not been treated with UV and represented as 
% survival. Strains containing plasmids pJV44 and pJV96 were empty vector control strains for pJV97 and pJV99 
strains, respectively.  
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A.4 PRELIMINARY CONCLUSIONS 
These experiments sought to assay for activity of the M. smegmatis RecBCD enzyme by two 
methods: (1) observing the UV phenotype of recB, recD, and Gam-expressing strains, and (2) 
by determining the recombineering frequencies in these strains. The UV sensitivity assay 
described above has been used previously in M. smegmatis with wild type and recA strains, 
although the recA strain survived ~100-fold better in this experiments than reported previously 
[155]. It is likely that this is due to variations in experimental procedures, since all repetitions of 
this assay consistently showed the same level of killing for both wild type and recA strains. 
Additional assays could be tested, such as mitomycin C sensitivity, which may have more 
reproducible results. Further, a standard gene replacement of M. smegmatis groEL1 was tested in 
each strain to determine the frequency of the recombination event compared to wild type. 
 The assays performed with λ Gam did not indicate that it had any effect on 
recombineering frequency or viability following UV treatment. It was not determined if the 
protein was expressed properly following induction, and it is also possible that the protein 
product was unstable or could not interact with the RecBCD complex. If protein expression 
and/or activity is an issue, alternative constructs could be tested. Another, possibly better, 
approach is to test additional proteins that inhibit nuclease activity that do not require protein-
protein interactions, such as T4 gp2 or Mu Gam. 
 In E. coli, a recB strain is decreased 30% in viability, ~100-fold in recombination 
activity, and 10-fold in survival in assays following treatment with DNA damaging agents 
[106,133]. These characteristics were not observed in the two M. smegmatis recB strains; both 
behaved similarly to wild type with regard to overall viability and survival following UV 
 241 
treatment. There are two likely, possibly independent, explanations for this. First, the two recB 
strains – which were made separately – could have acquired suppressor mutations that restored 
UV-resistance, but retained the positive effect on recombineering frequency conferred by recB. 
One category of suppressor mutations of recBC in E. coli occurs in the sbcB and sbcC genes. 
These mutations restore wild type levels of recombination, DNA repair, and viability by 
inactivating the SbcCD and ExoI exonucleases. [104,118,221]. Suppressors of recBC are also 
located in the sbcA gene only in certain strains of E. coli, which activate expression of recET 
(discussed in section 1.2.3). Therefore it is possible that the two M. smegmatis recB strains 
used in these studies contained suppressor mutations that restored UV-resistance but were still 
deficient in dsDNA exonuclease activity such that recombineering frequencies were increased. It 
is not clear if mycobacteria, specifically M. smegmatis, encode sbcBC-like genes in which 
suppressor mutations could arise. It appears that M. marium encodes a protein with similarity to 
the SbcC of several Bacillus species, although it appears to be interrupted by a large (~475 
amino acids) internal domain of unknown function. Further, the M. marinum SbcC does not have 
similarity to other mycobacterial proteins, and no SbcB or SbcC homologues have been 
identified thus far in other mycobacterial species. 
 An alternative possibility is that the AddA homologues – which are two different proteins 
for each mycobacterial genome – identified by bioinformatics form an active enzymatic complex 
that compensates for RecBCD. Specifically, the UV-resistant phenotype of the M. smegmatis 
recB strain could be a result of AddA-like activity. In addition, there may be activities of the 
RecBCD complex that are not completely complemented by AddA, such as dsDNA exonuclease 
activity. This could explain why only a moderate increase in recombineering frequencies was 
observed in the recB strain compared with the minimum of 10-fold increase observed in E. coli. 
 242 
Additional experiments will be required to determine the role of the putative AddA proteins in 
the recombination and UV-sensitive phenotypes of M. smegmatis recB. 
Ultimately, the recB strain showed a 3.7-fold increase in recombineering frequency, 
while the recD strain improved frequencies to a lesser extent. However, the recB strain could 
be useful for some recombineering approaches, particularly those in which phage genomes are 
the targets and the cell’s genetic background is not of critical importance. In these assays, a 
relatively small number of phage DNA molecules are productively taken up by cells to produce 
plaques in a typical phage recombineering experiment (~100-200), and mutants are isolated at a 
frequency of 10-40%, or 1 out of 12-18 plaques. Therefore, increasing the frequency of 
recombination in the cells by using a recB strain would enable easier identification of mutants 
for this particular application of recombineering, and potentially others.   
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